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Thrombotic events driven by platelet aggregation and activation of the coagulation 
system remain the leading cause of global morbidity and mortality. Antiplatelet and 
anticoagulant agents have proven effective in the treatment and prevention of these 
events in at-risk patients. However, bleeding remains a major concern and there is a 
large unmet clinical need for newer agents that can provide more effective 
antithrombotic protection. Novel candidates have been identified that may allow for a 
wider therapeutic index. Among these, platelet protease-activated receptor 4 (PAR4) 
and exosite 1 of thrombin have emerged as two of the most promising targets for 
antiplatelet and anticoagulant therapies, respectively.  
 
OBJECTIVES 
Given the central role of platelet aggregation to this thesis, we first sought to examine 
the feasibility of using a newer technique of platelet aggregometry, 96-well plate 
aggregometry (96-WPA), instead of the current gold standard, light transmission 
aggregometry (LTA). 96-WPA offers advantages over LTA but as yet there is almost 
no data regarding test-retest repeatability or agreement between the two techniques. 
Thereafter, the principal aims of this thesis were to explore the antiplatelet, 
anticoagulant and antithrombotic effects of PAR4 and exosite 1 thrombin inhibition in 
humans through a series of in vitro and ex vivo studies. Additional objectives included 
determination of whether platelet responses to PAR4 signaling are dependent on 
additional input from other agonist-receptor pathways or vice-versa and establishing the 
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safety and tolerability of intravenous PAR4 agonism in mice in order to facilitate future 
studies into establishing the wider role of PAR4 within the human vasculature. 
 
METHODS AND RESULTS 
Repeatability and agreement between two methods of platelet aggregometry 
Test-retest repeatability (standard deviation, coefficient of variation (CV) and 
coefficient of repeatability) and agreement between 96-WPA and LTA were assessed 
constructing replicate agonist-induced dose-response curves from which peak 
aggregation and EC50 were determined. The pre-specified selected agonists were 
adenosine diphosphate (ADP), arachidonic acid (AA) and PAR4-activating peptide 
(PAR4-AP). Within-day CV for 96-WPA was 3.4%, 3.6% and 3.6% for peak 
aggregation and 9.6%, 7.1% and 6.9% for EC50 with ADP, AA and PAR4-AP, 
respectively. Corresponding values for between-day CV were 8.7%, 5.4%, and 6.6% for 
peak aggregation and 23.4%, 28.5%, and 23.1% for EC50. Overall, results for test-retest 
repeatability were comparable to LTA, although the latter appeared marginally superior 
in terms of the between-day CV. With respect to agreement, ADP and PAR4-AP peak 
aggregation measured consistently higher with 96-WPA whereas the EC50 was 
consistently lower. No significant measurement bias was observed with AA. 
 
Dependence of PAR4 on other agonist-receptor pathways for the activation and 
aggregation of human platelets 
All studies were performed in vitro using blood from healthy volunteers with results 
pooled from a minimum of 6 subjects. Activation of platelets by PAR4-AP (25 µM) 
resulted in strong p-selectin expression (86.5 ± 2.6%), platelet-monocyte binding (85.8 
± 1.5%) and platelet aggregation (88.5 ± 3.4%). Platelet responses to PAR4-AP were 
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completely inhibited by the PAR4 antagonist BMS-986120 but were unaffected by 
SCH-79797 (PAR1 antagonist), apyrase (ADP scavenger) or indomethacin 
(cyclooxygenase inhibitor). In contrast, PAR1 platelet activation and aggregation were 
both partially inhibited by apyrase. BMS-986120 had no effect on platelet activation or 
aggregation in response to PAR1, ADP or AA stimulation. 
 
Tolerability and safety of systemic PAR4 agonism in mice 
PAR4-agonist peptide (PAR4-AP) AYPGKF-NH2 (target blood concentration 11.25 
µM and 112.5 µM) or control (0.9% saline) was administered intravenously to mice 
(n=15 total, 5 mice per group). Mice were observed for 24 hours then sacrificed with 
blood drawn for laboratory analyses and tissue samples prepared for histological 
examination. AYPGKF-NH2 was well tolerated with no evidence of systemic 
perturbation, thrombosis or change in any of the haematological, inflammatory, hepatic 
and renal blood markers examined. No distortion of parenchymal architecture, necrosis 
or inflammatory cell infiltrate of the lungs, spleen, liver and kidney was observed in 
any of the samples. 
 
Effect of oral PAR4 antagonism with BMS-986120 on platelets and thrombosis 
Forty volunteers were enrolled into a phase 1 parallel-group prospective randomized 
open-label blinded endpoint trial. Ex vivo platelet activation, platelet aggregation and 
thrombus formation were measured at 0, 2 and 24 hours after (a) oral BMS-986120, or 
(b) oral aspirin followed at 18 hours with oral aspirin and oral clopidogrel. BMS-
986120 demonstrated highly selective and reversible inhibition of PAR4-AP stimulated 
platelet activation and aggregation. Compared to pre-treatment, BMS-986120 reduced 
total thrombus area at high shear by 29.2% (p<0.001) at 2 hours and by 21.4% 
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(p=0.002) at 24 hours, driven by a decrease in platelet-rich thrombus formation. In 
contrast to aspirin and aspirin in combination with clopidogrel, BMS-986120 had no 
effect on thrombus formation at low shear (p=0.08). There were no serious adverse 
events. 
 
Effect of exosite 1 thrombin inhibition with JNJ-9375 on coagulation, platelets and 
thrombosis 
Fifteen healthy volunteers were enrolled into a double-blind randomized crossover 
study of JNJ-9375 (2.5, 25 and 250 μg/mL), bivalirudin (positive control) and matched 
placebo. JNJ-9375 caused concentration-dependent prolongation of blood coagulation 
and agonist-selective inhibition of platelet activation. Compared to placebo, JNJ-9375 
(250 µg/mL) reduced mean total thrombus area by 41.1% (p<0.001) at low shear and 
32.3% (p=0.025) at high shear. Under both shear conditions, there was a dose-
dependent decrease in fibrin-rich thrombus (p<0.001 for both). In contrast to 
bivalirudin, JNJ-9375 had no effect on platelet-rich thrombus formation. 
 
CONCLUSIONS 
This thesis demonstrates that a) both 96-WPA and LTA demonstrate good and 
comparable within- and between-day repeatability but owing to a systematic 
measurement bias the techniques should not be considered interchangeable, b) under 
conditions designed to replicate clinically relevant levels of thrombin, platelet responses 
to PAR4 stimulation were not dependent on input from other major agonist-receptor 
pathways or vice-versa, c) even at suprathreshold blood concentrations, intravenous 
PAR4 agonism with AYPGKF-NH2 was not associated with adverse effects in mice, d) 
oral PAR4 antagonism with BMS-986120 inhibits ex vivo human thrombus formation 
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at high shear driven by a reduction in platelet deposition, and e) exosite 1 thrombin 
antagonism with JNJ-9375 inhibits ex vivo human thrombosis formation driven by a 
reduction in fibrin deposition. Results from this thesis suggest PAR4 antagonism and 
exosite 1 thrombin inhibition have major potential as novel antiplatelet and 
anticoagulant strategies and that further investigation in clinical trials is warranted.   
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LAY SUMMARY  
 
Thrombosis refers to the development of a blood clot (thrombus) within a blood vessel. 
This can lead to obstruction of blood flow and is the most common cause of heart 
attacks, strokes, and clots within the deep veins (DVT) or lung (pulmonary embolus). 
Platelet aggregation and activation of the coagulation system are critical to blood clot 
formation. Consequently, antiplatelet agents (e.g. aspirin) and anticoagulants (e.g. 
warfarin) are the cornerstone of treatment and prevention of thrombotic events.  
 
Although the current antiplatelet and anticoagulant drugs are of undoubted benefit in a 
broad range of patients, important limitations persist. Bleeding remains a major concern 
and despite treatment many patients continue to suffer from recurrent life-threating 
thrombotic events. This has driven the continued search for safer and more effective 
therapies. BMS-986120 is a new type of antiplatelet agent that works by blocking the 
platelet receptor protease-activated receptor 4 (PAR4). JNJ-9375 is new type of 
anticoagulant that targets exosite 1 of thrombin. Preclinical studies have indicated these 
drugs may be effective new classes of antiplatelet and anticoagulant agents, 
respectively. However, it remains to be determined if either can prevent thrombus 
development in humans. Thus, the principal aims of this thesis were to examine for the 
first time the effect of PAR4 inhibition with BMS-986120 and exosite 1 thrombin 
inhibition with JNJ-9375 on human platelets, coagulation and thrombosis.  
 
One of the key methods in examining the effect on drugs on platelets and thrombus 
formation is platelet aggregometry. The current gold standard technique is light 
transmission aggregometry (LTA). However, LTA can be difficult and is limited in 
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terms of the number of tests that can be performed on each patient blood sample 
because of the volumes required. 96-well platelet aggregometry (96-WPA) is a newer 
technique of platelet aggregation that may address some of the issues of LTA. Prior to 
undertaking our main studies examining PAR4 and exosite 1 thrombin inhibition we 
undertook a series of experiments to determine if using 96-WPA could replace LTA for 
this thesis. Finally, there is evidence that PAR4 may have additional effects in humans 
beyond blood clot formation. Data from animal studies suggests PAR4 may be involved 
in blood pressure control or have other potentially important roles within the 
circulation. It would be very important to understand these effects in humans and there 
are a number of safe study methods that would allow this by injecting small doses of 
drugs that stimulate PAR4. These drugs are readily available but have never been given 
to humans and so it would be essential to first test them in animals to make sure they 
are not associated with any harmful effects. We therefore conducted a study in mice to 
determine if injection of AYPGKF-NH2, a drug that stimulates PAR4, was well 
tolerated and safe.   
 
The major findings of this thesis were that inhibiting PAR4 and thrombin exosite 1 both 
substantially prevented ex vivo human thrombus formation. PAR4 inhibition 
predominantly reduced thrombus formation under conditions similar to those found in 
narrowed coronary arteries whereas exosite 1 thrombin inhibition predominantly 
reduced thrombus formation under conditions found in veins and large arteries. 
Interestingly, platelet responses to PAR4 stimulation were not dependent on other 
common pathways that are targeted by current antiplatelet drugs or vice-versa. We also 
demonstrated that both 96-WPA and LTA provide good and comparable levels of 
precision for measuring platelet aggregation, but the two techniques should not be 
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considered interchangeable.  Overall, our results suggest PAR4 and exosite 1 thrombin 
inhibition have major potential as novel antiplatelet and anticoagulant strategies, 
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Cardiovascular disease remains among the primary causes of global mortality. One in 
four deaths worldwide are due to ischaemic heart disease or stroke, while venous 
thromboembolism (VTE) is the leading cause of disability-adjusted life-years lost in 
low- and middle-income countries [1,2]. The major pathological process common to all 
these conditions is thrombosis. Consequently, antithrombotic agents have been a 
cornerstone in the treatment and prevention of ischaemic cardiovascular events since 
the benefits of aspirin and warfarin were first established [3,4]. Over the past 3 decades, 
newer drugs have been developed in an effort to improve efficacy and reduce unwanted 
complications. However, despite progress, many individuals continue to experience 
recurrent thrombotic events and treatment-related bleeding remains a major concern [5–
10]. 
 
Previously, the pathways involved in thrombosis and haemostasis were thought to be 
inexorably linked suggesting a ceiling of treatment benefit may have been reached. In 
recent years, however, de novo signaling mechanisms have been identified that in 
theory could facilitate an improved therapeutic index because of their apparent greater 
role in thrombosis as compared to haemostasis. Among novel targets under 
investigation, platelet protease-activated receptor 4 (PAR4) and thrombin exosite 1 
have emerged as two of the most promising antiplatelet and anticoagulant candidates 
respectively. Accordingly, the primary purpose of this thesis was to examine the 
therapeutic potential of targeting these pathways in a series of in vitro and ex vivo 











1.1 HAEMOSTASIS AND THROMBOSIS OVERVIEW 
Haemostasis and thrombosis are two distinct but intrinsically related processes. 
Haemostasis is the normal physiological response to vascular injury, acting to prevent 
blood loss and maintain circulation by forming a temporary clot to seal the vessel wall. 
Primary haemostatic responses largely involve platelets, whereas secondary 
haemostatic processes are characterised by activation of the coagulation cascade and 
fibrin formation [11]. While useful, in reality this distinction is somewhat arbitrary with 
both systems working in parallel to prevent blood loss. Following development of a 
haemostatic plug, local antithrombotic and anticoagulant mechanisms act to prevent 
unwanted thrombus growth and support wound healing.  
 
Thrombosis is defined as inappropriate clot formation within a vascular compartment 
leading to obstruction and downstream infarction. It occurs when the balance between 
prothrombotic or procoagulant and antithrombotic or anticoagulant processes is 
disrupted leading to a hypercoagulable state. Thrombus consists largely of platelets, 
fibrin and entrapped red blood cells although the composition varies considerably 
depending on the vascular bed. In arteries, platelets predominate, whereas in veins and 
other low shear environments, fibrin has a much greater role [12,13]. Consequently, 
agents that inhibit platelets (antiplatelet agents) are the drugs of choice for the 
prevention and treatment of arterial thrombotic (atherothrombotic) events, whereas 





Platelet accumulation at sites of vascular injury is a complex process regulated by 
multiple interactions. Immobilized von Willebrand factor plays a critical role in the 
early stages, anchoring circulating platelets to the vessel wall via the platelet receptor 
complex glycoprotein (GP) Ib-V-IX [14]. This interaction is further supported by 
platelets binding to any exposed collagen through their GPVI and α2β1 receptors [15]. 
Following attachment, platelets undergo shape change and degranulation with release of 
multiple prothrombotic agonists, including thromboxane A2, adenosine diphosphate 
(ADP) and thrombin. Secretion of these agonists serves as an important positive 
feedback loop, leading to recruitment and activation of more platelets [16]. A cascade 
of intracellular signaling ensues, culminating in upregulation of activated GPIIb/IIIa 




1.1.2 Coagulation cascade 
 
 
The coagulation system acts in concert with platelet aggregation to maintain 
haemostasis, and under pathological conditions, promote thrombosis. Two pathways of 
coagulation are described, both of which converge to trigger activation of factor X, 
thrombin generation and fibrin formation (Figure 1.1). 
 
Intrinsic pathway 
The intrinsic (contact) pathway begins with activation of factor XII, a process that also 
involves plasma pre-kallikrein and high-molecular-weight kininogen [18]. Classically 
this occurs when blood is exposed to artificial surfaces, but other substrates include 
Tissue factor pathway 
inhibitor (TPFI) 
Antithrombin III 
Figure 1.1. Coagulation cascade 
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polyphosphates (e.g. from platelets or bacteria) [19,20], misfolded protein aggregates 
[21,22], and collagen [22]. Activation of the intrinsic pathway leads to assembly of the 
IXa : VIIIa tenase-complex, which efficiently activates factor X [23]. Studies have 
shown that while deficiencies in the intrinsic pathway affect thrombus formation, they 
may not be associated with an increased bleeding tendency [18].  
 
Extrinsic pathway 
The extrinsic (tissue factor) pathway is triggered by exposure of tissue factor expressing 
cells to the circulation, typically in the setting of vascular injury. Tissue factor (TF) is a 
potent procoagulant, binding to and activating factor VII. The resulting TF : factor VIIa 
complex can then efficiently activate the final common pathway either directly or 
indirectly through factor IX [24]. In contrast to the intrinsic pathway, the extrinsic 




Thrombin is a multifunctional enzyme and one of the most important agonists in the 
cardiovascular system [26]. It exerts procoagulant and prothrombotic as well as 
anticoagulant and antithrombotic effects and is thus central to the regulation of both clot 
promotion and inhibition (Figure 1.1). Thrombin is also a potent modulator of vascular 
tone and endothelial function [27], mitogen [28] and effector of inflammation [25,29]. 
 
1.2.1 Structure and generation 
Thrombin is a trypsin-like serine proteinase made up of 3 functionally important sites: 
the active (or catalytic) site, exosite 1 and exosite 2 [30]. Exosites 1 and 2 are anion-
binding sites on the surface of thrombin that play a critical role in directing function of 
the protease [31–33]. Thrombin is generated from its inactive precursor, prothrombin, 
by activated factor X. In the setting of normal haemostasis, this largely occurs on the 
surface of activated platelets [32]. Thrombin generation is initially driven by the 
extrinsic or intrinsic pathways, but as levels of the protease rise, feed-back activation of 
factors V, VIII and XI leads to auto-amplification and a burst in production [34].  
 
1.2.2 Procoagulant and prothrombotic activities 
The major procoagulant activity of thrombin is cleavage of fibrinogen to produce fibrin 
monomers. The resulting monomers can then polymerise to produce an insoluble 
meshwork that encases and supports the developing clot [35]. Other procoagulant 
activities of thrombin include feedback activation of factors V, VIII, XI, activation of 
factor XIII, and activation of thrombin activatable fibrinolysis inhibitor (TAFI). 
Activated factor XIII promotes fibrin cross-linking [36] whereas TAFI inhibits 
fibrinolysis [37].  
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Thrombin is also a potent platelet agonist, stimulating platelets directly via the surface 
receptors GP1b, protease-activated receptor 1 (PAR1) and PAR4 [38]. GP1b appears to 
principally act as a cofactor for PAR1 activation, although may directly contribute to 
platelet signaling [39]. PAR1 and PAR4 belong to the same family of G-protein 
coupled receptors but have distinct activation kinetics and downstream signaling 
pathways [40]. 
 
1.2.3 Anticoagulant / antithrombotic activities 
Thrombin binds to and activates protein C resulting in inhibition of the coagulation 
cascade and down-regulation of thrombin generation (Figure 1.1) [41]. Activation of 
protein C by thrombin is slow in the absence of thrombomodulin, a membrane protein 
present on the surface of intact endothelium [42]. Binding of thrombomodulin to 




1.2.4 Cofactors and inhibitors 
 
Table 1.1. Thrombin cofactors and inhibitors 
Cofactor / Inhibitor Enhances cleavage / activation Inhibits cleavage / activation 
Procoagulant cofactor   
Na+ Increased protease activity  
GP1b PAR1; GPV; Factor XI  
Fibrin  Factor XIII  
Anticoagulant cofactor   
Thrombomodulin Protein C; TAFI Fibrinogen; PAR1 
Inhibitor   
Antithrombin III  Inactivates thrombin 
Heparin cofactor II  Inactivates thrombin  
Abbreviations used: TAFI, thrombin activatable fibrinolysis inhibitor; PAR1, protease-activated 
receptor 1; and GP, glycoprotein. 
 
It is essential the many and opposing functions of thrombin are tightly regulated in 
order to ensure efficient haemostasis while avoiding widespread thrombosis. Here, 
cofactors play a critical role. Cofactors bind to and modulate thrombin substrate 
specificity thereby enabling direction of protease function appropriate to the local 
environment. They can be broadly classified into either procoagulant or anticoagulant 
depending on their actions [33,42,43,45–48].  
 
The principal inhibitors of thrombin are antithrombin III and heparin cofactor II, acting 
by binding to and irreversibly neutralising the active site of the protease. Antithrombin 
III also inhibits factors IXa, Xa, XIa, and XIIa [49]. Both antithrombin III and heparin 
cofactor II require glycosaminoglycan cofactors (GAGs; e.g. heparan sulfates) to 
function effectively [49,50]. Table 1.1 outlines the main effects of the most important 
thrombin cofactors and inhibitors described to date.   
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Currently there are 3 main classes of oral antiplatelet agents used in clinical practice. 
Aspirin, a cyclo-oxygenase-1 inhibitor, P2Y12 receptor antagonists, and vorapaxar, a 
PAR1 antagonist (Figure 1.2). Aspirin and P2Y12 receptor antagonists prevent 
thromboxane A2 and adenosine diphosphate (ADP) platelet activation, respectively 
[51,52]. Vorapaxar inhibits thrombin and PAR1-mediated platelet activation [53]. 
Figure 1.2. Platelet activation pathways and sites targeted by the most widely used 
current antiplatelet agents.  
Abbreviations used: AA, Arachidonic acid; ADP, adenosine diphosphate; c, cyclic; Ca2+, 
calcium; AMP, adenosinemonophosphate; COX-1, cyclo-oxygenase-1; DAG, diacylglycerol; 
GMP, guanosine monophosphate; GP, glycoprotein; IP3: inositol trisphosphate; PAR, 
protease-activated receptor; PDE, phosphodiesterase; PI3K, phosphatidylinositol 3-kinase; 
PIP2: phosphatidylinositol 4,5-bisphosphate; PLC, phospholipase C; TP, thromboxane 
receptor; TRPC, transient receptor potential channel; TXA2, thromboxane A2; vWF, von 
Willebrand factor. 
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GPIIb/IIIa inhibitors are a fourth major class of antiplatelet agents but are all 
administered intravenously. They inhibit the final common pathway of platelet 
aggregation and are therefore potent platelet antagonists. Due to the incidence of 
adverse events, principally bleeding [54–56], their use is restricted to selected patients 
and for a limited duration (< 108 hours) [57]. Cilostazol is licensed for the symptomatic 
relief of claudication in patients with peripheral vascular disease. It inhibits 
phosphodiesterase-III with antiplatelet effects but does not appear to reduce the 
incidence of thrombotic events [58]. 
 
1.3.1 Benefits and limitations 
Aspirin 
Aspirin is the first and most studied antiplatelet therapy. In acute coronary syndrome 
(ACS), aspirin has been shown to reduce the risk of mortality by 23% after 5 weeks 
[59] and the risk of myocardial infarction or death by 51 to 74% at 3 months [60,61]. 
Similar benefits were found in patients with acute ischaemic stroke [62]. The 
Antithrombotic Trialists’ Collaboration meta-analysis established longer-term use of 
aspirin in patients at high-risk of events reduced the incidence of death, myocardial 
infarction or stoke by approximately 20 to 25% [63]. However, this came at the cost of 
a 50% increased risk of major bleeding. This increased risk of bleeding cannot be 
separated from efficacy. As such, the net clinical benefit becomes progressively less 
favourable in lower risk populations. Consequently, while aspirin for primary 
prevention may reduce the incidence of cardiovascular events in selected groups, the 




P2Y12 receptor antagonists 
Intensification of aspirin monotherapy with a P2Y12 receptor antagonist (dual 
antiplatelet therapy; DAPT) has proven effective in selected high-risk populations.  
Compared to aspirin alone, combined treatment with aspirin and clopidogrel reduces 
the 1-year incidence of cardiovascular events in patients with ACS and following 
percutaneous coronary intervention (PCI) by approximately 20% [66–72]. Even greater 
benefits have been demonstrated with the more potent and consistent P2Y12 receptor 
antagonists, prasugrel and ticagrelor [69,70]. DAPT is the current standard of care in 
these patients and may also improve outcomes in acute stroke when given for short 
periods (< 90 days) [73,74]. 
 
As with aspirin, the major limitation of P2Y12 receptor antagonists is increased 
bleeding. This risk is incremental to aspirin and dependent on the strength of P2Y12 
inhibition [67,69,70,72]. Thus, while patients with ACS remain at higher risk of events 
for up to 3 years and perhaps longer, use of DAPT is generally limited to ≤ 6-12 months 
and the greater antithrombotic efficacy of ticagrelor or prasugrel reserved for selected 
patients [57,75]. Treatment-related bleeding also explains why DAPT has failed to 
deliver net clinical benefit in many other patient groups. This includes patients with 
chronic atherothrombotic disease [76,77] and those with acute ischaemic stroke beyond 
90 days [77–79]. 
 
Vorapaxar 
Two large phase 3 clinical trials have examined the benefit of vorapaxar added to 
standard care in patients with cardiovascular disease [9,80]. Vorapaxar proved effective 
in patients with established atherothrombotic disease but failed to meet the primary 
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efficacy endpoint in ACS. In both studies, there was a substantial increase in bleeding 
including intracranial haemorrhage, especially in patients with a history of stroke. On 
the basis of these trials, PAR1 antagonism with vorapaxar is only approved for the 
secondary prevention of events in patients with a history of myocardial infarction or 
peripheral vascular disease (Food and Drug Administration). It is not licensed in ACS 
and is contraindicated in patients with a history of stroke.  
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The major classes of anticoagulants used in clinical practice are unfractionated heparin, 
low molecular weight heparins (LMWHs), fondaparinux, vitamin K antagonists and 
direct oral anticoagulants (DOACs). Unfractionated and low molecular weight heparins 
bind to and increase the activity of antithrombin III, thereby potentiating factor Xa and 
thrombin inhibition [81]. Unfractionated heparin also inhibits factors IXa, XIa, and 
XIIa [82]. Fondaparinux potentiates the activity of antithrombin III against factor Xa 
[83], whereas vitamin K antagonists (e.g. warfarin) inhibit synthesis of clotting factors 
II, VII, IX, and X [84]. DOACs either directly inhibit thrombin (dabigatran) or factor 
Xa (rivaroxaban, apixaban and edoxaban; Figure 1.3) [84]. 
 
Figure 1.3. Mechanism of action of the most common anticoagulants in clinical use  
Abbreviations used: TF, tissue factor; ATIII, antithrombin III; VKAs, vitamin K antagonists 
(i.e. warfarin); LMWH, low molecular weight heparin; and UFH, unfractionated heparin. 
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1.4.1 Benefits 
Anticoagulants are of proven benefit in a wide range of thromboembolic disorders. In 
patients with or at risk of venous thromboembolism, their use is associated with a 
significant reduction in the incidence of recurrent non-fatal and fatal thromboembolic 
events [85–91]. Anticoagulants are also a mainstay in the treatment of inpatients with 
acute coronary syndrome, decreasing the risk of recurrent myocardial infarction and 
death [92–95]. Vitamin K antagonists reduce the incidence of thromboembolic 
complications in patients with mechanical heart valves and together with DOACs have 
proven effective in patients with atrial fibrillation at risk of embolic events [96–99]. 
 
1.4.2 Limitations 
All current anticoagulants share the same major limitation as antiplatelet drugs, namely 
increased bleeding. Estimates of risk depend on the indication and population studied 
but in general warfarin and LMWHs are associated with a several fold increased risk of 
major bleeding as compared to placebo [97,100–103]. Warfarin-related bleeding or a 
high INR are among the most common iatrogenic causes of unplanned hospital 
admissions [104]. While DOACs have addressed many of the practical issues 
surrounding warfarin, reductions in bleeding have largely been limited to the treatment 
of patients with acute venous thromboembolism [98,105] and to a lesser extent atrial 
fibrillation (AF) [98]. Indeed, DOACs are not licensed for thromboprophylaxis in non-
surgical patients due to an excess of bleeding [106] and are contraindicated in patients 
with mechanical heart valves owing to an increased incidence of ischaemic stroke and 
haemorrhagic events [107]. Thus, despite newer medications, treatment-related 
bleeding remains a significant problem and for many patients this leads to sub-optimal 
dosing or exclusion from anticoagulation altogether [102,105,108–112]. In AF, for 
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example, over one third of patients with a clinical indication for anticoagulation 
(CHADSVASC score ≥ 1) are not on any treatment and up to 50% prescribed a DOAC 
are inappropriately given a low dose because of bleeding concerns [108,109]. 
 
SUMMARY 
Thrombotic disease remains one of the leading causes of global morbidity and 
mortality. Antithrombotic drugs have proven effective in the treatment and 
prevention of thrombotic and thromboembolic events in a wide range of clinical 
settings. However, despite progress, many at-risk individuals continue to 
experience life-threatening events. All the current antithrombotic agents are 
associated with an increased risk of bleeding that restricts their potential for 
greater efficacy and limits their net clinical benefit. A ceiling of treatment 
potential would appear to have been reached suggesting that if more effective 
antithrombotic protection is to be afforded to a wide range of patients, novel 
antiplatelet and anticoagulant strategies are likely to be required. Among those of 




1.5 PROTEASE-ACTIVATED RECEPTOR 4 
PAR4 belongs to a family of four specialised G-protein coupled receptors (PAR1 to 4) 
expressed on the surface of cells [113]. PAR4 is found on a number of cell types within 
humans and is activated by several proteases. These include thrombin, plasmin, trypsin 
and cathepsin G. 
 
1.5.1 Platelet PAR4 
Human platelets express both PAR4 and PAR1. Together, these receptors are the 
principal target for thrombin-mediated platelet activation [114]. PAR1 was the first 
PAR discovered, but to date, trials of PAR1 antagonists have generally disappointed 
with limited reductions in ischaemic events largely off-set by increased bleeding [9,80]. 
PAR4 was initially viewed as a weak platelet agonist [115,116]. However, it is now 
clear PAR4 is active at lower thrombin concentrations than first suggested with distinct 












PAR receptors are activated in a unique manner. Proteolytic cleavage of the 
extracellular domain exposes a tethered ligand, which then binds intramolecularly to 
effect intracellular signal conduction [120]. PAR4 signaling is largely mediated by the 
G-protein subunits Gq and G13 [113,121]. Coupling to Gq induces platelet secretion, 
shape change and GPIIb/IIIa upregulation, mainly through activation of phospholipase 
C-b (PLC-b) [122]. G13 signaling triggers shape change via the Rho/Rho-kinase 
pathway (Figure 1.4) [123]. Phosphatidylinositol 3-kinase (PI3K) plays a major role in 
Figure 1.4. Simplified illustration of the major platelet PAR4 (and PAR1) intracellular 
signaling pathways.  
Abbreviations used: Ca++, calcium; DAG, diacylglycerol; IP3: inositol trisphosphate; PI3K, 
phosphatidylinositol 3-kinase; PIP3: phosphatidylinositol 3,4,5-trisphosphate; PLC, 
phospholipase C; PKC, protein kinase C; Rap 1, ras-related protein 1; RIAM, rap1–GTP-
interacting adapter molecule; RhoA, ras homolog gene family, member A; MLC, myosin 
light chain; akt, protein kinase B; cAMP, cyclic adenosine monophosphate; VASP-P, 





inside-out platelet signaling [124]. Although PAR1 and to a lesser extent PAR4 may 
activate PI3K directly, the principal mechanism appears to through released ADP acting 
on Gi coupled P2Y12 receptors [121,125].  
 




In response to thrombin, PAR1 and PAR4 signal with markedly different kinetics. 
PAR1 contains a hirudin-like sequence that interacts with exosite 1 [126] to facilitate 
rapid association and activation [127]. PAR4 does not contain this sequence but has 
optimized its cleavage sequence to allow high affinity interactions and contains an 
anionic cluster to slow dissociation [128]. Activation-dependent receptor 
phosphorylation and internalization are also significantly slower for PAR4 than for 
PAR1 [1].  
Figure 1.5. Illustration of the theoretical predominant roles of various agonists and 
receptors in platelet responses. 
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PAR1 is therefore the high-affinity receptor for thrombin, resulting in a rapid 
intracellular calcium spike and platelet aggregation to low levels of agonist. However, 
activation is transient with PAR1 dependent on input from the P2Y12 / PI3K pathway to 
sustain protein kinase C (PKC) signaling and platelet aggregation [40,129]. In contrast, 
PAR4 induces a slow but prolonged response to thrombin that, independent of 
additional support, acts to maintain the high late Ca2+ and PKC signals essential for 
irreversible aggregation [114,129,130]. Thus, whereas PAR1 and other agonist-platelet 
pathways appear to be important for initiating platelet activity, PAR4 appears to 
function primarily to sustain platelet aggregation and support thrombus growth (Figure 
1.5). These data suggest that targeting PAR4 may protect against thrombosis, while at 
the same time, avoid interfering with early haemostatic platelet responses to the same 
extent as PAR1 antagonists and other antiplatelet agents [131]. 
 
1.5.1.3 Existing PAR4 antagonists 
Pepducins 
Pepducins are cell-penetrating peptides that bind to G proteins, modulating receptor and 
G-protein interactions to effect downstream signaling [132]. The anti-PAR4 pepducin, 
P4pal-10 (N-pal-SGRRYGHALR-NH2), has been shown to inhibit PAR4-activating 
peptide (PAR4-AP) and thrombin stimulated human platelet aggregation [132]. P4pal-
i1 (N-pal-ATGAPRLPST-NH2) is an alternative anti-PAR4 pepducin that targets the 
first rather than the third intracellular loop. In a guinea pig carotid artery injury model, 
P4pal-i1 was found to prolong the time to occlusion [117]. There remains concern over 
the lack of specificity of anti-PAR4 pepducins [133,134] although in the study by Leger 




Peptidomimetics are based on the sequence of a naturally occurring protein, interacting 
with the target to either produce the same biological effect or competitively block 
function. tc-YPGKF-NH2 is a peptide analogue of the PAR4 tethered ligand sequence 
with the addition of a trans-cinnamoyl (tc) group. It has been shown to block thrombin-
induced platelet aggregation in rodents [135] but has limited capacity against human 
PAR4 [136,137]. 
 
Low molecular weight compounds 
Low molecular weight PAR4 antagonists include YD-3 (1-benzyl-3 (ethoxycarbonyl-
phenyl)-indazole) [138], an indazole derivative, and more recently ML354 (1-methyl-5-
nitro-3-phenyl-1H-indole-2-methanol) [139], a substituted indole-based derivative. 
These compounds inhibit PAR4-AP stimulated human platelet aggregation [140,141]. 
However, YD-3 is hampered by a lack of efficacy [142] and both suffer from a lack of 
specificity [141].  
 
Function-blocking antibodies 
Function-blocking antibodies selective for PAR4 have been developed [143]. They 
have been shown to prevent human platelet aggregation [144] and in animal models  
inhibit thrombosis with a much wider safety profile compared to clopidogrel [131]. 
Multiple new function-blocking anti-PAR4 antibodies are under investigation but to 







BMS-986120 is a high-affinity, potent, selective and reversible small-molecule PAR4 
antagonist (Bristol-Myers Squibb; Figure 1.6). It is the first orally bioavailable PAR4 
antagonist. 
 
In vitro studies 
In vitro studies have demonstrated the potency and selectivity of BMS-986120 for 
inhibiting human PAR4 [131]. BMS-986120 abolished PAR4-AP induced calcium 
mobilization in HEK cells expressing recombinant human PAR4 but was ineffective 
against PAR1-AP or PAR2-AP. Moreover, BMS-986120 strongly inhibited aggregation 
of human platelets to gamma-thrombin (a derivative of thrombin that is selective for 
PAR4) and PAR4-AP, but had no effect against PAR1-AP, collagen, ADP or the 
thromboxane A2 receptor agonist, U46619 [131].  
Figure 1.6. Chemical structure of BMS-986120 
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Wong and colleagues examined the pharmacodynamic effects of BMS-986120 in 
animal models of thrombosis and bleeding [131]. In a cynomolgus monkey model of 
carotid injury, BMS-986120 (1 mg/kg) maintained blood flow close to baseline and 
reduced thrombus formation by 82%. PAR4 antagonism with BMS-986120 also 
demonstrated substantially less impact on bleeding times relative to clopidogrel 
resulting in a much wider therapeutic index (Figure 1.7).   
 
Figure 1.7. Dose-dependent effect of clopidogrel and BMS-986120 on thrombus 
reduction and bleeding times (BTs) in cynomolgus monkeys. 
(A) Effects of clopidogrel on thrombus reduction and kidney BT. (B) Effects of BMS-
986120 on thrombus reduction and kidney BT. (C) Effects of clopidogrel on thrombus 
reduction and mesenteric BT. (D) Effects of BMS-986120 on thrombus reduction and 
mesenteric BT. Thrombus reduction was expressed as a percent reduction of drug-treated 
relative to the mean vehicle-treated thrombus weight. BT effect was expressed as a ratio of 
drug-treated versus the mean vehicle-treated value. Data are means ± SEM. Figure 




The safety and tolerability of BMS-986120 has been assessed in a double-blind, 
placebo-controlled, single- and multiple-ascending dose study [146]. BMS-986120 
inhibited PAR4-AP stimulated ex vivo platelet aggregation and p-selectin expression in 
a dose-dependent manner but had no clinically relevant effect on routine laboratory 
assessments including coagulation tests or template bleeding times. There were no 
drug-related discontinuations or bleeding-related clinical findings, and the frequency of 
treatment-related adverse events was similar to placebo. 
 
1.5.2 Wider role of PAR4 
Acting via PAR1, thrombin and other proteases elicit a number of important vascular 
effects beyond platelet activation and aggregation. These include endothelium-
dependent arterial vasodilatation, endothelium-independent venoconstriction, release of 
tissue plasminogen activator, smooth muscle cell hypertrophy, proliferation and 
migration, and extracellular matrix synthesis [27,147,148]. Activation of PAR1 also 
plays an important role in the maintenance of normal endothelial integrity [149] and it 
is proposed interference of this protective function may have contributed to the 
increased bleeding seen with PAR1 antagonists [150] 
 
PAR4 receptors are also expressed on a number of vascular cell types, including 
smooth muscle and endothelial cells [151–153]. In humans, functional PAR4 has been 
demonstrated in isolated coronary artery segments [151] with elevated expression 
reported in the tunica media of atherectomy and saphenous vein tissue from patients 
with diabetes mellitus [153]. Data from animal studies suggests PAR4 may be involved 
in the control of vascular tone, ischaemia reperfusion injury, and the exaggerated 
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intimal hyperplasia seen in diabetic conditions [137,154–156]. However, inter-species 
differences in PAR function and activation may limit extrapolation of these results to 
man [157,158] and to date there have been no studies examining the in vivo vascular 
effects of PAR4 in humans.  
 
Like PAR1, the vascular functions of human PAR4 may be diverse but are essentially 
unknown. Determining such effects would not only deepen our understanding of 
vascular biology but may have important implications regarding the safety and 
effectiveness of PAR4 inhibitors as future antiplatelet agents. We have previously 
characterised the in vivo vasomotor and endothelial effects of PAR1 agonism in healthy 
volunteers through local venous and arterial infusion of a PAR1-AP [27,148]. Similar 
studies with a PAR4 agonist can be expected to provide major insights and a number of 
highly specific PAR4-AP compounds are readily available. However, to date, there 
have been no reports of any PAR4 agonist being administered to man. This is an issue, 
particularly because in addition to vascular cells, PAR4 is found on neutrophils [159], 
alveolar macrophages [160], neurons [161], synovial cells [162], and within the kidneys 
[163,164], airways [165] and liver [166]. Indeed, topical administration of a PAR4 
agonist to mice mesenteric venules increased leucocyte rolling and adhesion, while 
intraperitoneal injection promoted leukocyte migration [159]. In rodents, intra-plantar 
and intra-articular injection of a PAR4 agonist resulted in localized oedema and 
granulocyte infiltration [137,167–169], whereas intranasal PAR4 agonism induced the 
recruitment of a small number of neutrophils into the airways of mice [160]. Studies 
have also suggested PAR4 may play a role in modulating nociceptive responses, which 
are both tissue and dose specific [167,169–171].  
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Given the multi-tissue and multi-organ distribution of PAR4, it would be crucial to 
examine the safety and tolerability of systemic PAR4 agonism in animals prior to 
undertaking in vivo studies in man. Such work would provide the platform for essential 





PAR4 is a G-protein coupled receptor on the surface of human platelets as well as 
a number of other cell types within the vasculature and beyond. Activated by 
several proteases including thrombin, mechanistic studies suggest the principal 
role of platelet PAR4 appears to be in the later stages of platelet activation, 
primarily acting to sustain thrombus growth and propagation. Therefore, it has 
been hypothesised that targeting PAR4 may provide effective antithrombotic 
protection while at the same avoid interfering with haemostatic platelet responses 
to the same extent as current agents. BMS-986120 is a first-in-class, highly 
selective oral PAR4 antagonist that in animal models of thrombosis and bleeding 
demonstrated a much wider therapeutic index as compared to clopidogrel. 
However, it remains to be determined what effect BMS-986120 might have on 
thrombus formation when administered to humans and how this compares to the 
current standard of care antiplatelet agents. 
 
Like PAR1, the vascular functions of PAR4 may extend beyond platelets but 
remain largely unknown. Defining these effects would not only add to our 
understanding of vascular biology but may have important implications regarding 
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the effectiveness and safety of PAR4 inhibitors as future antiplatelet agents. Our 
group has previously examined the in vivo effects of PAR1 agonism on vascular 
tone and endothelial function but to date no PAR4 agonist has ever been given to 
humans. Because of the potential for unwanted haemodynamic, inflammatory and 
end-organ effects, it would be essential to first examine the safety and tolerability 
of PAR4 agonism in animals. 
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1.6 THROMBIN EXOSITE 1 
Exosite 1 of thrombin (hereafter exosite 1) is an electropositive region on the surface of 
thrombin that together with exosite 2 plays an important role in regulating catalytic 
function of the protease. In general, exosite 1 binds thrombin to substrates, cofactors 
and inhibitors to promote access to the catalytic site, whereas exosite 2 localises 
thrombin to the surface of cells or proteins [31–33,172]. Both exosites promote 
procoagulant, prothrombotic and anticoagulant effects depending on the interaction. 
 
Exosite 1 is the predominant fibrinogen recognition site for thrombin, greatly enhancing 
fibrin production [173]. Exosite 1 also binds to PAR1 to support thrombin-mediated 
platelet activation [127,174], thrombomodulin [42], and ADAMTS13, a plasma 
protease responsible for cleaving anchored large multimers of von Willebrand factor 
[175]. Exosite 2 anchors thrombin to platelet GP1b, thereby facilitating activation of 
PAR1, GPV and factor XI [176], and GAGs [42]. Both exosites assist feedback 
activation of clotting factors V and VIII [177].  
 
1.6.1 Potential advantages of exosite 1 thrombin inhibition 
All the currently licensed anticoagulants act to either inhibit thrombin generation, 
promote antithrombin III activity or block the active site of the protease directly [178]. 
Consequently, they result in broad inhibition of thrombin function that invariably fails 
to discriminate between protease interactions relating to thrombosis and those essential 
to haemostasis. Targeting exosite 1 allows a more selective approach to thrombin 
inhibition, preventing fibrinogen binding while still maintaining catalytic function of 
the protease and exosite 2 substrate recognition. This capacity to avoid overly 
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interfering with other thrombin activities relating to haemostasis may offer advantages 
in terms of affording a wider therapeutic index [131,179]. 
 
Early evidence 
Functional blocking aptamers specific to exosite 1 and exosite 2 have been used to 
probe thrombin exosite function and examine the potential of exosite 1 thrombin 
inhibition. Using aptamers, Derszniak and colleagues demonstrated exosite 1 but not 
exosite 2 thrombin antagonism potently inhibited fibrin generation and ex vivo 
thrombus formation under flow conditions [180]. Similar outcomes were observed in a 
cone and plate chamber model [181]. In the same study, exosite 1 thrombin inhibition 
was found to have no effect on platelet adhesion. This potentially haemostatic sparing 
effect is consistent with reports exosite 1 thrombin inhibition does not affect collagen-
induced platelet responses [182] or the ability to form haemostatic plugs [183]. 
 
Further insights into the possible safety of exosite 1 thrombin inhibition come from a 
unique case report [184]. A patient presenting with a large traumatic subdural 
haematoma was found to have markedly prolonged coagulation times (prothrombin 
time, 40 s; activated partial thromboplastin time, 240 s; thrombin time, 173 s) owing to 
the presence of an anti-exosite 1 thrombin IgA antibody. Despite persistence of the 
antibody and continued evidence of intense anticoagulation, the patient made a full 
recovery without surgical intervention and had no abnormal bleeding events during 8 




JNJ-64179375 (hereafter JNJ-9375; Janssen Research and Development) is a first-in-
class, recombinant, fully human, IgG4 monoclonal antibody synthesized to mimic the 
anticoagulant effects of the anti-exosite 1 thrombin IgA antibody described above. It 
binds reversibly and with high affinity and specificity to the exosite 1 region of 
thrombin [179]. Animal studies of thrombosis and bleeding have raised considerable 
interest that exosite 1 thrombin inhibition with JNJ-9375 may represent a paradigm 
shift in anticoagulant therapy [179] 
 
JNJ-9375 has been shown to inhibit fibrinogen cleavage in a dose-dependent manner 
and reduce thrombomodulin-dependent activation of protein C approximately 7-fold 
[185]. Confirming selectively of action, JNJ-9375 had no effect on the interaction of 
thrombin with heparin and both unfractionated heparin and LMWH continued to 
dramatically accelerate antithrombin III protease inactivation [185]. In both rat and 
cynomolgus monkey models, JNJ-9375 potently inhibited thrombus formation with a 
much wider therapeutic index (TI) when compared to apixaban (TI 33 vs. 3 in rats; 40 
vs. 10 in monkeys). 
 
SUMMARY 
Exosite 1 thrombin inhibition is an attractive novel mechanism of anticoagulation 
because of the potential for antithrombotic efficacy without the same bleeding risk 
as current agents. JNJ-9375 is a first in class exosite 1 thrombin inhibitor that in 
animal models demonstrated potent antithrombotic effects with a substantially 
wider therapeutic index when compared to apixaban. However, inter-species 
differences in procoagulant pathways limit extrapolation of these results to 
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humans [186] and while unique insights into the low bleeding potential of JNJ-
9375 have been afforded by the antibody it was synthesized to mimic, it remains to 
be determined what effects exosite 1 thrombin inhibition with JNJ-9375 has on 




1.7 ASSESSMENT OF PLATELET AGGREGATION 
Platelet aggregometry is critical to the evaluation of patients with suspected platelet 
dysfunction and plays a central role in the development of novel antithrombotic agents. 
By determining the effect of a drug on platelet responses to a range of known agonists, 
aggregometry provides crucial information on the mode of action as well as the 
potential for in vivo efficacy. Consequently, platelet aggregation is essential for the 
characterisation and therapeutic assessment of platelet PAR4 and exosite 1 thrombin 
inhibition.  
 
The current ‘gold-standard’ technique for platelet function testing is light transmission 
aggregometry (LTA) [187]. Established in the 1960’s, LTA utilises changes in sample 
turbidity that occur when platelets aggregates [188,189]. However, because of the 
volume required for each test (typically >200 µL) and the limited number of channels 
available (typically between 4 and 8), LTA can be restrictive in terms of material costs 
and the range of test conditions examinable per blood draw [190]. LTA is also 
considered labour intensive and technically challenging. 
 
Ninety-six-well plate aggregometry (96-WPA) is a newer method of assessing platelet 
aggregation developed to address some of the limitations of LTA. Like LTA, 96-WPA 
measures changes in turbidity, but requires less than half the sample volume per test 
and allows for simultaneous examination of a much wider range of study conditions 
owing to the large number of channels available (n=96) [190,191]. 96-WPA does not 
provide as much secondary information compared to LTA (e.g. occurrence of the 
secondary wave of aggregation) but would seem ideally suited for many research and 
clinical applications that require probing of platelet function [190–192]. Platelet 
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aggregation is essential to this thesis and the technical advantages of 96-WPA could 
provide additional opportunities. However, before one test can replace another, it is 
essential to establish the test-retest repeatability and agreement between the two 





Following preliminary work to validate a new method of platelet aggregation, the 
principal aims of this thesis were to evaluate the effects of PAR4 and exosite 1 
thrombin inhibition on human platelet responses, coagulation and ex vivo thrombus 
formation. We also sought to examine the safety and tolerability of systemic PAR4 




The individual hypotheses of this thesis were: 
1.  96-WPA will demonstrate similar test-retest repeatability to LTA with good 
 agreement (Chapter 3). 
2. Human platelet responses to PAR4 activation will be independent of signaling 
 from other major agonist-receptor pathways (Chapter 4). 
3. Intravenous administration of the PAR4 agonist AYPGKF-NH2 to mice will be 
 well tolerated with no signs of systemic or organ toxicity (Chapter 5). 
4. Oral PAR4 antagonism with BMS-986120 will selectively inhibit human PAR4-
 mediated platelet responses with no effect on coagulation (Chapter 6). 
5.  Oral PAR4 antagonism with BMS-986120 will inhibit ex vivo human thrombus 
 formation with greater effect at high shear (Chapter 6). 
6. Exosite 1 thrombin antagonism with JNJ-9375 will prolong human coagulation 
 but have limited effect on platelet aggregation (Chapter 7). 
7. Exosite 1 thrombin antagonism with JNJ-9375 will inhibit ex vivo human 












2.1 HUMAN STUDIES 
2.1.1 Study subjects 
Study populations are described in detail in their respective chapters. Only healthy male 
and female volunteers were recruited. Exclusion criteria included any clinically 
significant coexisting condition including hypertension, hyperlipidaemia, diabetes 
mellitus, gastrointestinal disease, coagulopathy, known liver disease, and recent 
infective or inflammatory condition. Volunteers were not permitted to take any 
prescription or non-prescription medication (including acetylsalicylic acid, paracetamol, 
vitamins and herbal supplements) within at least 7 days (study specific) of an 
experimental visit. Prior to each visit, volunteers must have abstained from alcohol for 
at least 24 hours (study specific) or food including caffeine-containing products for at 
least 8 hours (study specific).  
 
Volunteers were not permitted to be involved in other clinical trials at the time of the 
study. 
 
2.1.2 General ethical considerations and consent 
Each study was approved by the local research ethics committee and conducted in 
accordance with the Declaration of Helsinki of the World Medical Association. All 
volunteers were given adequate time and opportunity to discuss their potential 
involvement and provided written informed consent prior to any study procedure.  
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2.1.3 Study specific ethical considerations 
2.1.3.1 Effects of PAR4 antagonism in healthy volunteers 
This was a phase I parallel group prospective randomized open-label blinded endpoint 
(PROBE) trial of a novel oral PAR4 antagonist. The study was conducted in accordance 
with Good Clinical Practice, as defined by the International Conference on 
Harmonisation, and the ethical principles underlying European Union Directive 
2001/20/EC and the United States Code of Federal Regulations, Title 21, Part 50 
(21CFR50). The study is registered on the clinicaltrials.gov website (NCT02439190). 
Clinical Trial Authorization was provided by the Medicines and Healthcare products 
Regulatory Agency of the United Kingdom. 
 
2.1.4 Recruitment 
Potential participants were recruited through paper and digital advertisement restricted 
to University of Edinburgh public places or from the existing research database of 
volunteers who had agreed to be contacted regarding inclusion in future studies. An 
email address was provided for potential participants to register their interest in taking 
part. A member of the study team then contacted the participant and provided an 
information sheet. If the participant was interested in taking part, a screening and study 
appointment was arranged.  
 
2.1.5 Study sites and conditions 
All study visits were conducted at the Queen's Medical Research Institute (QMRI) of 
Edinburgh or the Clinical Research Facility at the Royal Infirmary of Edinburgh. 
Studies were performed in a quiet, temperature-controlled room (22-24 °C) with the 
participants semi-recumbent.  
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2.1.6 Determination of drug concentrations  
Plasma concentrations of BMS-986120 were determined from blood samples drawn 
uncuffed through a 17-G cannula in the ante-cubital fossa into 3 mL K2EDTA 
vacutainers (Becton-Dickinson, Cowley, UK) and placed on wet ice. Within 1 hour of 
collection, samples were centrifuged at 1200 g (2-8 °C) for 10 minutes. Plasma was 
decanted and stored at -20 °C before analysis. From these samples, concentrations of 
BMS-986120 were determined using a validated liquid chromatography tandem-mass 
spectrometry method with a lower limit of quantification of 0.250 ng/mL, accuracy 
coefficient of variation of <5 % and precision (intra- and inter-assay) coefficients of 
variation of <10 %. 
 
Serum JNJ-9375 and plasma bivalirudin concentrations were determined from blood 
samples taken immediately distal to the perfusion chamber into 3.5 mL serum gel and 
2.7 mL sodium citrate (3.2%) tubes (Becton-Dickinson, Cowley, UK), respectively. 
JNJ-9375 samples were allowed to clot for 30 minutes then centrifuged at 1500 g (20 
°C) for 20 minutes. Bivalirudin samples were centrifuged at 1500 g (15 °C) for 15 
minutes within 1 hour of collection. Samples were then aliquoted and stored 
immediately at -70 °C before analysis. Concentrations of JNJ-9375 were determined by 
electro-chemiluminescence using the Meso Scale Discovery platform and plate reader 
(Rockville, Maryland, USA). Values were then regressed from the standard curve in 
Watson LIMS (version 7.4.1, Thermo, PA, USA) using a five-parameter logistic 
regression model with 1/Y2 weighting.  
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2.1.7 Platelet studies 
2.1.7.1 Blood sampling 
All blood samples were drawn uncuffed through a 17-G cannula in the ante-cubital 
fossa. For each sample, the first 2.5 to 5 mL of blood was discarded so as to avoid 
including platelets potentially activated from cannulation. 
 
2.1.7.2 Assessment of platelet activation 
Platelet p-selectin expression and platelet-monocyte aggregates are sensitive markers of 
in vivo platelet activation. They are routinely used as markers of platelet activation in 
response to clinical conditions, stimuli or drugs [193–195]. In all experiments, platelet 
p-selectin expression and platelet-monocyte aggregates were determined by flow 
cytometry.  
 
Whole blood was collected into either D-phenylalanyl-L-propyl-L-arginine 
chloromethylketone (PPACK; Enzo Life Sciences, Exeter, UK; final concentration 750 
nM) or sodium citrate (final concentration 0.38%) then aliquoted into micro-centrifuge 
tubes pre-filled with or without agonist and the following conjugated monoclonal 
antibodies: allophycocyanin (APC)-conjugated CD14, phycoerythrin (PE)-conjugated 
CD62P and fluorescein isothiocyanate (FITC)-conjugated CD42a (Becton-Dickinson). 
All antibodies were diluted 1:10. For studies involving thrombin, Pefabloc FG (final 
concentration 1.5 mg/mL; Quadratech Diagnostics, Surrey, UK) was added prior to the 
addition of agonists. Thrombin stimulation can provoke extensive fibrin formation that 
precludes flow cytometry. Pefabloc FG prevents this but does not interfere with platelet 
activation. Protocol specific details are provided in each chapter. 
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Samples were incubated for 15-20 minutes at room temperature before fixing with 1 % 
paraformaldehyde (p-selectin) or FACS-Lyse (Becton-Dickinson; platelet-monocyte 
aggregates). All samples were analysed within 24 hours using a FACSCalibur flow 
cytometer (Becton-Dickinson). Data analysis was performed using FlowJo v10 
(Treestar, Oregon, USA). 
 
2.1.7.3 Assessment of platelet aggregation 
Blood samples were drawn uncuffed from the antecubital fossa through a 17-G needle 
into sodium citrate (final concentration 0.38%). To obtain platelet-rich plasma (PRP), 
samples were immediately centrifuged at 250-300 g (room temperature) for 15 minutes. 
Platelet-poor plasma (PPP) was obtained by centrifugation of 5 mL of PRP at 5000 g 
for 6 minutes. PRP and PPP were then stored in a water bath at 37 °C prior to use.  
 
Light transmission aggregometry (LTA) was performed with the 8-channel PAP-8E 
aggregometer (Bio/Data Corp, Horsham, PA, USA). Prior to each test, each channel 
was blanked for reference with 250 µL of PPP. Two hundred and twenty-five mL of 
PRP was added to a channel maintained at 37 °C followed by 25 µL of agonist. Peak 
aggregation was recorded at the end of 12-15 minutes. 
 
Ninety-six-well plate aggregometry was performed using a Synergy HT plate reader 
(Biotek). Immediately prior to each test, 11.1 µL of agonist was added to a well. Using 
a multi-pipette, 100 µL of PRP was added by reverse pipetting and the plate then 
immediately placed in the reader. Absorbance was determined at 595 nm every 15 s for 
12 minutes between vigorous shaking at 37 °C. Changes in absorbance were converted 
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to percentage aggregation by reference to the absorbances of PRP and PPP. Protocol 
specific details are provided in each chapter. 
 
2.1.8 Ex-vivo thrombus formation 
2.1.8.1 Badimon perfusion chamber 
 
Vessel wall injury and examination of the effects of antithrombotic agents on thrombus 
formation cannot be undertaken safely in vivo in humans. While such agents may alter 
biomarker measures of platelet activity (e.g. platelet aggregation) or coagulation, ex 
vivo thrombosis assays provide more detailed assessment of the potential effects on 
thrombus formation.  
 
For all experiments in this thesis, thrombus formation was assessed using the Badimon 
chamber (Figure 2.1). This is one of the most validated perfusion models for measuring 
the effect of study drugs on ex vivo human thrombus formation [196–203]. A major 
Figure 2.1. Schematic of the Badimon perfusion chamber 
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advantage of the Badimon chamber is that it permits assessment using whole blood 
without the need for anticoagulants. Study drugs can be administered orally or through 
an extracorporeal circuit thereby avoiding exposure of the volunteer to the study 
compound if desired or indicated. 
 
The Badimon chamber has been extensively described [196–203]. In brief, a pump is 
used to draw native blood from the antecubital vein directly through a series of three 
cylindrical perfusion chambers maintained at 37°C in a water bath. In all our 
experiments, each chamber contained a strip of porcine aorta from which the intima and 
a thin layer of media has been removed. Porcine aorta closely resembles the structure of 
a human artery and by removing the intima and a thin layer of media, the model 
represents one of vascular and deep arterial injury (e.g. plaque rupture). After the 
porcine strips are sited, warm saline (37°C) is drawn through each chamber. This serves 
to ensure each strip is at body temperature and that any loose surface material is 
removed. Next, blood is drawn through the chambers and as it flows across the strips, 
thrombus forms. At the end of the study, the strips are again washed with warm saline 
(37°C) for precisely 1 minute to remove any blood and unbound thrombus. The strips 
are then removed, sectioned and stained for thrombus quantification.  
 
Preparation of aortic strips 
The porcine aortic strips were prepared from whole untouched aorta (Pel-Freez 
Biologicals). First, the arch and distal aorta were removed along with any branches, 
excess perivascular adipose or other tissue. The prepared aorta was then opened out by 
incising rostral to caudal along the mid-anterior surface and strips cut using a template 
to ensure a standard size. Finally, each strip was carefully denuded by making a small 
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incision and removing the intima and a thin layer of media from rostral to caudal. Each 
strip was checked under a microscope to ensure there were no tears, flaps or loose 
tissue as this may lead to exaggerated thrombus formation.  
 
Rheological conditions 
Table 2.1. Shear rate   
Lumen diameter (mm) Blood flow (mL/min) Wall shear rate (s-1) 
1.0 5 840 
 10 1680 
 20 3360 
 30 5040 
 40 6720 
2.0 5 105 
 10 212 
 20 425 
 30 640 
 40 850 
 
Rheological conditions in the Badimon chamber can be altered to mimic different 
vascular compartments. In each study, flow conditions in the first chamber were set to 
simulate those of patent medium-sized arteries (inner lumen diameter, 2.0 mm; vessel 
wall shear rate, 212 s-1; mean blood velocity, 5.3 cm/s; Reynolds number: 30), whereas 
those in the second and third chambers were set to simulate those of mild to moderately 
stenosed coronary arteries (inner lumen diameter, 1.0 mm; vessel wall shear rate: 1690 
s-1; mean blood velocity, 21.2 cm/s; Reynolds number: 60). Shear conditions at the 
vessel wall were calculated from the theoretical expression for shear rate given for a 
Newtonian fluid in tube flow (Table 2.1) [204,205]. Each study lasted for exactly 5 
minutes during which flow was maintained at a constant rate of 10 mL/min. All studies 
were performed using the same perfusion chamber and by the same operator. 
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2.1.8.2 Histomorphometric analysis 
As thrombus forms along the entire length of the exposed porcine aortic strip, the mean 
transverse cross-sectional area gives a reliable reflection of total thrombus [206]. 
Following fixation, the proximal and distal 1 mm of the exposed substrate were 
discarded, and the remainder cut into eight segments. Individual segments were then 
embedded in paraffin wax from which 4-µm sections were prepared for 
histomorphometric analysis. 
 
Total thrombus area 
To detect total thrombus area, endogenous hydrogen peroxide activity was blocked 
using 3 % hydrogen peroxide solution (Leica Microsystems GmbH, Wetzlar, Germany) 
for 5 minutes. Sections were then incubated at room temperature for 1 hour with 
polyclonal rabbit anti-human fibrin(ogen) antibody (1.2 µg/mL, Dako, Glostrup, 
Denmark) and monoclonal mouse anti-human CD61 antibody (1.28 µg/ml, Dako). 
Antigen visualization was performed using a Bond Polymer refine detection kit (Leica 
Microsystems GmbH) and treatment with 3,3'-diaminobenzidine substrate chromogen 
(66 mM, Dako). Finally, sections were counterstained with a modified Masson’s 
trichrome (hematoxylin and sirius red 0.1 %). 
 
A semi-automated slide scanner (Axioscan Z1; Zeiss, Jena, Germany) and image 
analysis software (Definiens, Munich, Germany) were used to quantify total thrombus 
area. Digital images of each section were acquired at ×20 magnification. High-
resolution classifiers based on colour were established, allowing automated detection of 






Figure 2.2. Representative cross-section examples (x20 magnification) of thrombus 
formed at [A] low shear and [C] high shear in the Badimon perfusion chamber.  
High-resolution classifiers based on colour were established allowing automated 
detection of total thrombus area [B+D] with a high level of precision.  
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Fibrin- and platelet-rich thrombus area 
To examine the effect of study drug(s) on fibrin-rich and platelet-rich thrombus 
formation, endogenous hydrogen peroxide activity was blocked using 3 % hydrogen 
peroxide solution (VWR, Radnor, PA, USA) for 10 minutes and non-specific binding 
blocked using 20 % normal goat serum (Biosera, Nuaille, France) in Tris-Buffered 
Saline with 0.01% Tween (TBST)). Sections were then incubated with polyclonal rabbit 
anti-human fibrin(ogen) antibody (1.2 µg/mL) to detect fibrin and CD61 monoclonal 
mouse anti-human antibody (0.32 µg/mL) to detect platelets. Following TBST washes, 
goat anti-rabbit peroxidase (1:500; Abcam, Cambridge, UK) was applied and the 
presence of antigen visualized with Tyramide Cy3 (1:50; Perkin Elmer, Boston, MA, 
USA) and FITC (1:50; Perkin Elmer, Waltham, MA, USA) before nuclear 
counterstaining with DAPI (5 µg/mL; Sigma-Aldrich). 
 
As for detection of total thrombus formation, a semi-automated slide scanner (Axioscan 
Z1) and image analysis software (Definiens) were used to quantify thrombus 
composition. Digital images of each section were acquired at ×20 magnification. High-
resolution classifiers based on colour were established, allowing automated detection of 














Figure 2.3. Representative images of immunofluorescent staining of thrombus formed 
at high shear in the Badimon chamber.  
[A] Sections were stained with CD61 monoclonal mouse anti-human antibody to detect 
platelets (green) and polyclonal goat antihuman fibrin(ogen) antibody to detect fibrin (red) 
before nuclear counterstaining with DAPI (light blue. Channels were then split to allow 
quantification of [B] platelet-rich thrombus and [C] fibrin-rich thrombus. Digital images of 
each section were acquired at ×20 magnification. High-resolution classifiers based on colour 
were established, allowing automated detection of fibrin-rich and platelet-rich thrombus 
formation with a high level of precision. 
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Controls 
Prior to the first experimental sample, non-specific binding of the primary antibodies 
was excluded using tissue negative controls (perfusion chamber porcine sections 
exposed to saline rather than blood). To ensure staining for platelets and fibrin(ogen) 
was the result of detection of the intended antigen, secondary antibody controls (with 




2.2 ANIMAL STUDIES 
2.2.1 Animals 




Mice were housed in the animal unit of the University of Edinburgh and fed a diet of 
normal chow.  
 
2.2.3 Ethics 
All experiments were conducted in accordance with the UK Scientific Procedures Act 
1986 and had local institutional ethics approval. 
 
2.2.4 Dosing 
Fifteen mice exhibiting normal behaviour in the observation period were selected for 
dosing. Study drug (AYPGKF-NH2) or control (0.9% saline) was administered by 
intravenous tail vein injection.  
 
2.2.5 Observation and fate of mice 
Following study drug administration, mice were observed for 24 hours for signs of 
distress including pain, fever or abnormal behaviour. All mice were then sacrificed by 
intraperitoneal injection of Euthatal followed by withdrawal of the maximum volume of 
blood possible (via the abdominal vena cava or heart) directly into sodium citrate (final 
concentration 0.32% sodium citrate) and dissection. 
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2.2.6 Laboratory analyses 
Standard clinical chemistry assays for bilirubin, alanine transaminase (ALT), aspartate 
transaminase (AST), albumin, alkaline phosphatase, urea and creatinine were 
performed on whole blood.  
 
Creatinine 
Creatinine was determined using the creatininase / creatinase specific enzymatic 
method described by Börner and colleagues [207] utilising a commercial kit (Alpha 
Laboratories Ltd., UK) adapted for use on a Cobas Fara centrifugal analyser (Roche 
Diagnostics Ltd., UK). Within run coefficient of variation (CV) was < 3% while intra-
batch CV was < 5%. 
 
Urea 
Urea was determined by hydrolysis and measurement of NAD production (monitored at 
340 nm) in the presence of glutamate-dehydrogenase. The enzymatic method employed 
was a commercial kit from Alpha Laboratories Ltd. adapted for use on a Cobas Fara 
centrifugal analyser. Within run CV was < 3% while intra-batch CV was < 5%. 
 
Albumin 
Serum albumin measurements were determined using a commercial serum albumin kit 
(Alpha Laboratories Ltd.) adapted for use on a Cobas Fara centrifugal analyser. The 
measurement of serum albumin is based on its quantitative binding to bromocresol 
green (BCG). The albumin-BCG-complex absorbs maximally at 578 nm, the 
absorbance being directly proportional to the concentration in the sample. Within run 
CV was < 2.5% while intra-batch CV was < 4%. 
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Bilirubin 
Total bilirubin was determined by the acid diazo method described by Pearlman and 
Lee [208] using a commercial kit (Alpha Laboratories Ltd.) adapted for use on a Cobas 
Fara centrifugal analyser. In this method a surfactant is used as a solubiliser. 
Conjugated and solubilised unconjugated bilirubin react with diazotised sulphanilic acid 
to produce an acid azobilirubin, the absorbance of which (measured at 550 nm) is 
proportional to the concentration of bilirubin in the sample. Within run CV was < 4% 
while intra-batch precision was CV < 5%. 
 
Alanine Aminotransferase 
Alanine Aminotransferase (ALT) was measured using the method described by 
Bergmeyer and colleagues [209] utilising a commercial kit (Alpha Laboratories Ltd.) 
adapted for use on a Cobas Fara analyser. Within run CV was < 4% while intra-batch 
CV was < 8%. 
 
Aspartate Aminotransferase 
Aspartate Aminotransferase (AST) was determined by a commercial kit (Alpha 
Laboratories Ltd.) adapted for use on a Cobas Fara analyser. Alpha-oxogluterate reacts 
with L-aspartate in the presence of AST to form L-glutamate plus oxaloacetate. The 
indicator reaction utilises the oxaloacetate for a kinetic determination of NADH 
consumption. Within run CV was < 4% while intra-batch precision CV was < 5%. 
 
Alkaline Phosphatase 
Alkaline Phosphatase (ALP) was determined by a commercial kit (Alpha Laboratories 
Ltd.) adapted for use on a Cobas Fara analyser. In the presence of magnesium ions, the 
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substrate p-nitriphenyl phosphate is hydrolysed by ALP from the sample to form p-
nitophenol which is yellow in colour and can be monitored at 405 nm. Within run CV 
was < 4% while intra-batch CV was < 5%. 
 
2.2.7 Flow cytometry 
Quantification of total white cell count (WCC), monocyte count, neutrophil count, and 
platelet count was performed on whole blood using flow cytometry. Twenty µL 
samples were mixed with either 1 µL of each of the following antibodies CD45-AF488, 
CD11b-BV421, Ly6g-APC (BioLegend, San Diego, CA, US) for the detection of 
leucocytes, monocytes, and neutrophils respectively or 1 µL of CD42a-FITC (Becton-
Dickinson) for the detection of platelets. Samples were then fixed with FACS-Lyse and 
washed twice in Dulbecco's phosphate-buffered saline. 
 
White blood cells and platelets were identified based on forward and side scatter 
characteristics and the expression of CD45 and CD42a respectively. CD45+ cells were 
further gated with those positive for CD11b identified as monocytes and those positive 
for Ly6g identified as neutrophils. All samples were processed within 24 hours using 
the Accuri C6 flow cytometer (Becton-Dickinson) and analysed using FlowJo v10. 
platelets gated by characteristic forward and side scatter properties and CD42a 
expression using appropriate isotype controls.  
 
2.2.8 Histological analyses 
The lungs, liver, spleen and a single kidney were removed intact and fixed in 4 % 
paraformaldehyde for 24 hours at room temperature prior to being transferred into 70% 
ethanol for a further 24 hours. Following fixation, segments from each organ were 
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embedded in paraffin wax and 4-µm sections prepared. Sections were stained with 
haematoxylin and eosin for histological analysis. Digital images of each section were 
acquired at ×200 magnification using a semi-automated slide scanner (Axioscan Z1; 






Reproducibility and agreement between two 




3 Repeatability and agreement between two methods 
of platelet aggregation 
 
3.1 SUMMARY  
Background 
Light transmission aggregometry is the ‘gold standard’ for assessing platelet function 
but suffers from a number of technical limitations. Ninety-six-well plate aggregometry 
(96-WPA) offers practical advantages over LTA but to date there is limited data 
regarding test-retest repeatability and agreement between the two methods. 
 
Objective 
To determine the within-day (intra-assay) and between-day (inter-assay) repeatability of 
96-WPA and LTA as well as agreement between the two methods. 
 
Method and Results 
Repeatability was determined by pooling results from dose-response curves constructed 
for each agonist (adenosine diphosphate (ADP), arachidonic acid (AA), protease-
activated receptor 4-activating peptide (PAR4-AP)) repeated a) 7 times (within-day) or 
b) on 7 consecutive weekdays (between-day) in two volunteers. To examine agreement, 
dose-response curves for each agonist were compared in 10 volunteers. 96-WPA 
demonstrated good within- and between-day repeatability for the assessment of peak 
aggregation and EC50 in each of the agonists studied. Results were comparable to LTA, 
although the latter appeared marginally superior in terms of the between-day coefficient 
of variation. With respect to agreement, ADP and PAR4-AP peak aggregation 
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measured consistently higher with 96-WPA compared to LTA while the EC50 was 
consistently lower. No significant bias was observed with AA. 
 
Conclusion 
96-WPA demonstrated good within- and between-day repeatability for the assessment 
of peak aggregation and EC50 to various agonists with results comparable to LTA. 
However, there was a systematic measurement bias with two of the three agonists 




Platelet aggregometry plays a central role in the investigation and development of novel 
antithrombotic agents. The current ‘gold-standard’ technique for assessing platelet 
aggregation is light transmission aggregometry (LTA) [187]. However, LTA is 
considered technically challenging and can be restrictive in terms of the number of test 
conditions permitted per blood draw [190]. Ninety-six-well plate aggregometry (96-
WPA) is a newer method of platelet aggregation that may offer advantages over LTA, 
but there remain little data regarding the test-retest repeatability and agreement between 
the two techniques [190,191]. Accordingly, we sought to determine the within-day 
(intra-assay) and between-day (inter-assay) repeatability of 96-WPA and LTA as well 
as the agreement between the two methods. 
 
3.3 METHODS 
3.3.1 Study population 
Ten healthy non-smoking male and female volunteers between the ages of 18 and 40 
years (inclusive) were recruited. Exclusion criteria were any clinically significant 
coexisting condition including hypertension, hyperlipidaemia, diabetes mellitus, 
gastrointestinal disease, coagulopathy, known liver disease, and recent infective or 
inflammatory condition. Volunteers must not have been taking any prescription 
medications for 4 weeks, over-the-counter medications, herbal supplements and 




All patients provided written informed consent prior to any study procedure. The study 
was approved by the local ethics committee and conducted in accordance with the 
Declaration of Helsinki. 
 
3.3.2 Agonists 
Adenosine diphosphate (ADP) and the protease-activated receptor 4-activating peptide 
(PAR4-AP) AYPGKF-NH2 were purchased from Sigma-Aldrich (Gillingham, UK). 
Arachidonic acid (AA) was purchased from Alpha Laboratories (Eastleigh, UK). Each 
agonist was prepared at 7 different concentrations then aliquoted and frozen (-40°C) 
prior to the start of the study. 
 
3.3.3 Study protocol 
For each agonist, repeatability and agreement were determined for peak aggregation 
and EC50. The EC50 is the concentration of a drug that gives half-maximal response and 
is commonly used in research and clinical practice. Moreover, we hypothesised that 
because most agonist dose-response relationships are sigmoidal, the EC50 may be more 
sensitive than peak aggregation for the detection of variability. 
 
Blood sampling and preparation 
Blood samples (60 mL) were drawn uncuffed from the antecubital fossa through a 17-G 
needle into tri-sodium citrate (0.32% final concentration). For each sample, the first 5 
mL of blood was discarded. To obtain PRP, samples were immediately centrifuged at 
300 g (room temperature) for 20 minutes. PPP was obtained by centrifugation of 5 mL 
of PRP at 5000 g for 6 minutes. PRP and PPP were then stored in a water bath at 37°C 




Dose-response curves for each agonist were repeated 7 times in two different 
volunteers. Replicates for both instruments were performed at the same time and from 
the same preparation of PRP and platelet-poor plasma (PPP). All sample preparation 
and tests were undertaken by the same operator. All testing was completed within 115 
minutes of blood withdrawal.  
 
Time since sampling is known to affect platelet function beyond a certain limit 
[194,195]. To examine whether this had influenced our results, within-day changes in 
peak aggregation and EC50 for replicate 7 were compared to replicate 1. 
 
Between-day repeatability 
Dose-response curves for each agonist were repeated on 7 consecutive weekdays at   
the same time of day (± 1 hour) in two different volunteers.  Each replicate for both 
instruments was performed at the same time and from the same preparation of PRP and 
PPP. All sample preparation and tests were undertaken by the same operator.  All 
testing was completed within 115 minutes of blood withdrawal. 
 
Agreement 
To examine the agreement between the two techniques, dose-response curves for each 
agonist were determined in both instruments at the same time and from the same 
preparation of PRP and PPP in 10 volunteers. All testing was completed within 115 
minutes of blood withdrawal. 
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3.3.4 Platelet aggregation 
Light transmission aggregometry 
LTA was performed with the 8 channel PAP-8E aggregometer (Bio/Data Corp, 
Horsham, PA, USA). Prior to each test, each channel was blanked for reference with 
250 µL of PPP. Two hundred and twenty-five µL of PRP was added to a channel 
maintained at 37°C followed by 25 µL of agonist. The 7 different concentrations of 
each agonist were studied simultaneously. Peak aggregation was recorded at the end of 
12 minutes. 
 
96-well plate aggregometry 
Immediately prior to each test, 11.1 µL of agonist was added to a well. The 7 different 
concentrations of each agonist were studied simultaneously. Using a multi-pipette, 100 
µL of PRP was added by reverse pipetting and the plate then immediately placed in the 
reader (Biotek, Synergy HT plate reader). Absorbance was determined at 595 nm every 
15 s for 12 minutes between vigorous shaking at 37 °C. Changes in absorbance were 
converted to percentage aggregation by reference to the absorbances of PRP and PPP. 
 
3.3.5 Statistical analysis  
Peak aggregation from each test was used to plot agonist dose-response curves using a 
four-parameter logistic model (GraphPad v7.0e; GraphPad Software Inc, CA, USA) 
from which the EC50 was determined. To assess repeatability, the standard deviation 
(SD), coefficient of variation (CV) and coefficient of repeatability (CR) were examined. 
CR quantifies absolute measurement error in the same units as the test result and was 
calculated by multiplying the standard error of measurement (√∑σ/n) by 2.77. 
Agreement between methods was determined by plotting the difference in peak 
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aggregation or EC50 for each agonist against the mean according to the method of Bland 
and Altman [210]. A paired t-test was used to determine if the estimated biases were 





3.4.1 Within-day temporal changes in peak aggregation and EC50 
96-WPA 
Mean peak aggregation with ADP (20 µM), AA (2 mM) and PAR4-AP (400 µM) were 
75.8%, 85.4%, and 89.1% for replicate 1 and 77.4%, 83.1% and 87.4% for replicate 7 
respectively. The corresponding mean EC50 were 0.74 µM, 242.8 mM, and 81.3 µM for 
replicate 1 and 0.84 µM, 242.4 mM, and 85.3 µM for replicate 7 respectively. 
 
LTA  
Mean peak aggregation with ADP (20 µM), AA (2 mM) and PAR4-AP (400 µM) was 
67.5%, 80.0%, and 80.5% for replicate 1 and 68.5%, 76.0% and 76.0% for replicate 7 
respectively. The corresponding mean EC50 were 1.18 µM, 247.0 mM, and 99.0 µM for 
replicate 1 and 1.10 µM, 247.4 mM, and 94.1 µM for replicate 7 respectively.  
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Figure 3.1. Within- and between-day dose-response curves for each replicate (n=7) 
by agonist studied. 
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Dose-response curves for each replicate and within-day measures of test-retest 
repeatability are presented in Figure 3.1 and Table 3.1, respectively. LTA and 96-WPA 
demonstrated good and comparable within-day measures of repeatability with each 
agonist for both peak aggregation and EC50. The mean EC50 CRs for ADP, AA, and 
PAR4-AP were 0.19 µM, 32.8 µM, and 19.8 µM for LTA and 0.19 µM, 40.7 µM, and 
14.1 µM for 96-WPA, indicating that a change above these values would be sufficient 
to be 95% confident that a true change had occurred (Table 3.1). 
 
 
Table 3.1.  Within-day measures of repeatability 
 Light transmission aggregometry 96-well plate aggregometry 
Peak Aggregation Mean, % SD CV CR Mean, % SD CV CR 
ADP 68.8 3.8 5.4 9.7 76.1 2.6 3.4 6.6 
AA 77.8 3.0 3.8 7.6 84.1 3.0 3.6 8.4 
PAR4-AP 76.5 2.9 3.8 7.5 87.0 3.0 3.6 7.8 
         
EC50 Mean, µM SD CV CR Mean, µM SD CV CR 
ADP 1.22 0.07 5.8 0.19 0.77 0.07 9.6 0.19 
AA 234.2 12.8 5.3 32.8 232.3 15.9 7.1 40.7 
PAR4-AP 97.8 7.7 7.9 19.8 81.1 5.5 6.9 14.1 
SD indicates standard deviation; CV, coefficient of variation (%); CR, coefficient of repeatability; ADP, 




3.4.3 Between-day repeatability 
 
Table 3.2.  Between-day measures of repeatability 
 Light transmission aggregometry 96-well plate aggregometry 
Peak Aggregation Mean, % SD CV CR Mean, % SD CV CR 
ADP 67.9 3.5 5.1 8.9 72.7 6.2 8.7 17.3 
AA 75.1 3.7 4.9 9.4 82.2 4.4 5.4 11.3 
PAR4-AP 76.1 6.1 8.0 15.6 83.4 5.5 6.6 14.0 
         
EC50 Mean, µM SD CV CR Mean, µM SD CV CR 
ADP 1.29 0.26 20.1 0.66 0.73 0.17 23.4 0.43 
AA 242.9 37.6 16.1 96.6 252.2 67.1 28.5 172.1 
PAR4-AP 107.8 19.7 18.6 50.6 84.7 19.5 23.1 49.9 
SD indicates standard deviation; CV, coefficient of variation (%); CR, coefficient of repeatability; ADP, 
adenosine diphosphate; AA, arachidonic acid; and PAR4 AP, protease-activated receptor 4 activating peptide. 
 
Dose-response curves for each replicate are presented in Figure 3.1. Compared to LTA, 
96-WPA was generally associated with a numerically less favourable coefficient of 






 Figure 3.2. Bland-Altman plots 
Bland-Altman plots by agonist examining agreement between LTA and 96-WPA for peak 
aggregation [A, C, E] and EC50 [B, D, F].  
 
 


























































































































































Table 3.3.  Agreement between LTA and 96-WPA 
 Bias* 95% CI LLOA 95% CI ULOA 95% CI 
Peak Aggregation       
ADP -7.5 -10.6, -4.4 -16.0 -21.3, -10.6 1.0 -4.4, 6.4 
AA -1.2 -15.0, 12.6 -39.1 -63.0, 15.2 36.6 12.7, 60.6 
PAR4-AP -11.2 -14.8, -7.5 -21.1 -27.4, -14.8 -1.24 -7.5, 5.0 
EC50       
ADP 0.32 0.18, 0.45 -0.05 -0.28, 0.18 0.68 0.45, 0.91 
AA 8.6 -52.2, 69.3 -157.9 -263.2, -52.7 175.1 69.8, 280.3 
PAR4-AP 27.5 19.0, 35.9 4.3 -10.3, 19.0 50.6 36.0, 65.2 
*LTA minus 96-WPA. CI indicates confidence interval; LLOA, lower limit of agreement; ULOA, upper limit of 
agreement; ADP, adenosine diphosphate; AA, arachidonic acid; and PAR4 AP, protease-activated receptor 4 
activating peptide. 
 
Bland-Altman plots for measurement agreement between LTA and 96-WPA are 
presented in Figure 3.2 with bias and limits of agreement in Table 3.3. Compared to 
LTA, peak aggregation measured consistently higher with 96-WPA for ADP (bias 
7.5%, p <0.001) and PAR4-AP (bias 11.2%, p <0.001), and the EC50 measured 
consistently lower (ADP bias 0.32 µM, p <0.001; PAR-AP bias 27.5 µM, p <0.001). 
The bias appeared constant for both ADP and PAR4-AP over the range of peak 
aggregation and EC50 measured.  
 
Individual point differences between LTA and 96-WPA for EC50 with AA were spread 
around the line of equality indicating an absence of a systematic difference (bias 8.6 
µM, p = 0.76). For peak aggregation, the bias was small and not significant (-1.2%, p = 





We examined the test-retest repeatability and agreement of 96-WPA and LTA for the 
determination of peak platelet aggregation and EC50 with 3 common agonists. The main 
findings were a) 96-WPA demonstrated good within- and between-day repeatability 
with comparable results to LTA, but that b) there was a systematic measurement bias 
for 2 out of 3 of the agonists studied and the two methods should not be considered 
interchangeable.  
 
96-WPA offers practical advantages over LTA but to date there are limited data 
regarding test-retest repeatability. With respect to within-day precision of 96-WPA, we 
found an absolute change in peak aggregation of 6.6%, 7.8% and 8.7% in response to 
ADP, AA and PAR4-AP, respectively, would be sufficient to be 95% certain a true 
change had occurred. For EC50, the corresponding values were 0.14 µM, 40.7 µM, and 
14.1 µM. These results along with other measures of repeatability were similar to those 
obtained with LTA. Changes in peak platelet aggregation and EC50 induced by 
clinically relevant compounds are typically more than 50% or one order of magnitude 
[191,211–213]. Thus, under the experimental conditions of the study, we conclude that 
both 96-WPA and LTA demonstrated good and equivocal intra-assay repeatability.  
 
Outcome measures for between-day test-retest repeatability were less favourable for 
both 96-WPA and LTA, especially for EC50. One possible explanation is greater 
between-day analytical imprecision. However, as between-day repeatability also takes 
into account pre-analytical and biological factors, other sources are likely to contribute. 
These include blood sampling and centrifugation as well as temporal changes in an 
individual’s platelet reactivity. Irrespective of the cause, between-day repeatability 
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remained good with respect to the magnitude of change that can be detected. 
Comparing methods, results for 96-WPA were largely similar to LTA, although LTA 
appeared marginally superior in terms of the coefficient of variation.  
 
An interesting finding was that both ADP and PAR4-AP peak aggregation measured 
consistently higher with 96-WPA compared to LTA, while the EC50 was consistently 
lower. No significant differences occurred with AA, although for peak aggregation 
examining a greater range of values is recommended as the bias may not have been 
constant. 96-WPA uses polystyrene or polypropylene wells with shaking to promote 
mixing and platelet aggregation. Effects are determined by alterations in light 
absorbance. In contrast, LTA uses a glass cuvette and stir bar with aggregation 
measured by changes in light transmission. Our observations suggest these, or other 
technical differences, may have differential and agonist-specific effects on platelet 
reactivity. This requires further evaluation but ultimately results from this study 
indicate 96-WPA and LTA should not be considered interchangeable. 
 
3.6 LIMITATIONS 
Inclusion of a greater number of replicates or broader range of agonists would have 
been desirable and feasible if assessment of precision had been limited to peak 
aggregation only. However, we felt it was important to include EC50 as this is a central 
parameter and as hypothesised proved more sensitive to the detection of variability. 
Platelet reactivity is known to decline after a period of time, potentially affecting our 
results. To mitigate this, all processing was completed within the pre-determined 115-
minute time limit (based on in-house data) and importantly there were no notable 
differences in platelet responses between first and last replicates. The intensive study 
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protocol imposed limitations in terms of the number of volunteers that could be 
included. In order to provide greater certainty of the intra- and inter-assay precision of 
96-WPA, data should be pooled from a larger study population. 
 
3.7 CONCLUSION 
96-WPA demonstrated good within- and between-day repeatability for the assessment 
of peak aggregation and EC50 with results comparable to LTA. However, there was a 
systematic measurement bias with two of the three agonists studied and the two 
methods should not be considered interchangeable. Given the lack of published 
reference data for 96-WPA and absence of superiority in terms of precision we intend 
to use LTA for the remainder of this thesis. We do though support use of 96-WPA, 
especially when examining a large number of test conditions is paramount or compound 
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4 Dependence of PAR4 on other agonist-receptor 





Protease-activated receptor 4 (PAR4) antagonists have shown promise in animal studies 
for the prevention of atherothrombotic events. However, whether platelet responses 
coupled to PAR4 are dependent on signaling from other agonist-receptor pathways or 
vice-versa remains uncertain. This may have important therapeutic implications. 
 
Objective 
To examine if platelet activation and peak aggregation coupled to PAR4 stimulation is 
conditional on reinforcement from other major agonist-receptor pathways and vice-
versa. 
 
Method and Results 
All studies were performed in vitro using blood from healthy volunteers not taking any 
medication. Platelet activation was determined by p-selectin expression and platelet-
monocyte binding using flow cytometry. Peak platelet aggregation was determined by 
light transmission aggregometry. Results were pooled from a minimum of 6 volunteers. 
Activation of platelets by PAR4-AP (25 µM) resulted in strong p-selectin expression 
(86.5% ± 2.6), platelet-monocyte binding (85.8% ± 1.5) and platelet aggregation 
(88.5% ± 3.4). Platelet responses to PAR4-AP were completely attenuated by the PAR4 
antagonist BMS-986120 but were unaffected by SCH-79797 (PAR1 antagonist), 
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apyrase (ADP scavenger) or indomethacin (cyclooxygenase inhibitor). In contrast, 
PAR1 platelet activation and aggregation were both partially inhabited by apyrase. 
BMS-986120 had no effect on platelet activation or aggregation in response to PAR1, 
ADP or AA stimulation.  
 
Conclusions 
Our results demonstrate that under conditions designed to mimic thrombin levels found 
within the local environment of a developing clot, platelet responses to PAR4 
stimulation are not dependent on input from PAR1, ADP or AA. Equally, platelet 
responses to PAR1, ADP or AA stimulation were not affected by PAR4 inhibition. This 
lack of functional overlap highlights the potential of targeting PAR4 as a promising 





Platelet aggregation is central to thrombus formation and a major contributor to 
atherothrombotic disease [11]. Protease-activated receptor 4 (PAR4) is a thrombin 
activated G-protein coupled receptor present on the surface of platelets [115]. PAR4 
stimulation results in marked platelet activation and aggregation with recent evidence 
suggesting PAR4 inhibition may provide safer and more effective antithrombotic 
protection than current agents [114,129–131]. However, whether PAR4-coupled 
platelet responses are conditional on input from other major agonist-receptor pathways 
or vice-versa remains uncertain. This may have important therapeutic implications. 
Accordingly, we sought to examine the interaction between PAR4 and other major 
receptor-agonist pathways for the activation and aggregation of platelets.   
 
4.3 METHODS 
4.3.1 Study aims 
The primary objectives were to determine a) if PAR4-coupled platelet responses are 
dependent on adenosine diphosphate (ADP), thromboxane A2 or PAR1 signaling, and 
compare this to PAR1, and b) if platelet responses coupled to ADP, thromboxane A2 or 
PAR1 are dependent on PAR4.  
 
4.3.2 Study population 
Healthy non-smoking male and female volunteers between the ages of 18 and 40 years 
(inclusive) were recruited. Exclusion criteria were any clinically significant coexisting 
condition including hypertension, hyperlipidaemia, diabetes mellitus, gastrointestinal 
disease, coagulopathy, known liver disease, and recent infective or inflammatory 
condition. Volunteers must not have been taking any prescription medications for 4 
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weeks, over-the-counter medications, herbal supplements and vitamins for 1 week, and 
alcohol or caffeine containing products for 24 hours prior to blood sampling. 
 
All patients provided written informed consent prior to any study procedure. The study 
was approved by the local ethics committee and conducted in accordance with the 
Declaration of Helsinki. 
 
4.3.3 Materials 
Adenosine diphosphate (ADP), indomethacin (a cyclooxygenase inhibitor) and apyrase 
(an ADP scavenger) were purchased from Sigma-Aldrich (Gillingham, UK), 
arachidonic acid (AA) from Alpha Laboratories (Eastleigh, UK), SCH-79797 (a 
selective PAR1 antagonist) from Tocris (Abingdon, UK) and tirofiban (a GPIIb/IIIa 
antagonist) from Beacon Pharmaceuticals (Swadlincote, UK). PAR4-activating peptide 
(PAR4-AP; A-Phe(4-F)-PGWLVKNG), PAR1-AP (SFLLRN) and BMS-986120 
(PAR4 antagonist) were courtesy of Bristol-Myers Squibb (Princeton, USA). All 
compounds were dissolved in either phosphate-buffered saline (PBS; ADP, SCH-
79797, tirofiban, PAR4-AP and PAR1-AP), de-ionised water (AA) or dimethyl 
sulphoxide (indomethacin and BMS-986120) and stored in frozen aliquots (-40°C) prior 
to the start of the study. On the day of the study, indomethacin and BMS-986120 were 
diluted to their target concentrations with phosphate-buffered saline and platelet-poor 
plasma, respectively.  
 
4.3.4 Compound concentration selection 
Concentrations of PAR4-AP and PAR1-AP were selected to reflect higher thrombin 
levels present during thrombosis with all agonist concentrations chosen to achieve near 
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maximum platelet responses while at the same time avoiding excessive dosing given 
this can mask the effects of antagonists on non-cognate pathways. A similar approach 
was applied to antagonists. Based on in-house data and consistent with other 
publications [214], the following compound concentrations were selected: PAR4-AP, 
25 µM; PAR1-AP, 25 µM; ADP, 10 µM; AA 5 mM; BMS-986120, 200 nM; SCH-
79797, 64 µM; tirofiban, 400 nM; apyrase, 2 U/mL; and indomethacin, 20 µM. 
 
4.3.5 Blood sampling and preparation 
Blood samples (60 mL) were drawn uncuffed from the antecubital fossa through a 17-G 
needle into tri-sodium citrate (0.32% final concentration). For each sample, the first 5 
mL of blood was discarded. To obtain PRP, samples were immediately centrifuged at 
300 g (room temperature) for 20 minutes. PPP was obtained by centrifugation of 5 mL 
of PRP at 5000 g for 6 minutes. PRP and PPP were then stored in a water bath at 37°C 
prior to use.  
 
4.3.6 Aggregometry 
Platelet aggregation was determined by aggregometry using an 8 channel PAP-8E 
aggregometer (Bio/Data Corp, Horsham, PA, USA). Prior to each test, each channel 
was blanked for reference with 250 µL of PPP. Two hundred and twenty-five mL of 
PRP and either 12.5 µL of antagonist or control (PBS) were added to a channel 
maintained at 37°C and allowed to incubate for 5 minutes before spiking with 12.5 µM 
of agonist or control (PBS). Peak aggregation was recorded at the end of 12 minutes. 
All testing was completed within 60 minutes of blood draw. Results were pooled from a 
minimum of 6 volunteers. 
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4.3.7 Flow cytometry 
Platelet activation was assessed by p-selectin expression and platelet-monocyte 
aggregates using flow cytometry. These are sensitive measures of platelet degranulation 
and widely used markers of platelet activation [193–195]. Blood (5 mL) was collected 
into 50 µL of 75 mM D-phenylalanyl-L-propyl-L-arginine chloromethylketone 
(PPACK; Enzo Life Sciences, Exeter, UK) then immediately aliquoted into micro-
centrifuge tubes pre-filled with control (PBS) or antagonist and allowed to incubate for 
5 minutes before spiking with agonist or control (PBS) and the following conjugated 
monoclonal antibodies: allophycocyanin (APC)-conjugated CD14, phycoerythrin (PE)-
conjugated CD62P and fluorescein isothiocyanate (FITC)-conjugated CD42a (Becton-
Dickinson). All antibodies were diluted 1:10. Samples were incubated for a further 20 
minutes at room temperature before fixing with 1 % paraformaldehyde (p-selectin) or 
FACS-Lyse (Becton-Dickinson; platelet-monocyte aggregates). A FACSCalibur flow 
cytometer (Becton-Dickinson) was used with all samples processed within 24 hours. 
Data analysis was performed using FlowJo v10 (Treestar, Oregon, USA). Results were 
pooled from a minimum of 6 volunteers. 
 
4.3.8 Statistical analysis  
Unless otherwise stated, data is presented as mean ± standard deviation (SD) for 
continuous variables and percentages with counts for categorical variables. A one-way 
ANOVA with Dunnett’s or Sidak’s multiple comparisons test were used to determine if 
the differences in mean platelet responses were significant. Two-sided p-values of 
≤0.05 were considered statistically significant. Analyses were performed using R 


































































** ** ns ns nsns
[A] P-Selectin Expression
[B] Platelet-Monocyte Binding
Figure 4.1. Plots of PAR4-AP stimulated platelet activation in the presence or absence 
of antagonists. 
Data shown are the mean [A] p-selectin and [B] PMB responses with standard deviation 
(n=6). Statistical comparisons (Dunnett’s multiple comparison test) versus PAR4-AP are 
shown above each plot: * p<0.05, ** p<0.01, *** p<0.001. Abbreviations used: PMB, 
platelet monocyte binding; BMS, BMS-986120; SCH, SCH-79797; Indo, indomethacin; and 
Tiro, tirofiban.  
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Activation of platelets by PAR4-AP (25 µM) resulted in strong p-selectin expression 
(86.5 ± 2.6%) and platelet-monocyte binding (85.8 ± 1.5%). BMS-986120 potently 
inhibited PAR4-AP platelet activation (absolute difference (ê) for p-selectin -78.3%, 
p<0.001; PMB ê-44.8%, p<0.01). In contrast, SCH-79797 (p-selectin ê1.8%, p=0.7; 
PMB ê-4.8%, p=0.7), apyrase (p-selectin ê-4.5, p=0.6; PMB ê-6.0%, p=0.1), 
indomethacin (p-selectin ê-2.3%, p=0.3; PMB ê-6.0%, p=0.07) and tirofiban (p-
selectin ê0%, p=1.0; PMB ê-2.5%, p=0.5) had no effect on PAR4-AP stimulated 
platelet activation (Figure 4.1). 
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PAR4-AP (25 µM) resulted in strong platelet aggregation (88.5 ± 3.4%) and was 
potently inhibited by both BMS-986120 (absolute difference (ê) -86.5%, p<0.001) and 
tirofiban (ê-88.5%, p<0.001; Figure 4.2). SCH-79797 (ê0.25%, p=1.0), apyrase (ê-
1.0%, p=0.97) and indomethacin (ê0.8%, p=0.96) had no effect on PAR4-stimulated 


































*** *** ns ns ns ***
Figure 4.2. Plots of PAR4-AP stimulated platelet aggregation in the presence or 
absence of antagonists. 
Data shown are the mean max platelet aggregation responses ± standard deviation (n=6). 
Statistical comparisons (Dunnett’s multiple comparison test) versus PAR4-AP are shown 
above each plot: * p<0.05, ** p<0.01, *** p<0.001. Abbreviations used: BMS, BMS-
986120; SCH, SCH-79797; and Indometh., indomethacin. 
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** ***ns ns ns**
Figure 4.3. Plots of PAR1-AP stimulated platelet activation in the presence or absence 
of antagonists. 
Data shown are the mean [A] p-selectin and [B] PMB responses with standard deviation 
(n=6). Statistical comparisons (Dunnett’s multiple comparison test) versus PAR1-AP are 
shown above each plot: * p<0.05, ** p<0.01, *** p<0.001. Abbreviations used: PMB, 
platelet monocyte binding; BMS, BMS-986120; SCH, SCH-79797; and Indo, indomethacin. 
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PAR1-AP (25 µM) resulted in strong p-selectin expression (85.0 ± 6.1%) and platelet-
monocyte binding (80.5 ± 3.1%; Figure 4.3). Responses to PAR1-AP were potently 
inhibited by SCH-79797 (absolute difference (ê) for p-selectin -73.5%, p=0.002; PMB 
ê-40.8%, p<0.001) but not affected by coadministration of BMS-986120 (p-selectin 
ê0.5%, p=1.0; PMB ê-0.8%, p=1.0), apyrase (p-selectin ê-3.0, p=0.6; PMB ê-
2.8%, p=0.3) or tirofiban (p-selectin ê0.8%, p=1.0; PMB ê0%, p=1.0). In contrast to 
PAR4 stimulation, the ADP scavenger apyrase appeared to attenuate platelet activation 
to PAR1-AP. This effect was not statistically significant for p-selectin expression (ê-












PAR1-AP (25 µM) resulted in strong platelet aggregation (79.8 ± 2.5%) that was 
potently inhibited by both SCH-79797 (absolute difference (ê) -77.8%, p<0.001) and 
tirofiban (ê-78.8%, p<0.001; Figure 4.4). As with platelet activation, PAR1-AP 
platelet aggregation was not affected by BMS-986120 (ê-0.25%, p=1.0) or 


































*** ***ns ns ****
Figure 4.4. Plots of PAR4-AP stimulated platelet aggregation in the presence or 
absence of antagonists. 
Data shown are the mean max platelet aggregation responses with standard deviation 
(n=6). Statistical comparisons (Dunnett’s multiple comparison test) versus PAR1-AP are 
shown above each plot: * p<0.05, ** p<0.01, *** p<0.001. Abbreviations used: BMS, 
BMS-986120; SCH, SCH-79797; Indo, indomethacin; and Tiro, tirofiban.  
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PAR4 antagonism with BMS-986120 resulted in potent inhibition of PAR4-AP 
stimulated p-selectin expression (absolute difference (ê) -76.8%, p<0.001), platelet-
monocyte binding (ê-44.3%, p<0.001) and platelet aggregation (ê-83.2%, p<0.001) 
but had no effect on platelet responses to PAR1-AP, ADP or AA stimulation (p=ns for 


























Unstim. PAR4-AP PAR1-AP ADP AA
[C] Platelet Aggregation
Figure 4.5. Plots of agonist-stimulated platelet responses in the presence or absence of 
PAR4 antagonism. 
Data shown are the individual points for [A] p-selectin expression [B] PMB and [C] max 
platelet aggregation responses with mean and standard deviation (n=6). Statistical 
comparisons (Sidak’s multiple comparison test) for BMS-986120 versus no BMS-986120 
are shown for each agonist above the corresponding plot: * p<0.05, ** p<0.01, *** 
p<0.001. Abbreviations used: ADP, adenosine diphosphate; AA, arachidonic acid; and 
PMB, platelet-monocyte binding. 
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4.5 DISCUSSION 
We conducted a panel of studies to determine if platelet responses coupled to PAR4 
activation are contingent on input from other major agonist-receptor pathways and vice 
versa. The principal findings were that observed platelet responses to a) PAR4 
stimulation were not dependent on PAR1, ADP or thromboxane A2 signaling, b) PAR1, 
ADP and thromboxane A2 stimulation were not dependent on PAR4 signaling, and c)  
PAR1 stimulation were not dependent on PAR4 or thromboxane A2 signaling but were 
partially attenuated by ADP inhibition.  
 
There is conflicting evidence as to whether platelet activation and aggregation 
responses to PAR signaling are conditional on additional input. Dawood and colleagues 
found that both PAR1- and PAR4-coupled platelet responses were dependent on 
thromboxane A2 and ADP signaling [214] with similar findings reported elsewhere 
[215]. Adam and colleagues observed that only PAR1-mediated platelet activation was 
reliant on feedback and from ADP alone [216], whereas Holinstat and colleagues 
demonstrated the reverse to be true [217]. 
 
We selected agonist concentrations of PAR4-AP to mimic thrombin levels within the 
local environment of a developing clot. Under these conditions, PAR4-stimulated 
platelet activation and peak aggregation were unaffected by inhibition of PAR1, ADP 
and thromboxane A2 signaling. This apparent lack of co-dependence on other major 
agonist-receptor pathways is consistent with evidence PAR4 activation occurs well 
after platelet degranulation [130] and induces sustained intracellular Ca2+ and protein 
kinase C signals independent of additional support [114,129,130]. PAR4 is thought to 
be an attractive target for antiplatelet therapy because of its more selective role toward 
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the later stages of platelet activation involved in thrombus stabilisation and propagation. 
Our results add to this, identifying PAR4 signaling as a major mechanism through 
which pathological platelet activation and aggregation can continue despite current 
standard of care antiplatelet agents.  
 
In contrast to PAR4, PAR1-coupled platelet activation and aggregation were attenuated 
by the ADP scavenger apyrase. Previous studies have demonstrated ADP to be of major 
importance for platelet responses induced by low but not high thrombin concentrations 
[218–220]. Our results are consistent with this given PAR1 is cleaved by sub-
nanomolar concentrations of thrombin whereas PAR4 is active at higher protease 
concentrations [114]. [218–220]Collectively these data strongly support that PAR1 
platelet signaling is reinforced by ADP feedback and that the clinical effect of P2Y12 
antagonists may partly relate to PAR1 inhibition. Indeed, in patients taking clopidogrel, 
platelet aggregation to PAR1 stimulation has been shown to be inversely correlated to 
the degree of P2Y12 inhibition [221]. 
 
Examination of the platelet effects of PAR4 inhibition has previously been limited by a 
lack of antagonist availability and specificity [117,141,222]. BMS-986120 is a first in 
class, potent and highly selective PAR4 antagonist [131,146]. Compared to earlier 
compounds, including P4pal-10, YD-3 and ML354, BMS-986120 has antiplatelet 
activity against alpha thrombin and demonstrated greater potency and selectivity of 
effect in preclinical studies [133,141,223]. PAR4 inhibition with BMS-986120 resulted 
in near complete inhibition of both PAR4-AP mediated platelet activation and 
aggregation but had no effect on platelet responses to other tested agonists. Thus, we 
add to existing evidence that BMS-986120 is PAR4 specific and demonstrate that 
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platelet activation and aggregation to ADP, thromboxane A2 and PAR1 stimulation is 
not dependent on PAR4 signaling. 
 
4.6 LIMITATIONS 
Agonist doses were selected to provide the most clinically relevant results. While 
inclusion of a broader range of agonist and antagonist concentrations would have been 
desirable, we believe it unlikely this would have altered our principal findings at the 
cost of a major impact on study feasibility. All tests were performed in vitro and in 
healthy volunteers. Future studies should examine the interaction between PAR4 and 
other agonist-receptor pathways ex vivo and in patients taking one or more of the 
current antiplatelet agents. 
 
4.7 CONCLUSION 
Under conditions designed to approximate clinically relevant levels of thrombin, 
platelet responses to PAR4 stimulation were not dependent on input from other major 
agonist-receptor pathways and vice-versa. This lack of functional overlap adds to 
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5 Safety and tolerability of systemic PAR4 agonism in 
mice 
 
5.1 SUMMARY  
Background 
Targeting protease-activated receptor 4 (PAR4) has emerged as a promising new 
antiplatelet strategy. PAR4 is also expressed on human vascular endothelium and 
smooth muscle cells but its function remains to be established.  
 
Objective 
To examine the safety and tolerability of the PAR4-activating peptide AYPGKF-NH2 
given intravenously to mice so as to enable future studies into the in vivo vascular 
effects of PAR4 in man. 
 
Method and Results 
Male Rodentia mice aged 10 to 12 weeks were fed a diet of normal chow and observed 
for 1 week. Fifteen mice exhibiting normal behaviour were selected and administered 
low (systemic concentration 11.25 µM) or high dose (systemic concentration 112.5 
µM) AYPGKF-NH2, or control (0.9% saline), via tail vein injection (5 mice per group). 
Mice were observed for 24 hours then sacrificed for necropsy. AYPGKF-NH2 was well 
tolerated with no notable adverse effects including fever, pain, distress or abnormal 
behaviour. Compared to control, AYPGKF-NH2 was not associated with change in any 
of the haematological, inflammatory, hepatic and renal blood markers examined. No 
distortion of parenchymal architecture, necrosis or inflammatory cell infiltrate was 
observed on histological analysis of the lungs, spleen, liver or kidney. 
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Conclusion 
In mice, systemic administration of the PAR4 activating peptide AYPGKF-NH2 was 
well tolerated with no evidence of acute toxicity, inflammation or organ injury. Our 








Previous studies have shown that PAR1 stimulation elicits a number of important 
vascular effects beyond platelet activation and aggregation. These include resistance 
vessel vasodilatation, venoconstriction, smooth muscle cell proliferation and 
maintenance of normal endothelial integrity [27,147,148]. PAR4 is also expressed on 
vascular smooth muscle cells and the endothelium but to date there have been no in 
vivo studies in man [151–153]. Data from animal studies suggests PAR4 may be 
involved in the control of vascular tone, ischaemia-reperfusion injury and the 
exaggerated intimal hyperplasia seen in diabetic conditions [137,154–156]. However, 
inter-species differences in PAR function and activation [157,158] may limit 
extrapolation of these results to man and the wider role of PAR4 within the human 
vasculature essentially remains unknown. 
 
Like PAR1, the vascular actions of PAR4 may be diverse and such effects may mitigate 
or enhance the effectiveness of PAR4 inhibitors as future antiplatelet agents. While a 
number of highly specific PAR4 agonists are readily available, there have been no 
reports of such compounds being administered to man. Given the multi-tissue and 
multi-organ distribution of PAR4, including inflammatory cells, lung, kidneys and liver 
[159,160,163,164,166], it would be essential to first examine the effects of systemic 
PAR4 agonism in animals prior to undertaking in vivo studies in man. Accordingly, we 
set out to examine the safety and tolerability of the PAR4-activating peptide (PAR4-
AP) AYPGKF-NH2 given intravenously to mice with the aim of enabling future 





5.3.1 Study objectives 
To determine the safety and tolerability in mice of AYPGKF-NH2 administered 
intravenously at low and suprathreshold doses as compared to control. All experiments 
were conducted in accordance with the UK Scientific Procedures Act 1986 and had 
local institutional ethics approval. 
 
5.3.2 AYPGKF-NH2 
AYPGKF-NH2 (Ala-Tyr-Pro-Gly-Lys-Phe-NH2) is a PAR4-AP based on the native 
PAR4 tethered ligand sequence GYPGKF. An alanine substitution at position one 
increases selectivity and specificity for PAR4 [242]. High purity (95.85%) AYPGKF-
NH2 was purchased from GL Biochem Ltd (Shanghai, China) and manufactured 
according to current Good Manufacturing Practice standards. On receival, product 
testing and analysis were repeated by the active pharmaceutical ingredient laboratory of 
the Queens Medical Research Institute, Edinburgh. 
 
5.3.2.1 Preliminary human studies 
Prior to the study, in vitro platelet testing with human blood was performed to confirm 
the specificity of our clinical-grade AYPGKF-NH2 for PAR4. These studies also 
served to establish the relevant dose range for future in vivo human vascular studies 
(see Appendix A) from which the appropriate systemic concentrations for this safety 
and tolerability study in mice could be agreed. On the basis of these data, 200 µM was 
determined to be the maximum local concentration of AYPGKF-NH2 of interest. 
Assuming a minimum total blood volume of 3.5 L and no metabolism, this would 
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equate to volunteers being exposed to a maximum systemic concentration of 7.87 µM 
over the entire proposed protocol. 
 
5.3.3 Mice 
Twenty adult male Rodentia mice (Charles River, UK) aged 8 to 10 weeks were housed 
in the animal unit of the University of Edinburgh and observed for 1 week. Animals 
were grouped 2 to 3 per cage and fed a diet of normal chow throughout the study.  
 
5.3.4 Study protocol 
5.3.4.1 Dosing 
Fifteen mice exhibiting normal behaviour during the observation period were selected for 
dosing. AYPGKF-NH2 (low or high dose) or control (0.9% saline) was administered to 
mice via tail vein injection (n=15 total, 5 mice per group). Low dose refers to 100 µL of 
164 μM AYPGKF-NH2, equating to a systemic concentration of 11.25 µM assuming a 
mice blood volume of 1.46 ml. High dose refers to 100 µL injection of 1.64 mM 
AYPGKF-NH2, equating to a systemic concentration of 112.5 µM. This is 14-fold 
greater than the maximum theoretical accumulated systemic dose volunteers would be 
exposed to in our proposed future studies. Following dosing, mice were observed for 24 
hours with signs of pain, distress or abnormal behaviour recorded. 
 
5.3.4.2 Necropsy 
At 24 hours mice were culled by intraperitoneal injection of Euthatal followed by 
withdrawal of the maximum volume of blood possible (by abdominal vena cava or the 
heart) directly into 3.2% sodium citrate (final concentration 0.32%) and dissection. 
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5.3.5 Laboratory analyses 
Standard clinical chemistry assays for bilirubin, alanine transaminase (ALT), aspartate 
transaminase (AST), albumin, alkaline phosphatase, urea and creatinine were performed 
on whole blood by Dr F Howie (MRC Centre of Inflammation Research, Queen's Medical 
Research Institute, Edinburgh). A detailed description of the methodology for each test 
is described in Chapter 2: Methods. 
 
5.3.6 Flow cytometry 
Quantification of total white cell count, monocyte count, neutrophil count and platelet 
count was performed on whole blood by flow cytometry by Dr J Raftis (MRC Centre of 
Inflammation Research, Queen's Medical Research Institute, Edinburgh). A detailed 
description of the methodology is described in Chapter 2: Methods. 
 
5.3.7 Histopathology 
The lungs, liver, spleen and a single kidney were removed intact and fixed in 4% 
paraformaldehyde for 24 hours at room temperature prior to being transferred into 70% 
ethanol for a further 24 hours. Following fixation, segments from each organ were 
embedded in paraffin wax and 4 µm sections prepared. Sections were stained with 
haematoxylin and eosin. Digital images of each section were acquired at ×200 
magnification for analysis using a semi-automated slide scanner (Axioscan Z1; Zeiss, 
Jena, Germany). 
 
5.3.8 Statistical analysis 
Unless otherwise stated categorical data are presented as percentages and continuous 
data as means ± standard deviation (SD). The effects of study agents on laboratory 
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endpoints were assessed by one-way analysis of variance with Tukeys test for multiple 
comparisons. Two-sided p-values of ≤0.05 were considered statistically significant. All 
statistical calculations were performed using PRISM version 7.0a (GraphPad Software, 










Intravenous injection of AYPGKF-NH2 (or control) was well tolerated with no notable 
adverse effects including fever, pain, distress or abnormal behaviour in any of the mice. 
There were no deaths prior to planned necropsy at 24 hours. 
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Systemic administration of AYPGKF-NH2 (low or high dose) was not associated with 
a significant rise or fall in any of the haematological or inflammatory markers examined 
(Figure 5.1). Total white cell count was 138 ± 46, 101 ± 50 and 119 ± 74 cells/µL, 
neutrophil count 26 ± 11, 19 ± 14 and 26 ± 22 cells/µL, monocyte count 70 ± 28, 61 ± 
24 and 63 ±33 cells/µL, and platelet count 4.18 ± 3.96, 3.13 ± 3.89 and 3.72 ± 3.97 
log10 cells/mL for control, low, and high dose AYPGKF-NH2, respectively. 
Figure 5.1. Effect of systemic PAR4 agonism with AYPGKF-NH2 versus control on 
haematological and renal laboratory indices 
Data shown are the mean values ± 95% confidence intervals at 24 hours following exposure 
to control (0.9% NaCl, n=5), AYPGKF-NH2 at a systemic concentration of 11.25 uM (n=5), 
and AYPGKF-NH2 at a systemic concentration of 112.5 M (n=5). Statistical comparisons are 










AYPGKF-NH2 was not associated with evidence of respiratory distress (e.g. rasping) 
throughout the observation period. Compared to control, there was no distortion of lung 
parenchymal architecture, necrosis or inflammatory cell infiltrate at either low or high 
dose (Figure 5.2).  
  
Figure 5.2. Effect of systemic PAR4 agonism with AYPGKF-NH2 on lung parenchymal 
tissue 
Representative sections (x200 magnification) of lung parenchymal tissue from mice exposed 
to [A] control (n=5), [B] AYPGKF-NH2 at a systemic concentration of 11.25 µM (n=5), and 
[C] AYPGKF-NH2 at a systemic concentration of 112.5 µM (n=5). Sections are stained with 











AYPGKF-NH2 was not associated with a change in blood markers of renal function as 
compared to control (Figure 5.1). Urea was 4.7 ± 0.5, 4.4 ± 0.7 and 4.0 ± 0.8 mmol/L, 
and creatinine 5.8 ± 1.5, 4.4 ± 0.5 and 4.8 ± 2.4 mmol/L for control, low dose and high 
dose AYPGKF-NH2, respectively. No distortion of renal parenchymal architecture, 
necrosis or inflammatory cell infiltrate was observed at either low or high dose (Figure 
5.3).  
  
Figure 5.3. Effect of systemic PAR4 agonism with AYPGKF-NH2 on renal parenchymal 
tissue 
Representative sections (x200 magnification) of renal parenchymal tissue from mice exposed 
to [A] control (n=5), [B] AYPGKF-NH2 at a systemic concentration of 11.25 µM (n=5), and 
[C] AYPGKF-NH2 at a systemic concentration of 112.5 µM (n=5). Sections are stained with 










Figure 5.4. Effect of systemic PAR4 agonism with AYPGKF-NH2 versus control on 
hepatic laboratory indices 
Data shown are the mean values ± 95% confidence intervals at 24 hours following exposure 
to control (0.9% NaCl, n=5), AYPGKF-NH2 at a systemic concentration of 11.25 uM (n=5), 
and AYPGKF-NH2 at a systemic concentration of 112.5 M (n=5). Statistical comparisons 









AYPGKF-NH2 was not associated with a change in blood markers of hepatic injury or 
dysfunction as compared to control (Figure 5.4). Bilirubin was 3.02 ± 1.2, 2.76 ±0.6 
and 3.12 ±0.6 µmol/L, ALT was 44.4 ± 9.2, 36.8 ± 5.2 and 30.0 ± 3.5 units/L, AST 
72.3 ± 7.1, 69.2 ± 17.6 and 58.8 ± 13.7 units/L, alkaline phosphatase 179.6 ± 38.1, 
195.0 ± 9.6 and 184.4 ± 23.1 units/L, and albumin 15.4 ± 1.8, 16.3 ±1.5 and 15.9 ±1.0 
g/L for control, low dose AYPGKF-NH2, and high dose AYPGKF-NH2, respectively 
(Figure 5.4). No distortion of hepatic parenchymal architecture, necrosis or 
inflammatory cell infiltrate was observed at either low or high dose (Figure 5.5). 
 
  
Figure 5.5. Effect of systemic PAR4 agonism with AYPGKF-NH2 on hepatic 
parenchymal tissue 
Representative sections (x200 magnification) of hepatic parenchymal tissue from mice 
exposed to [A] control (n=5), [B] AYPGKF-NH2 at a systemic concentration of 11.25 µM 
(n=5), and [C] AYPGKF-NH2 at a systemic concentration of 112.5 µM (n=5). Sections are 










AYPGKF-NH2 was not associated with distortion of splenic parenchymal architecture, 
necrosis or inflammatory cell infiltrate at either low or high dose, as compared to 




Figure 5.6. Effect of systemic PAR4 agonism with AYPGKF-NH2 on splenic 
parenchymal tissue 
Representative sections (x200 magnification) of splenic parenchymal tissue from mice 
exposed to [A] control (n=5), [B] AYPGKF-NH2 at a systemic concentration of 11.25 µM 
(n=5), and [C] AYPGKF-NH2 at a systemic concentration of 112.5 µM (n=5). Sections are 






The main findings of this study are that in mice, intravenous administration of the 
PAR4 agonist AYPGKF-NH2 was well tolerated with no signs of distress, systemic 
inflammation, thrombosis or organ-specific dysfunction, even at suprathreshold 
concentrations. Our results provide support for the safety of intravascular AYPGKF-
NH2 to examine the in vivo vascular actions of PAR4 in humans.  
 
One of the major concerns for in vivo studies of PAR4 agonism in man is the potential 
for harmful thrombus formation given PAR4’s role in platelet activation and 
aggregation. In the present study, AYPGKF-NH2 was given intravenously to mice at 
very high doses. Despite this, no signs of end-organ infarction or necrosis were 
observed. There were also no significant changes in platelet numbers or adverse splenic 
pathology. Our findings are even more reassuring given that, in contrast to humans, 
mice platelets do not express PAR1 [114,224–228]. Thus, our data indicates that at the 
intended doses of AYPGKF-NH2 for future in vivo studies in man, the risk of occlusive 
thrombosis is likely to be very low. 
 
It has been suggested PAR4 may have an important role in inflammation with PAR4 
identified on the surface of neutrophils [159], macrophages [160] and B cells [229]. 
Vergnolle and colleagues demonstrated topical administration of AYPGKF-NH2 to rat 
mesenteric venules increased leucocyte rolling and adhesion, while intraperitoneal 
injection caused an increase in leukocyte migration [159]. In rodents, high-dose 
intraplantar and intraarticular injection of AYPGKF-NH2 resulted in localized oedema 
and granulocyte infiltration [137,167–169] PAR4 inhibition or deficiency in mice has 
been shown to block neutrophil migration to injury [230], attenuate systemic and 
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localised inflammatory responses to endotoxaemia [231], and reduce paw swelling to 
tissue factor-initiated inflammation. In the present study, intravenous AYPGKF-NH2 
was not associated with fever, leucocytosis or organ-specific inflammation at either low 
or high dose. Consequently, while PAR4 would appear to act as a chemoattractant and 
promote proinflammatory responses to local or systemic stress, our data indicates PAR4 
stimulation in isolation is not sufficient to trigger clinically relevant inflammation. 
 
PAR4 is found in the lungs, including alveolar macrophages [160] and airway epithelial 
cells [165]. Moffat and colleagues demonstrated intranasal administration of a PAR4 
agonist in mice induced the recruitment of a small number of neutrophils into the 
airways. By contrast, trypsin (200–2000 U /kg) caused profound inflammation and lung 
damage [160]. We did not observe any sign of respiratory distress following systemic 
PAR4 stimulation, either clinically or pathologically. Our results therefore add to 
current evidence that PAR4 signaling is not a powerful mediator of inflammation in the 
lungs of mice, even at supra-physiological levels.  
 
Studies in mice have revealed a possible role for PAR4 signaling in the progression of 
acetaminophen-induced [166] and experimental cholestatic liver injury [232]. However, 
in healthy mice, we found that PAR4 stimulation was not associated with hepatic injury 
or dysfunction. PAR4 has been detected in renal parenchyma but unlike PAR1 and 
PAR 2 there is little evidence PAR4 has any significant function [163,164,233]. Our 
results support these findings with intravenous AYPGKF-NH2 not associated with any 
sign of acute renal impairment or injury.   
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PAR4 is expressed on peripheral nerves and plexus bodies [161]. Animal data has 
suggested PAR4 may modulate local nociceptive responses that are both tissue and 
dose specific. For example, in rodents, intraarticular injection of a PAR4 agonist was 
pronociceptive [169,171] whereas intracolonic and intraplantar injection was 
proanalgesic [170]. In the current study, systemic PAR4 agonism with AYPGKF-NH2 
was not associated with visible pain or distress. However, in the absence of exploring 
responses to noxious stimuli, modulation of nociception cannot be discounted. 
 
5.6 LIMITATIONS 
Inter-species differences in PAR expression could limit the applicability of our results. 
Platelet expression of PAR1 and PAR3 varies considerably and this includes important 
distinctions between mice and humans [114,224–228]. Fortunately, PAR4 appears 
much more conserved, with mice, rats, guinea pigs, rabbits, dogs, monkeys and humans 
all sharing similar PAR4 expression throughout the vasculature [158]. However, it 
remains unclear whether species expression of PAR4 is conserved across non-vascular 
cells or indeed if PAR4 functions the same. Mice received a single dose and were 
culled after 24 hours. It is therefore conceivable harmful effects may not have 
manifested and the effects of chronic PAR4 stimulation remain unknown. However, 
AYPGKF-NH2 can be expected to have a short half-life based on other similar small 
peptides [24,260] and we believe our study protocol was appropriate with respect to our 
proposed future studies in man. This study provides evidence of the safety and 
tolerability of systemic PAR4 agonism with AYPGKF-NH2. It was not designed to 
determine the organ-specific functions of PAR4 and our results do not provide any 




In mice, intravenous administration of the PAR4 activating peptide AYPGKF-NH2 was 
well tolerated with no evidence of acute systemic toxicity, inflammation, thrombosis or 
organ injury, even at suprathreshold concentrations. Our results support the safety of 
AYPGKF-NH2 to investigate the vasomotor and vascular endothelial actions of PAR4 












Figure 5.7. Dose response curves for platelet responses to AYPGKF-NH2 in the 
presence or absence of selected antagonists 
Dose response curves for in vitro human platelet activation (P-selectin expression and 
platelet-monocyte aggregates) and platelet aggregation with AYPGKF-NH2 (A-C) alone, (D-
G) in the presence of the PAR4 antagonist YD-3 (1000 nM), (G-I) in the presence of the 
GPIIb/IIIa inhibitor tirofiban (400 nM), and (J-L) in the presence of the PAR1 antagonist 
SCH-79797) (64 µM). 
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Prior to our toxicology studies, preliminary studies with blood from healthy volunteers 
(n=6) were conducted to confirm the specificity of our clinical grade AYPGKF-NH2 
and to establish the dose range of interest [234–236]. AYPGKF-NH2 platelet activation 
and aggregation were fully inhibited by the PAR4 antagonist YD-3 but were not 
affected by the PAR1 antagonist SCH-79797. At a concentration of 200 µM, AYPGKF-
NH2 induced full platelet activation and aggregation but remained almost completely 
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6 Effects of PAR4 Antagonism on Ex-Vivo Human 






There is an unmet clinical need for novel antiplatelet agents that can provide equivalent 
(or superior) antithrombotic efficacy to existing drugs but with a reduced bleeding risk. 
BMS-986120 is a novel first-in-class oral protease-activated receptor 4 (PAR4) 
antagonist that in animal models demonstrated potent antithrombotic effects with a 
substantially wider therapeutic index when compared to clopidogrel. 
 
Objective 
To determine the effect of oral PAR4 antagonism with BMS-986120 
on human ex vivo platelet aggregation and thrombus formation. 
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Method and Results 
Forty healthy volunteers completed a phase 1 parallel-group prospective randomized 
open-label blinded endpoint trial. Ex vivo platelet activation, platelet aggregation and 
thrombus formation were measured at 0, 2 and 24 hours after (a) oral BMS-986120 (60 
mg), or (b) oral aspirin (600 mg) followed at 18 hours with oral aspirin (600 mg) and 
oral clopidogrel (600 mg). BMS-986120 demonstrated highly selective and reversible 
inhibition of PAR4-activating peptide (PAR4-AP; 100 µM) stimulated p-selectin 
expression, platelet-monocyte aggregates and platelet aggregation (p<0.001 for all). 
Compared to pre-treatment, total thrombus area (µm2/mm) at high shear was reduced 
by 29.2% (95% CI, 18.3-38.7%; p<0.001) at 2 hours and by 21.4% (9.3-32.0%; 
p=0.002) at 24 hours. Reductions in thrombus formation were driven by a decrease in 
platelet-rich thrombus deposition: 34.8% (19.3-47.3%; p<0.001) at 2 hours and 23.3% 
(5.1-38.0%; p=0.016) at 24 hours. In contrast to aspirin alone, or in combination with 
clopidogrel, BMS-986120 had no effect on thrombus formation at low shear (p=ns). 
BMS-986120 administration was not associated with an increase in coagulation times 
or serious adverse events. 
 
Conclusions 
BMS-986120 is a highly selective and reversible oral PAR4 antagonist that 
substantially reduces platelet-rich thrombus formation under conditions of high shear 
stress. Our results suggest PAR4 antagonism with BMS-986120 has major therapeutic 




Having examined the impact of PAR4 agonism and antagonism on platelet activation 
and aggregation in vitro, we sought to determine the effect of oral PAR4 antagonism on 
platelets and thrombus formation in healthy volunteers. A phase 1 study was undertaken 
with subjects randomised to either PAR4 inhibition with BMS-986120 or the current 
standard of care antiplatelet agents, aspirin and clopidogrel. Compound effects were 




6.3.1 Study design 
This was a phase I parallel group (n=20 per treatment arm) prospective randomized 
open-label blinded endpoint (PROBE) trial conducted at a single site (Clinical Research 
Facility, Royal Infirmary of Edinburgh, Scotland) between the 23rd September 2015 and 
1st March 2016. Subjects were admitted to the Clinical Research Facility on Day 1. A 
total of 3 perfusion runs were performed per subject in each treatment arm. At each 
perfusion run, ex vivo platelet aggregation, platelet activation (treatment arm A only) 
and thrombus formation were measured. Aspirin ± clopidogrel were included as a 






For treatment arm A, a baseline chamber run was performed immediately prior to 
BMS-986120 administration. A second run was performed 2 hours following oral 
administration of 60 mg BMS-986120. This second chamber run was designed to be 
conducted at the predicted Tmax. Subjects remained in the research facility overnight 
and a final chamber run was performed on day 2, approximately 24 hours post-dose. 
Subjects were discharged from the research facility after the conclusion of this run, with 
final discharge from the study following telephone follow-up on day 8.  
 
For treatment arm B, a baseline chamber run was performed immediately prior to 
aspirin administration. A second run was performed on day 1, 2 hours following oral 
administration of 600 mg aspirin. Subjects remained in the research facility overnight. 
On day 2, subjects received oral administration of 600 mg aspirin and 600 mg 
clopidogrel. Four hours following oral administration of aspirin and clopidogrel, a final 
chamber run was performed. Subjects were discharged from the research facility after 
Figure 6.1. Schematic overview of study design 
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the conclusion of this run, with final discharge from the study following telephone 
follow-up on Day 8. The study design schematic is presented in Figure 6.1.  
 
The trial was sponsored by Bristol-Myers Squibb (BMS) and was designed 
collaboratively with the host academic center. The study was approved by the local 
research ethics committee, conducted in accordance with the Declaration of Helsinki 
and with the written informed consent of all volunteers. Clinical Trial Authorization 
was provided by the Medicines and Healthcare products Regulatory Authority of the 
United Kingdom. 
 
6.3.2 Treatment assignment 
Subjects meeting inclusion and exclusion criteria were eligible to be randomized. 
Subjects were randomized to receive either BMS-986120 (treatment arm A) or aspirin 
and clopidogrel (treatment arm B) according to a computer-generated randomization 
scheme prepared by a Randomization Coordinator within the Drug Supply Management 
Department of BMS Research and Development.  
 
6.3.3 Study objectives 
The primary study endpoint was the effect of BMS-986120 on total thrombus area as 
compared to pre-treatment. Secondary and exploratory endpoints included the effect of 
study drug (BMS-986120 or control) on platelet activation, platelet aggregation, 
platelet-rich and fibrin-rich thrombus formation, and blood coagulation.  
 
The primary safety endpoint was the incidence of serious adverse events (SAEs) or 
death during and for up to 30 days post dosing. Additional safety endpoints included 
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changes in haematological and biochemical indices, haematuria (including 
microhaematuria), alteration in the 12-lead electrocardiogram (ECG), or abnormal 
findings on physical examination performed at baseline, 2 and 24 hours post dosing.  
 
6.3.4 Study population 
Healthy non-smoking male and female volunteers between the ages of 18 and 65 years 
(inclusive) and with a body mass index (BMI) of 18 to 32 kg/m2 underwent screening 
including detailed medical history, physical examination, laboratory blood tests, 
urinalysis and 12-lead ECG. Exclusion criteria were women of child-bearing potential 
and any clinically significant coexisting condition including hypertension, 
hyperlipidemia, diabetes mellitus, gastrointestinal disease that could affect drug 
absorption, coagulopathy, recent infective or inflammatory condition, known liver 
disease or screening blood tests indicative of renal, liver, clotting, thyroid or 
hematological abnormality. Volunteers must not have been taking any prescription 
medications for 4 weeks, over-the-counter medications, herbal supplements and 
vitamins for 1 week, and alcohol or caffeine containing products for 72 hours prior to 
and for the duration of the study. 
 
6.3.5 Sample size 
Based on previous data, a sample size of 18 volunteers per study arm was determined to 
provide at least 80% power to reject the null hypothesis that a single 60 mg dose of 
BMS-986120 will reduce thrombus formation in the Badimon model of ex vivo human 
thrombosis, when the true mean change is a 20% decrease at the two-sided 5% level of 
significance [201–203,237]. This calculation assumes that thrombus area is log-
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normally distributed and the differences on the log scale have a standard deviation of 
0.31.  
 
6.3.6 Dose selection 
BMS-986120 is a competitive, reversible inhibitor of PAR4-activating peptide (PAR4-
AP) induced platelet aggregation (Kon = 0.12 ± 0.043 nM-1min-1, Koff = 0.0082 ± 0.0016 
min-1, Kd = 0.098 ± 0.016 nM). In cynomolgus monkeys, BMS-986120 demonstrated 
dose-dependent (0.2-1.0 mg/kg) preservation of carotid arterial flow following 
electrolytic injury at the expense of a slight increase in mesenteric and kidney bleeding 
times [131]. In a single ascending (0.5-180 mg) and multiple ascending dose study (2.5-
100 mg daily for up to 14 days) in healthy volunteers, BMS-986120 was found to be 
safe and well tolerated with complete and reversible inhibition of PAR4-AP stimulated 
platelet aggregation at ≥ 10 mg daily [146]. On the basis of these studies, a 60 mg dose 
was selected for the present phase 1 trial as this was calculated to be sufficient to inhibit 
platelet aggregation 2 hours post dose and would be at the edge of a potential 
pharmacodynamic effect at 24 hours. This would allow for “dose ranging” with a single 
dose of BMS-986120 whilst remaining well within the safety experience.  
 
Doses of aspirin (600 mg) and clopidogrel (600 mg) were selected to reflect the 
maximal antithrombotic efficacy that might reasonably be expected in clinical practice 
following initiation of these antiplatelet agents in an acute setting.  
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6.3.7 Study outcome measures 
6.3.7.1 Blood sampling and agonists 
All blood samples for pharmacodynamic and pharmacokinetic assessments were drawn 
uncuffed through a 17-G cannula in the ante-cubital fossa. For each time point, the first 
2.5 mL of blood was discarded. PAR1- and PAR4-APs (SFLLRN and A-Phe(4-F)-
PGWLVKNG respectively) were provided by Bristol-Myers Squibb (Princeton, USA), 
adenosine diphosphate (ADP) by Sigma-Aldrich (Gillingham, UK) and arachidonic 
acid (AA) by Alpha Laboratories (Eastleigh, UK). 
 
6.3.7.2 Pharmacokinetic assessment 
Plasma concentrations of BMS-986120 were determined at 0, 1, 2, 3, 4, 5, 6, 9 and 24 
hours post treatment using a validated liquid chromatography tandem-mass 
spectrometry method with a lower limit of quantification of 0.250 ng/mL, with an 
accuracy coefficient of variation of < 5%, and precision (intra- and inter-assay) 
coefficient of variation of < 10%. Blood samples were collected into 3 mL K2EDTA 
vacutainers (Becton-Dickinson, Cowley, UK) and placed on wet ice. Within 1 hour of 
collection, samples were centrifuged at 1200 g (2-8 °C) for 10 minutes. Plasma was 
decanted and stored at -20 °C before analysis. 
 
6.3.7.3 Platelet activation 
Platelet p-selectin expression and platelet-monocyte aggregates were determined by 
flow cytometry. Blood (5 mL) was collected into 50 µL of 75 mM D-phenylalanyl-L-
propyl-L-arginine chloromethylketone (PPACK; Enzo Life Sciences, Exeter, UK) then 
immediately aliquoted into micro-centrifuge tubes pre-filled with or without agonist 
and the following conjugated monoclonal antibodies: allophycocyanin (APC)-
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conjugated CD14, phycoerythrin (PE)-conjugated CD62P and fluorescein 
isothiocyanate (FITC)-conjugated CD42a (Becton-Dickinson). All antibodies were 
diluted 1:10. Samples were incubated for 20 minutes at room temperature before fixing 
with 1 % paraformaldehyde (p-selectin) or FACS-Lyse (Becton-Dickinson; platelet-
monocyte aggregates). All samples were analysed within 24 h using a FACSCalibur 
flow cytometer (Becton-Dickinson). Data analysis was performed using FlowJo v10 
(Treestar, Oregon, USA). 
 
6.3.7.4 Platelet aggregation 
Platelet aggregation was assessed by optical aggregometry (PAP-8E; Bio/Data Corp, 
Horsham, PA, USA) of platelet-rich plasma (PRP). To obtain PRP, 18 mL of blood was 
collected, mixed immediately with 2 mL of 3.8 % sodium citrate, and then centrifuged 
at 300 g (room temperature) for 15 minutes. For reference, 2 mL of PRP was 
centrifuged at 5500 g for 6 minutes to obtain platelet-poor plasma (PPP). All samples 
were allowed to equilibrate for 10 minutes (37 °C) after the addition of agonist and the 
peak aggregation recorded. 
 
6.3.7.5 Ex vivo perfusion model of thrombosis 
The effect of study compound on ex vivo thrombus formation was assessed using the 
Badimon perfusion chamber as described in detail in Chapter 2: Methods.   
 
6.3.7.6 Histomorphometric analysis 
Total thrombus formation, fibrin-rich thrombus formation and platelet-rich thrombus 
formation were assessed as described in detail in Chapter 2: Methods.   
 
 141 
6.3.7.7 Safety and tolerability 
The incidence of SAEs or death during and for up to 30 days post dosing were 
recorded. Adverse events (AEs) not meeting the SAE threshold were also recorded. All 
volunteers received telephone follow up on day 8. Reports of SAEs and AEs could 
originate from the volunteer, investigator or study personnel.  
 
6.3.8 Statistical analysis 
Following study completion, the database was locked and all statistical analyses carried 
out independent of the sponsor. The demographic and baseline characteristics of 
volunteers are expressed as mean ± standard deviation (SD) for continuous variables 
and percentages for categorical variables. The effect of study drug(s) on endpoints was 
assessed by general linear mixed effects models, with perfusion procedure (baseline, 2 
and 24 hours) as fixed effects and subjects as random effects. Mean within-subject 
differences for the change from baseline were generated and analysed using the Least 
Significance Difference test. Prior to model fitting, total thrombus area, platelet area 
and fibrin area were log-transformed. Associations between plasma concentrations of 
BMS-986120 and study end-points were determined by Spearman’s rank-order 
correlation (ρ). Two-sided p-values of ≤0.05 were considered statistically significant. 
Analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, New York) 





6.4.1 Study population characteristics 
 
 
Table 6.1. Baseline characteristics of study volunteers 
Test variable BMS-986120 (n=20) 
Aspirin ± Clopidogrel 
(n=20) 
Male (%) 20 (100) 20 (100) 
Age, years (SD) 23.6 (3.4) 28.7 (10.0) 
BMI, kg/m2 (SD) 23.6 (2.6) 25.4 (3.5) 
Race (%)   
Caucasian 19 (95) 19 (95) 
Black/African 1 (5) 0 
Asian 0 1 (5) 
Haemoglobin, g/dL (SD) 14.2 (0.42) 14.6 (0.85) 
Platelet count, x109 c/L (SD) 230 (45) 221 (49) 
APTT, seconds (SD) 30.9 (2.2) 30.8 (2.6) 
PT, seconds (SD) 12.3 (0.9) 11.9 (0.7) 
Abbreviations used: SD, standard deviation; BMI, body mass index; APTT, activated partial 
thromboplastin time; PT, prothrombin time 
 
 
All 40 volunteers (81 volunteers were screened) completed the study in full. The 
demographics and baseline characteristics of study volunteers were similar in the two 













BMS-986120 was rapidly absorbed with peak plasma concentrations occurring at 2 
hours (255 ± 136 ng/mL; Figure 6.2). Plasma concentrations of BMS-986120 were 
halved by 4 hours (133 ± 100 ng/ml) and < 10% of the peak concentration by 24 hours 






Figure 6.2. Pharmacokinetics of BMS-986120. 
BMS-986120 was rapidly absorbed with a half-life of 4 hours. Data shown are mean plasma 
concentrations of BMS-986120 (± 95% confidence intervals) following administration of a 
single oral 60 mg dose (n=20). 
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Figure 6.3. BMS-986120 demonstrated highly selective, potent and reversible inhibition 
of PAR4 stimulated platelet activation and aggregation. 
Box plots of platelet activation and aggregation in response to (A-C) PAR4 AP [100μM], 
(D-E) PAR1 AP [100μM], (F) PAR1 AP [25μM], (G) ADP [10μM] and (H) AA [5mM], in 
volunteers randomised to BMS-986120 (n=20). Data shown are the adjusted mean (+) 
normalised to unstimulated values. The line within the box represents the median, upper and 
lower edges of the box represent the 75th and 25th percentiles, and upper and lower 
whiskers represent the 95th and 5th percentiles. Statistical comparisons (Least Significance 
Difference test) versus 0 hour are represented above each plot: ns=not significant, * p<0.05, 





BMS-986120 demonstrated strong and reversible inhibition of PAR4-AP (100 µM) 
stimulated platelet activation and aggregation (p<0.001 for all). Compared to pre-
treatment, PAR4-AP stimulated increases in platelet p-selectin expression (%), platelet-
monocyte aggregates (%) and platelet aggregation (%) were reduced by 91.7% (95% 
CI, 81.0 to 102.4), 80.6% (95% CI, 68.6 to 92.6%) and 85.0% (95% CI, 82.0 to 88.1) at 
2 hours and by 53.9% (95% CI, 43.2 to 64.7%), 41.1% (95% CI, 28.9 to 53.2%) and 
6.0% (95% CI, 2.9 to 9.0%) at 24 hours (p<0.001 for all; Figure 6.3). There was no 









Plasma concentrations of BMS-986120 correlated with p-selectin expression (ρ=-0.87), 
platelet-monocyte aggregates (ρ=-0.88), and platelet aggregation (ρ=-0.82; p<0.001 for 
all). 
  
Figure 6.4. Correlations between plasma concentrations of BMS-986120 and platelet 
responses. 
Data shown are scatter plots of [A] PAR4-AP stimulated p-selectin expression, [B] PAR4-
AP stimulated platelet-monocyte aggregates, and [C] PAR4-AP stimulated platelet 
aggregation in volunteers randomised to BMS-986120 (n=20). Correlation coefficients (!) 












Aspirin administration reduced AA stimulated platelet aggregation by 74.5% (95% CI, 
71.6 to 77.3%; p<0.001). In combination with clopidogrel, aspirin reduced AA 
stimulated platelet aggregation by 73.7% (95% CI, 70.9 to 76.5%; p<0.001) and ADP 
stimulated platelet aggregation by 41.9% (95% CI, 35.2 to 48.7%; p<0.001) 





Figure 6.5. Box plots of platelet aggregation in response to (A) arachidonic acid [5 
mM] and (B) adenosine diphosphate [10 µM] in volunteers randomised to aspirin 
± clopidogrel (n=20). 
Data shown are the adjusted means (+) normalised to unstimulated values. The line 
within the box represents the median, upper and lower edges of the box represent the 
75th and 25th percentiles, and upper and lower whiskers represent the 95th and 5th 
percentiles. Statistical comparisons (Least Significance Difference test) versus 0 hour 




6.4.5 Effect of BMS-986120 on ex vivo thrombus formation 






BMS-986120 reduced total thrombus formation at high shear (p<0.001) but not at low 
shear (p=ns; Figure 6.6). Compared to pre-treatment, total thrombus area (µm2/mm) at 
high shear was reduced by 29.2% (95% CI, 18.3 to 38.7%; p<0.001) at 2 hours and by 









Figure 6.6. BMS-986120 reduced thrombus formation at high shear but not at low 
shear. 
Effect of [A] BMS-986120 (n=20) and [B] aspirin ± clopidogrel (n=20) on total thrombus 
area at high and low shear. Statistical comparisons (Least Significance Difference test) 
versus 0 hour are represented above each plot: ns=not significant, * p<0.05, ** p<0.01, *** 









Plasma concentrations of BMS-986120 correlated with total thrombus formation at high 
shear (ρ=-0.47, p<0.001), but not at low shear (ρ=-0.18; p=ns; Figure 6.7). 
 
  
Figure 6.7. Correlations between plasma concentrations of BMS-986120 and total 
thrombus formation. 
Data shown are scatter plots of total thrombus formation at [A] high shear and [B] low 
shear in volunteers randomised to BMS-986120 (n=20). Correlation coefficients (!) 











Reductions in total thrombus area were driven by a decrease in platelet deposition 
(Figure 6.8). At high shear, platelet-rich thrombus area was reduced by 34.8% (95% CI, 
19.3 to 47.3%; p<0.001) at 2 hours and 23.3% (95% CI, 5.1 to 38.0%; p=0.016) at 24 
hours. Reductions in fibrin-rich thrombus area at 2 h (-14.7%; 95% CI, -22.5 to -6.2%; 
p=0.002) and 24 h (-7.9%; 95% CI, -16.3 to 1.4%, p=0.09) were small by comparison. 
Figure 6.8. Reductions in thrombus were driven by a decrease in platelet-rich 
thrombus formation. 
Effect of [A] BMS-986120 (n=20) and [B] aspirin ± clopidogrel (n=20) on platelet-rich and 
fibrin-rich thrombus formation at low and high shear. Data shown are adjusted means ± 95% 
confidence intervals. Statistical comparisons (Least Significance Difference test) versus 0 
hour are represented above each plot: ns=not significant, * p<0.05, ** p<0.01, *** p<0.001. 
Abbreviations used: ASA, aspirin; Clop., clopidogrel.  
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BMS-986120 had no effect on platelet-rich or fibrin-rich thrombus formation at low 
shear (p=ns for all). 
 
6.4.6 Effect of aspirin ± clopidogrel on ex vivo thrombus formation 
Aspirin and aspirin in combination with clopidogrel both reduced thrombus 
development at high and low shear, also driven by decrease in platelet-rich thrombus 
formation. Aspirin reduced total thrombus area and platelet-rich thrombus area by 
30.2% (95% CI, 15.6 to 42.2%; p<0.001) and 41.7% (95% CI, 22.9 to 56.0%; p<0.001) 
respectively, and by 32.4% (95% CI, 18.3 to 44.0%; p<0.001) and 46.4% (95% CI, 
29.1% to 59.5%; p<0.001) respectively when used in combination with clopidogrel. 
 
In contrast to BMS-986120, aspirin and aspirin in combination with clopidogrel both 
reduced total thrombus area at low shear (-17.4%; 95% CI, -27.0 to -6.5%; p=0.003 and 
-13.5%; 95% CI, -23.6 to -2.1%; p=0.02). There was no effect on fibrin-rich thrombus 




6.4.7 Effect of study drug on coagulation and safety assessments 
 
Table 6.2.  Biochemical and ECG assessments  
Test variable BMS-986120 (n=20) Aspirin ± Clopidogrel (n=20) 
 0 hour 2 hour 24 hour 0 hour ASA ASA+Clo 
ALT, U/L (SD) 19.0 (6.1) 18.7 (6.2)   17.8 (6.4)** 26.3 (14.8) 25.9 (14.2) 25.4 (13.3) 
AST, U/L (SD) 20.7 (4.6) 20.9 (5.7)    18.0 (3.6)*** 23.6 (7.4) 23.4 (6.8)   21.0 (4.5)** 
Bilirubin, mg/dL (SD) 0.70 (0.3) 0.80 (0.3)* 0.62 (0.3) 0.76 (0.2) 0.73 (0.2)   0.66 (0.2)** 
Creatine Kinase, U/L (SD) 197 (190) 187 (188)    115 (83)*** 186 (144) 171 (128)    108 (61)*** 
Urea, mmol/L (SD) 5.1 (0.96)   4.6 (0.76)**    4.1 (0.77)*** 5.0 (1.0) 4.7 (0.93)   4.5 (0.98)** 
Creatinine, mg/dL (SD) 0.83 (0.06) 0.81 (0.09) 0.82 (0.08) 0.89 (0.11) 0.86 (0.09) 0.86 (0.10) 
Haemoglobin, g/dL (SD) 14.2 (0.4) 14.2 (0.4) 14.2 (0.3) 14.6 (0.8) 14.4 (0.8) 14.3 (1.3) 
Platelet count, x109 c/L (SD) 229 (45) 227 (46) 228 (46) 221 (49) 220 (50) 216 (53) 
APTT, sec (SD) 30.9 (2.1) 30.3 (2.7) 30.4 (2.1) 30.8 (2.5) 30.3 (3.3) 30.1 (2.9) 
PT, sec (SD) 12.3 (0.9) 12.3 (0.9) 12.1 (0.8) 11.9 (0.7) 12.3 (0.7)** 12.1 (0.7) 
QTCf interval, millisec (SD) 405 (11.8) 411 (17.9) 405 (15.9) 401 (16.3) 402 (13.4) 399 (10.8) 
Data shown are the adjusted means. All statistically significant differences versus 0 hour are presented: * p<0.05, ** 
p<0.01, *** p<0.001. Abbreviations used: ASA, aspirin; Clo, clopidogrel. ALT, alanine transaminase; ASA, Aspirin; 
AST, aspartate transaminase; APTT, activated partial thromboplastin time; Clop, Clopidogrel; PT, prothrombin time; 
QTCf, QTC interval corrected for heart rate by Fridericia's formula; and SD, standard deviation 
 
BMS-986120 did not prolong coagulation and was not associated with clinically 
significant effect on any of the biochemical, haematological or ECG safety assessments 
conducted throughout the study (Table 6.2). Similarly, BMS-986120 was not associated 
with haematuria or impact on physical assessments including heart rate, blood pressure 
and temperature.  
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6.4.8 Adverse events 
 
Table 6.3. Overview of adverse events 
 BMS-986120 
(n=20) 
Aspirin ± Clopidogrel 
(n=20) 
Any AE, n (%) 7 (35.0) 2 (10.0) 
Headache 3 (15.0) 0 
Nasopharyngitis 2 (10.0) 0 
Abdominal discomfort 0 1 (5.0) 
Dizziness 1 (5.0) 0 
Pruritus 1 (5.0) 0 
Rash 1 (5.0) 0 
Rectal bleeding 0 1 (5.0) 
Treatment-related AE, n (%) 2 (10.0) 2 (10.0) 
SAE, n (%) 0 0 
Death, n (%) 0 0 
Discontinued due to AE, n (%) 0 0 
Abbreviations used: AE, adverse event; SAE, serious adverse event. 
 
BMS-986120 was well tolerated with no serious adverse events. One episode of minor 





In this phase 1 PROBE designed clinical trial, we have shown that PAR4 antagonism 
with BMS-986120 reduces ex vivo human thrombus formation under conditions 
representative of deep arterial injury in a stenosed coronary artery. BMS-986120 
demonstrated selective and reversible antiplatelet effects with concentration-dependent 
inhibition of thrombus formation and PAR4-AP stimulated platelet activation and 
aggregation. Our results provide further insights into the role of PAR4 in human 
thrombogenesis and raise major promise for oral PAR4 antagonism with BMS-986120 
in the treatment and prevention of arterial thrombosis.  
 
BMS-986120 is the first orally bioavailable PAR4 antagonist [131,146]. A 60 mg oral 
dose of BMS-986120 resulted in near complete inhibition of PAR4-AP stimulated 
platelet activation and aggregation at 2 hours, with a return towards baseline at 24 
hours. Consistent with earlier data from in vitro testing (Chapter 4), there was no effect 
on PAR1-AP, ADP or AA stimulated platelet activity. Our results therefore confirm 
previous reports that oral administration of BMS-986120 results in highly selective and 
reversible inhibition of PAR4-mediated platelet activation and aggregation in humans 
[146]. 
 
To examine the antithrombotic effects of PAR4 antagonism we used the Badimon 
perfusion chamber, a well validated model for measuring ex vivo thrombus formation 
[196–203]. Under similar experimental conditions, previous studies have demonstrated 
reductions in high shear thrombus formation of 18.7% following a 300 mg oral dose of 
clopidogrel, 28% with a 60 mg oral dose of edoxaban, and 56% with extracorporeal co-
administration of tirofiban (50 ng/mL) [200,203,238]. In the present study, a single 60 
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mg dose of BMS-986120 reduced high shear thrombus formation by nearly a third. This 
is consistent with pre-clinical animal data [117,131] with reductions in thrombus 
formation also comparable to those observed with high loading doses of aspirin and 
clopidogrel. Thus, we have shown for the first time, that PAR4 inhibition with BMS-
986120 substantially reduces ex vivo human thrombus formation. Moreover, given 
reductions were similar in magnitude to clinically approved antiplatelet agents, our data 
suggests a high probability of in vivo antithrombotic efficacy. 
 
BMS-986120 appeared to have less of an effect on thrombus formation at low shear 
than either aspirin alone or in combination with clopidogrel. Low shear rates reflect 
flow conditions found in patent epicardial arteries and veins, whereas the majority of 
atherothrombotic events occur at sites of high shear stress seen in diseased arteries 
[239,240]. Indeed, most myocardial infarctions arise from stenotic atherosclerotic 
plaques with rheological conditions comparable to those in our high shear chamber 
[241,242]. Accordingly, antiplatelet agents that are more selective for inhibiting 
thrombus formation at high shear may allow at-risk vascular beds to be targeted with 
greater specificity and this may have significant advantages in terms of widening the 
safety profile given many treatment-related bleeding events occur from vessels with 
low shear rates [243–245]. Further studies are required to confirm if PAR4 antagonism 
is more high-shear selective than existing agents. However, it is noteworthy that distinct 
mechanisms of platelet adhesion and aggregation are known to operate under different 
rheological conditions [246,247].  
 
As expected from an antiplatelet agent, reductions in thrombus were driven by a 
decrease in platelet aggregates. However, there was also a small but significant 
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reduction in fibrin-rich thrombus formation. PAR4 is reported to be the predominant 
platelet PAR responsible for phosphatidylserine exposure, micro-particle shedding and 
thrombin generation [248]. Our results add to these findings, indicating that PAR4 may 
have a role in platelet procoagulant activity during ex vivo human thrombus formation. 
Whether this is beneficial or not is uncertain, but it is notable that no bleeding-related 
clinical findings or serious adverse events occurred in this or a previous phase 1 single- 
and multiple-ascending dose study [146].  
 
6.6 LIMITATIONS 
Our study has some potential limitations. First, although the exposed porcine aortic 
media presents many of the common constituents of a disrupted atherosclerotic plaque, 
it may not contain tissue factor (TF) [249–251]. TF activates the coagulation cascade 
and is an important contributor to thrombogenicity [252,253]. Nevertheless, this does 
not overly limit our model for the assessment of thrombosis because binding of blood 
borne circulating TF is sufficient to allow activation of the coagulation cascade and 
thrombus propagation [249,250,254–256]. Indeed, previous studies have demonstrated 
that thrombus formed from human blood perfused over exposed porcine tunica media 
(devoid of TF) stains heavily for TF [249,250]. Second, we assessed a single oral dose 
of BMS-986120 and did not explore the effect of prolonged BMS-986120 
administration on thrombus formation, such as would occur with the secondary 
prevention of myocardial infarction and stroke. However, as this was the phase 1 trial 
designed to examine the antithrombotic effects of oral PAR4 antagonism in humans for 
the first time, we felt our study design was appropriate. Third, BMS-986120 was dosed 
in isolation, and future studies to determine the antiplatelet and antithrombotic effects 
of PAR4 antagonism in combination with current agents would be of interest. Finally, 
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while no episodes of bleeding occurred in volunteers administered BMS-986120, and 
BMS-986120 was not associated with an increase in bleeding times in a previous phase 
1 safety and tolerability study [146], the safety profile of PAR4 antagonism in humans 
remains to be defined. 
 
6.7 CONCLUSION 
We have demonstrated for the first time that oral PAR4 antagonism with BMS-986120 
substantially reduces ex vivo human thrombus formation under conditions of high shear 
stress. BMS-986120 was well tolerated with no change in coagulation assays or serious 
adverse events. Our results suggest PAR4 antagonism has major potential as a novel 







Effects of Exosite 1 Thrombin Inhibition on 
Humans Coagulation, Platelets and Thrombosis 
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7 Effects of Exosite 1 Thrombin Inhibition on Human 






JNJ-64179375 (hereafter JNJ-9375) is a first-in-class, highly specific, large molecule, 
exosite 1 thrombin inhibitor. In preclinical studies, JNJ-9375 demonstrated robust 
antithrombotic protection with a wider therapeutic index when compared to apixaban. 
 
Objective 
To examine the antiplatelet, anticoagulant and antithrombotic effects of exosite 1 




Methods and Results 
Fifteen healthy volunteers participated in a double-blind randomized crossover study of 
JNJ-9375 (2.5, 25 and 250 μg/mL), bivalirudin (6 μg/mL; positive control) and matched 
placebo. Coagulation, platelet activation and thrombus formation were determined 
using coagulation assays, flow cytometry and an ex vivo perfusion chamber 
respectively. JNJ-9375 caused concentration-dependent prolongation of all measures of 
blood coagulation (prothrombin time, activated partial thromboplastin time, thrombin 
time; p<0.001 for all) and agonist selective inhibition of thrombin (0.1 U/mL) 
stimulated platelet p-selectin expression (p<0.001) and platelet-monocyte aggregates 
(p=0.002). Compared to placebo, JNJ-9375 (250 µg/mL) reduced mean total thrombus 
area by 41.1% (95% confidence intervals, 22.3 to 55.3%; p<0.001) at low shear and 
32.3% (4.9 to 51.8%; p=0.025) at high shear. Under both shear conditions, there was a 
dose-dependent decrease in fibrin-rich thrombus (p<0.001 for both) but not platelet-rich 
thrombus (p=ns for both). 
 
Conclusion 
Exosite 1 inhibition with JNJ-9375 caused prolongation of blood coagulation, selective 
inhibition of thrombin-mediated platelet activation, and reductions in ex vivo 
thrombosis driven by a decrease in fibrin-rich thrombus formation. JNJ-9375 represents 





JNJ-64179375 (hereafter JNJ-9375) is a first-in-class, recombinant, fully human, IgG4 
monoclonal antibody anticoagulant that binds reversibly and with high affinity and 
specificity to the exosite 1 region of thrombin [179]. JNJ-9375 therefore acts to inhibit 
the interaction of thrombin with its exosite 1 substrates, which include fibrinogen, but 
retains function of both the active site and exosite 2 [185]. It is hypothesised this unique 
capacity to inhibit fibrinogen binding while preserving other non-exosite 1 protease 
interactions will allow for a wider therapeutic index. Building on encouraging animal 
data [179], the present study sought to examine for the first time the anticoagulant and 
antithrombotic effects of exosite 1 thrombin inhibition with JNJ-9375 in human blood 









This was a double-blind randomised controlled five-way crossover study conducted at a 
single site (Clinical Research Facility, Royal Infirmary of Edinburgh, Scotland) 
between the 24th May 2016 and 1st July 2016. Study measures were performed during 
extracorporeal infusion of JNJ-9375 (estimated final concentration of 2.5, 25 and 250 
μg/mL), bivalirudin (positive control; estimated final concentration of 6 μg/mL; The 
Medicines Company, Abingdon, UK) at a dose equivalent to recommendations at the 
time of percutaneous coronary intervention (PCI), and matched placebo (10 mM 
phosphate, 8.5% (w/v) sucrose, 0.04 % (w/v) polysorbate 20, 10 μg/mL EDTA, pH 7.1; 
Janssen Research and Development) upstream of the perfusion chambers. Three 
perfusion chamber studies were performed at the first experimental visit and two 
perfusion chamber studies at the second experimental visit (Figure 7.1). 
 
Figure 7.1. Schematic overview of study design 
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7.3.2 Study objectives 
The primary objective was to assess the relationship of JNJ-9375 dose concentrations to 
ex vivo thrombus formation under conditions of both low and high shear stress, and to 
compare these effects with placebo under the same rheological conditions. Bivalirudin, 
which blocks both exosite 1 and the active site of thrombin, was used as a positive 
control. Secondary objectives included a similar comparison of compound effects on 
platelet activation, markers of coagulation, and the fibrin and platelet components of 
thrombus formation. Finally, correlations between measured chamber concentrations of 
study drug and pharmacodynamic end-points were explored. 
 
7.3.3 Study population 
Healthy non-smoking male and female volunteers aged between 18 and 45 years 
(inclusive) with a body-mass index (BMI) of 18 to 35 kg/m2 were enrolled in this study. 
All volunteers underwent a detailed screening assessment for eligibility. Exclusion 
criteria included women who were pregnant or still lactating, or any clinically 
significant coexisting condition including hypertension, hyperlipidaemia, diabetes 
mellitus, cardiovascular disease, recent infective or inflammatory condition, 
coagulopathy, known liver disease or screening blood tests indicative of renal, liver, 
clotting, thyroid or haematological abnormality. Volunteers were not permitted to take 
any prescription or non-prescription medication (including acetylsalicylic acid, 
paracetamol, vitamins and herbal supplements) within 14 days of an experimental visit. 
Prior to each visit, volunteers must have abstained from alcohol for 24 hours and food 
including caffeine-containing products for 8 hours. Informed written consent was 
obtained from all volunteers before enrolment. The study was approved by the local 
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research ethics committee (reference 16-HV-025) and conducted in accordance with the 
Declaration of Helsinki. 
 
7.3.4 Sample size 
A sample size of 15 volunteers was selected based on previous data the average total 
thrombus formation under experimental conditions is approximately 12750 µm2 and for 
low shear is approximately 7500 µm2 with a standard deviation of approximately 550 
µm2 [201]. Therefore, a sample size of 13 completers is needed to detect a 10% (750 
µm2) difference in total thrombus area with 90% power and two-sided alpha of 0.05 
under low shear conditions.  
 
7.3.5 Study outcome measures 
7.3.5.1 Chamber concentrations of study drug 
Blood samples for determination of serum JNJ-9375 and plasma bivalirudin 
concentrations were taken immediately distal to the perfusion chamber into 3.5 mL 
serum gel and 2.7 mL sodium citrate (3.2%) tubes (Becton-Dickinson, Cowley, UK). 
JNJ-9375 samples were allowed to clot for 30 minutes then centrifuged at 1500 g (20 
°C) for 20 minutes. Bivalirudin samples were centrifuged at 1500 g (15 °C) for 15 
minutes within 1 hour of collection. Samples were then aliquoted and stored 
immediately at -70 °C before analysis. Concentrations of JNJ-9375 were determined by 
electro-chemiluminescence using the Meso Scale Discovery platform and plate reader 
(Rockville, Maryland, USA). Values were then regressed from the standard curve in 
Watson LIMS (version 7.4.1, Thermo, PA, USA) using a five-parameter logistic 
regression model with 1/Y2 weighting.  
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7.3.5.2 Coagulations assays 
Blood samples for coagulations assays (prothrombin time, activated partial 
thromboplastin time and thrombin time (undiluted and diluted)) were collected 
immediately distal to the final perfusion chamber into 4.5 mL sodium citrate (0.38% 
final v/v) tubes (Becton-Dickinson). Samples were centrifuged at 1500 g (15 °C) for 20 
minutes within 1 hour of collection. Plasma was then aliquoted and stored immediately 
at -70 °C before analysis using a STA-Compact-Max analyser (Stago, Parsippany, NJ, 
USA). The following reagents were used, for prothrombin time, STA-Neoplastine CI 
Plus, for activated partial thromboplastin time, STA-PTT Automate, and for thrombin 
time, STA-Thrombin. 
 
7.3.5.3 Platelet activation 
Blood (2.7 mL) was collected immediately distal to the final perfusion chamber into 
tubes containing 0.3 mL of 3.8% sodium citrate and Pefabloc FG (final concentration 
1.5 mg/mL; Quadratech Diagnostics, Surrey, UK). Pefabloc FG was added because it 
prevents excessive fibrin formation in response to thrombin that would preclude flow 
cytometry but does not interfere with platelet activation. After 5 minutes, samples were 
aliquoted into micro-centrifuge tubes pre-filled with or without agonist (adenosine 
diphosphate 20 µM, Sigma-Aldrich, Gillingham, UK; human alpha thrombin 0.1 U/mL, 
Enzyme Research Laboratories, Swansea, UK) and the following conjugated 
monoclonal antibodies: allophycocyanin (APC)-conjugated CD14, phycoerythrin (PE)-
conjugated CD62P and fluorescein isothiocyanate (FITC)-conjugated CD42a (Becton-
Dickinson). All antibodies were diluted 1:10. Samples were incubated for 15 minutes at 
room temperature before fixing with 1 % paraformaldehyde (p-selectin) or FACS-Lyse 
(Becton-Dickinson; platelet-monocyte aggregates). All samples were analysed within 
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24 h using a FACSCalibur flow cytometer (Becton-Dickinson). Data analysis was 
performed using FlowJo v10 (Treestar, Oregon, USA). 
 
7.3.5.4 Ex vivo perfusion model of thrombosis 
The effect of study compound on ex vivo thrombus formation was assessed using the 
Badimon perfusion chamber as described in detail in Chapter 2: Methods.   
 
7.3.5.5 Histomorphometric analysis 
Total thrombus formation, fibrin-rich thrombus formation and platelet-rich thrombus 
formation were assessed as described in detail in Chapter 2: Methods.   
 
7.3.6 Statistical Analysis 
After study completion, the database was locked and all statistical analyses carried out 
by an independent statistician. Categorical variables are expressed as percentages, 
continuous variables are expressed as mean ± standard deviation (SD). The effects of 
study compounds on study end-points were assessed by general linear mixed effect 
models with period and study compound as fixed effects, subjects as random effects. 
Chamber end-points were log-transformed and assessed separately by shear rate (low 
and high). From the models, point and interval estimates for means and mean 
differences versus placebo (absolute and %) were generated and analysed using the 
Least Significance Difference test. The correlation between plasma JNJ-9375 
concentrations and study end-points were determined by Pearson’s (r) or Spearman’s 
rank-order correlation (ρ) as appropriate. Two-sided p values of ≤0.05 were considered 







All 15 enrolled volunteers (10 male) completed the study in full, with no safety 
concerns. Mean age of the volunteers was 26 ± 5 years with a body-mass index of 24 ± 
3 kg/m2. 
 
7.4.1 Chamber concentrations of study drug 
 
Compound concentrations in the effluent of the perfusion chamber closely matched the 










Table 7.1. Target versus measured study drug concentrations 
Concentration  JNJ-9375  Bivalirudin 
Target, µg/mL 2.5 25 250 6 
Measured, µg/mL (SD) 1.93 (0.68) 22.3 (5.86) 214.0 (20.8) 6.92 (11.3) 
Figure 7.2. Correlation between plasma concentrations of JNJ-9375 and coagulation 
assays (n=15).  
Plots of plasma concentrations of JNJ-9375 versus [A] prothrombin time (PT), [B] activated 
partial thromboplastin time (APTT), and [C] thrombin time (TT). Data shown includes the 




JNJ-9375 caused dose-dependent prolongation of all measured blood coagulation 
markers, with thrombin time the most sensitive to the anticoagulant effect (Table 7.2). 
Pearson’s correlation coefficient between chamber plasma concentrations of JNJ-9375 
and coagulation assays was 0.98 for prothrombin time, 0.87 for activated partial 
thromboplastin time, and 0.91 for thrombin time (p<0.001 for all; Figure 7.2). 
 





































Dilute TT (secs) < LLOQ < LLOQ < LLOQ 151.5  [126.5, 176.6] > 501* 
Data shown are statistical means with 95% confidence intervals. *14 of 15 results > 501 s. Abbreviations used: PT, 
prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; and LLOQ, less than lower 




































































Figure 7.3. Impact of study drug on ex vivo platelet activation. 
Extra-corporeal administration of JNJ-9375 inhibited thrombin-simulated [A] p-selectin 
expression and [B] platelet-monocyte aggregates in a dose-dependent manner but had no 
effect on ADP activity. Data shown are the adjusted means (± 95% confidence intervals) and 
individual points. Statistical comparisons (Least Significance Difference test) versus placebo 
are represented above each plot: * p<0.05, ** p<0.01, *** p<0.001. Abbreviations used: 




Compared to placebo, JNJ-9375 2.5, 25 and 250 µg/mL inhibited thrombin (0.1 U/mL) 
stimulated platelet p-selectin expression (geometric mean fluorescent intensity, GMFI) 
by 46.5% [95% confidence intervals (CI), 4.6 to 97.5%; p=0.07], 95.2% [95% CI, 43.2 
to 147.2%; p<0.001] and 99.0% [95% CI, 46.1 to 151.9%; p<0.001] and platelet-
monocyte aggregates (GMFI) by -3.4% [95% CI, -56.1 to 49.4%; p=0.90], 56.3% [95% 
CI, 2.2 to 110.4%; p=0.04] and 69.9% [95% CI, 16.2 to 123.6%; p=0.01] (Figure 7.3). 
Chamber plasma concentrations of JNJ-9375 correlated with both platelet p-selectin 
expression (ρ=-0.83, p<0.001) and platelet-monocyte aggregates (ρ=-0.64, p <0.001). In 
contrast, JNJ-9375 had no effect on ADP (20 µM) stimulated platelet activation (p=ns 
for all). Bivalirudin exhibited a similar selective profile (Figure 7.3). 
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Ex vivo total thrombus formation was reduced at both low and high shear stress at the 
250 µg/mL concentration (Figure 7.4). Compared to placebo, JNJ-9375 (2.5, 25 and 
250 µg/mL) reduced mean total thrombus area by -7.4% (95% CI, -41.6 to 18.5%; 
p=0.60), 6.6% (95% CI, -23.1 to 29.2%; p=0.62) and 41.1% (95% CI, 22.3 to 55.3%; 
p<0.001) at low shear and by 9.8% (95% CI, -26.6 to 35.7%; p=0.54), 3.3% (95% CI, -
35.8 to 31.1%; p=0.85) and 32.3% (95% CI, 4.9 to 51.8%; p=0.025) at high shear. 
  
Figure 7.4. The effect of study compound on ex vivo total thrombus formation 
Extra-corporeal administration of JNJ-9375 inhibited total thrombus formation in a dose-
dependent manner at both [A] low shear stress (212 s-1) and [B] high shear stress (1690 s-1) 
shear stress. Data shown are the adjusted means (± 95% confidence intervals) for [Log] total 
thrombus area (µm2/mm) and individual points (n=15). Statistical comparisons (Least 
Significance Difference test) versus placebo are represented above each plot: * p<0.05, ** 
p<0.01, *** p<0.001. Abbreviations used: 9375, JNJ-9375. 
  
[A] Low shear [B] High shear 
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Figure 7.5. The effect of study compound on the platelet- and fibrin-rich thrombus 
formation 
Extra-corporeal administration of JNJ-9375 inhibited fibrin-rich thrombus deposition in a 
dose-dependent manner at both [A] low shear stress (212 s-1) and [C] high shear stress (1690 
s-1) shear stress, as compared to placebo. JNJ-9375 had no effect on platelet-rich thrombus 
deposition at either shear stress. Bivalirudin reduced fibrin-rich thrombus deposition at low 
and high shear stress, and platelet-rich thrombus deposition at high shear stress. Data shown 
are the adjusted means (± 95% confidence intervals) for [Log] fibrin- or platelet-rich 
thrombus area (µm2/mm) and individual points (n=15). Statistical comparisons (Least 
Significance Difference test) versus placebo are represented above each plot: * p<0.05, ** 
p<0.01, *** p<0.001. Abbreviations used: 9375, JNJ-9375. 
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Reductions in total thrombus area were driven by a dose-dependent decrease in fibrin-
rich thrombus deposition under both shear conditions (Figure 7.5). At peak dose (250 
µg/mL), JNJ-9375 reduced fibrin-rich thrombus area by 59.5% [95% CI, 37.8 to 73.7%; 
p<0.001] at low shear and 51.8% [95% CI, 37.7 to 62.7%; p<0.001] at high shear. 







Chamber plasma concentrations of JNJ-9375 correlated with total thrombus area at low 
(ρ=-0.56, p<0.001) and high (ρ=-0.32, p=0.03) shear; and fibrin-rich thrombus area at 
low (ρ=-0.66, p<0.001) and high (ρ=-0.70, p<0.001) shear (Figure 7.6). There was no 
correlation with platelet-rich thrombus area (p=ns for all). 
Figure 7.6. Correlation between plasma concentrations of JNJ-9375 and thrombus 
area.  
Plots of plasma concentrations of JNJ-9375 versus [A] total thrombus formation at low 
shear, [B] fibrin-rich thrombus formation at low shear, [C] platelet-rich thrombus formation 
at low shear, [D] total thrombus formation at high shear, [E] fibrin-rich thrombus formation 
at high shear, and [F] platelet-rich thrombus formation at high shear (n=15). ρ = Spearman’s 
rank order correlation. 
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7.4.5 Effect of bivalirudin on ex vivo thrombus formation 
Bivalirudin reduced total thrombus area at both low and high shear, also driven by a 
decrease in fibrin-rich thrombus formation (Figures 7.4 and 7.5). In contrast to JNJ-
9375, there was a modest reduction (p=0.01) in platelet-rich thrombus formation at high 





In this double-blind randomised controlled crossover study, ex vivo administration of 
JNJ-9375, a highly specific exosite 1 thrombin inhibitor, resulted in dose-dependent 
prolongation of blood coagulation and selective inhibition of thrombin-stimulated 
platelet activation. Thrombosis was reduced under rheological conditions of both low 
and high shear stress, driven principally by a reduction in fibrin-rich thrombus 
formation. We conclude that JNJ-9375 holds promise as an anticoagulant for the 
prevention and treatment of thromboembolic events and provide further insights into 
the role of exosite 1 in human thrombogenesis.  
 
This is the first description of the ex vivo antithrombotic effects of exosite 1 thrombin 
inhibition in native human blood under flow conditions. At a dose of 250 µg/mL, JNJ-
9375 reduced total thrombus area by over 40% and 30% at low and high shear 
respectively. Under the same conditions, high dose bivalirudin (equivalent to that used 
at the time of PCI) reduced thrombus formation by 65% at low shear and 56% at high 
shear; while in previous studies reductions of 14% with heparin (70 IU/kg bolus plus 15 
IU/kg/h infusion) [198], 26-28% with oral edoxaban (60 mg) [238], and up to 40% with 
serial dosing of the parenteral direct factor Xa inhibitor, DX-9065a [199], were 
reported. Importantly, therefore, we have shown that exosite 1 thrombin antagonism 
alone is sufficient to substantially reduce ex vivo human thrombus formation. 
Moreover, given reductions were comparable (if not superior) in magnitude to the 
clinically approved anticoagulant edoxaban, our results suggest a high probability of in 
vivo antithrombotic efficacy. 
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JNJ-9375 resulted in dose-dependent prolongation of prothrombin time, activated 
partial thromboplastin time and thrombin time. As expected, thrombin time was most 
sensitive to the anticoagulant effect. Although direct oral anticoagulants are licensed for 
use without the need for routine monitoring, there are clinical situations in which 
readily available assays to measure anticoagulant activity may be useful. Our data 
suggests that if indicated, thrombin time, and to a lesser extent prothrombin time and 
activated partial thromboplastin time, may provide a useful assay for measuring the 
extent of exosite 1 inhibition and JNJ-9375 activity. 
 
The outstanding challenge in anticoagulation is the development of drugs that can 
provide equivalent (or superior) antithrombotic efficacy but with a significantly lower 
bleeding risk. While the safety of JNJ-9375 has yet to be demonstrated in clinical trials, 
several lines of evidence indicate the potential for favourable outcomes. On a 
mechanistic level, selective inhibition of thrombin through exosite 1 specific 
antagonism is attractive because of the capacity to prevent fibrin formation without 
necessarily interfering with other (active site and exosite 2 dependent) protease 
interactions relating to haemostasis. For example, both the active site and exosite 2 are 
involved in catalytic feedback activation of clotting cofactors V, VIII, XI and XIII, with 
deficiencies of each of these factors associated with bleeding diatheses [257–259].  
 
Thrombin is also a potent platelet agonist, and whereas over-aggregation may lead to 
pathological events, early platelet responses are central to haemostasis. Thrombin 
activates platelets through binding to platelet surface GPIb and protease-activated 
receptors 1 (PAR1) and 4 (PAR4). Exosite 1 interacts with PAR1 to facilitate efficient 
receptor cleavage [127], whereas PAR4 activation and GPIb binding are largely 
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dependent on the active site and exosite 2 respectively [116,260]. In the present study, 
JNJ-9375 selectively inhibited thrombin stimulated platelet activation but was not 
associated with a reduction in platelet deposition. This is consistent with previous 
reports that exosite 1 inhibition only weakly inhibits thrombin-induced platelet 
aggregation and does not affect platelet collagen binding [183,261]. Collectively, these 
results suggest potentially favourable differential effects on thrombin-platelet 
responses, that could be especially useful in clinical situations where combined 
treatment with an antiplatelet is required [262,263]. This is speculative and requires 
further exploration. Future studies are required to examine the effects of JNJ-9375 on 
platelet adhesion, thrombosis and bleeding, alone and in combination with existing 
antiplatelet agents. 
 
Indirect evidence that exosite 1 thrombin inhibition may be associated with a low 
haemorrhagic potential is supported by data from animal studies of thrombosis and 
bleeding. Using a baboon arteriovenous shunt model, Cadroy and colleagues found that 
exosite 1 thrombin inhibition prevented thrombus formation but did not affect the 
ability to form haemostatic plugs [183]. More recently, JNJ-9375 demonstrated a 
substantially wider therapeutic index when compared to apixaban in rats and 
cynomolgus monkeys [179]. Further insight comes from the case report of an anti-
exosite 1 thrombin IgA antibody (from which JNJ-937 was subsequently synthesized to 
mimic) identified in a patient presenting with a large traumatic subdural haematoma 
and persistently abnormal clotting studies [184]. Despite continued evidence of intense 
anticoagulation (prothrombin time, 40 s; activated partial thromboplastin time, 240 s; 
thrombin time with bovine thrombin, 173 s), the patient made a full recovery without 
surgical intervention and had no abnormal bleeding events during 8 years of follow up. 
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7.6 LIMITATIONS 
Our study has some potential limitations. First, only a modest number of volunteers 
were studied. However, problems associated with intra-group variability were 
minimised by the crossover design that allowed each volunteer to serve as their own 
control. Second, although the exposed porcine aortic media used in the perfusion model 
presents many of the common constituents of an injured human blood vessel (including 
type I collagen), it is unlikely to contain tissue factor (TF) [249–251]. TF activates the 
coagulation cascade and is an important contributor to thrombogenicity [252,253]. 
Nevertheless, this does not overly limit our model for the assessment of thrombosis 
because binding of blood borne circulating TF is sufficient to allow activation of the 
coagulation cascade and thrombus propagation [249,250,254–256]. Indeed, previous 
studies have confirmed that thrombus formed from human blood perfused over porcine 
tunica media (devoid of TF) stains heavily for TF [249,250]. Third, we used an anti-
fibrin(ogen) antibody, which recognises both fibrinogen and fibrin, to examine the 
fibrin component of thrombus formation. However, the chamber is perfused by saline at 
the end of the experiment washing away unbound cells, proteins and other molecules, 
such as fibrinogen, leaving only adherent thrombus. Thus, histomorphometric 
quantification of fibrin-rich thrombus area is unlikely to be affected by this cross-
reacting antibody and our findings are consistent with previous studies using the same 
immunohistochemical approach [264–267]. Fourth, while we have shown that exosite 1 
thrombin inhibition reduces fibrin-rich thrombus formation, determining how JNJ-9375 
alters the dynamics of clot development, stabilisation and dissolution might further 
inform therapeutic potential and are areas for future exploration. Finally, the study 
included ex vivo experiments only and thus lacked hard clinical end-points necessary to 
draw any conclusions regarding the safety or efficacy of this novel anticoagulant in 
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practice. However, given this was a translational study designed to examine for the first 
time the effects of exosite 1 thrombin inhibition with JNJ-9375, we felt our study 
design appropriate.   
 
7.7 CONCLUSION 
In conclusion, JNJ-9375, a highly specific exosite 1 thrombin inhibitor, demonstrated 
substantial reductions in ex vivo thrombosis in native human blood under flow 
conditions. These reductions were driven by a decrease in fibrin-rich thrombus 
formation and were comparable in magnitude to clinically approved anticoagulants. Our 
findings suggest JNJ-9375 represents a promising novel class of anticoagulant, and that 
further clinical studies are warranted. A phase 2 trial comparing the safety and efficacy 
of JNJ-9375 to apixaban in patients undergoing elective total knee replacement surgery 











8 Conclusions and future directions 
 
8.1 THESIS DIRECTION AND METHODOLOGY 
The primary purpose of this thesis was to examine the therapeutic potential of novel 
targets for the prevention of thrombosis in humans. Given the central role of platelet 
aggregometry in this process, it was important to first establish the repeatability and 
agreement between traditional LTA and the most widely used method in our institute, 
96-WPA. This allowed determination of the most appropriate methodology for the 
remainder of the thesis and crucially provided reference values above which we could 
be 95% confident in future studies a true change in aggregation had occurred. 
 
The original target of interest was PAR4, a platelet receptor for thrombin. After a series 
of in vitro studies exploring PAR4 agonism and antagonism in the presence and 
absence of other major platelet agonists and their cognate inhibitors, a phase 1 
randomised open label blinded endpoint trial was designed to examine for the first time 
the effect of oral PAR4 antagonism in healthy volunteers on ex vivo human thrombosis. 
After presenting early results, we were approached to conduct a similar study with 
another novel antithrombotic agent, JNJ-9375. This represented an excellent 
opportunity on a number of levels. Like PAR4 inhibition, exosite 1 thrombin inhibition 
specifically targets direct functions of thrombin in mediating thrombosis. However, in 
contrast to PAR4 inhibition, the primary mechanism of action is one of anticoagulation 
rather than platelet blocking. Moreover, the antithrombotic effects of exosite 1 thrombin 
inhibition in native human blood under flow conditions were previously unknown. 
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In the early stages, the intention was to investigate the wider actions of PAR4 in the 
vasculature if an effect on thrombosis was demonstrated. Our group has previously 
shown that PAR1 is an important mediator of vascular tone and function in humans. A 
similar panel of studies was proposed; however, a number of significant challenges 
were encountered. No PAR4 agonist had ever been given to humans before. 
Accordingly, and in line with the phase 1 review committee, we felt it important to first 
conduct a safety and tolerability study in mice. Manufacturing the agonist to sufficient 
purity and to Current Good Manufacturing Practice regulations within Europe proved 
prohibitively expensive. This was overcome by sourcing from a non-European site but 
mandated further quality and sterility testing on arrival to the UK, followed by stability 
testing for several months. This process took over 12 months with a further 4 months to 
conduct the study. While these delays enabled the JNJ-9375 studies to be undertaken, 
an important part of this thesis, they invariably resulted in insufficient time to go on and 
examine the in vivo vascular effects of PAR4 agonism in humans. Nevertheless, the 
data represents the culmination of an enormous effort and provides the key groundwork 
for future researchers.   
 
One of the major challenges in developing more effective antithrombotic drugs is the 
avoidance of increased bleeding. However, determination of bleeding risk prior to 
undertaking large trials is challenging. There are no safe human models, while data 
from animal studies has repeatedly proven to have significant limitations. Bleeding risk 
and the impact of an increase in bleeding on therapeutic efficacy are also person and 
situation specific. Key to maximising gain is to develop agents with high selectivity and 
specificity for the principal pathways associated with driving occlusive thrombus for 
that specific pathology. This had a strong influence on the methodology and materials 
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used, particularly the Badimon chamber. By adopting this model of thrombosis, we 
were not only able to determine an antithrombotic effect, but also whether this was 
shear dependent and driven by reductions in platelet-rich thrombus, fibrin-rich 
thrombus, or both. Such data provides important insights into what pathologies and 





8.2 96-WELL PLATE AGGREGOMETRY 
Platelet aggregometry is critical to the evaluation of patients with suspected platelet 
dysfunction and plays a central role in the investigation and development of 
antithrombotic agents. 96-WPA is a newer method of platelet aggregation that may 
offer advantages over the current gold standard LTA. However, data regarding the test-
retest repeatability of 96-WPA and agreement between these two methods was lacking. 
 
96-WPA demonstrated good within- and between-repeatability for the determination of 
peak platelet aggregation and EC50 with results comparable to LTA. Conversely, there 
was a systematic measurement bias with two of the three agonists studied and the 
methods should not be considered interchangeable. Bednar and colleagues reported 
similar results. Compared to LTA, 96-WPA was associated with a numerically lower 
EC50 in 3 out of the 4 thrombin-agonists studied with results identical for the fourth 
[268]. Thus, our findings are consistent with the only other published data. As to the 
cause of the measurement bias, this remains uncertain. 96-WPA uses shaking to induce 
mixing and aggregation whereas LTA uses vortexes. This can lead to differences in the 
physical forces applied, which are a key aspect of platelet activation [269]. However, as 
there was no significant bias for AA, physical forces alone are unlikely to fully explain 
these differences and further research is required.   
 
It has been suggested 96-WPA may be technically easier than LTA. Given the 
requirement for reverse pipetting and smaller test volumes, this is not our experience. 
Nonetheless, 96-WPA undoubtedly facilitates a much greater throughput and in our 
research institute we are increasingly using this approach. 96-WPA also continues to 
evolve. The Optimul method is an iteration of 96-WPA in which individual wells are 
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precoated with one of seven concentrations of AA, ADP, collagen, epinephrine, 
ristocetin, TRAP-6 amide or U46619, before being lyophilised, vacuum-sealed, foil-
packed and stored for up to 24 weeks [211]. By removing the need for daily preparation 
and pipetting of agonists, this approach further simplifies and standardizes 96-WPA. 
Further benefits including improved test-retest repeatability would not be surprising but 




8.3 PAR4 AGONISM AND ANTAGONISM 
PAR4 is a promising novel target for antiplatelet therapy with mechanistic and animal 
data indicating the potential for a wide therapeutic index. A phase 1 parallel group 
prospective randomized open-label blinded endpoint trial was conducted to examine for 
the first time the antiplatelet, anticoagulant and antithrombotic effects of oral PAR4 
antagonism with BMS-986120 in humans. We also sought to determine whether 
platelet responses to PAR4 stimulation are dependent on additional input or vice-versa. 
 
BMS-986120 mechanism of action 
To be confident in our conclusions, it was important to confirm the selectivity of BMS-
986120 for inhibiting PAR4 under the study conditions. Both in vitro and oral 
administration of BMS-986120 markedly attenuated PAR4-AP induced platelet 
activation and aggregation with no effect on PAR1-AP, AA or ADP platelet 
stimulation. Following a single oral dose, platelet responses made an almost complete 
recovery within 24 hours. Our results therefore add to previous data that BMS-986120 
is a highly selective, potent and reversible PAR4 antagonist [131]. 
 
PAR4 platelet activation and aggregation 
There is conflicting evidence as to whether platelet responses to PAR4 signaling are 
dependent on additional input. Covic and colleagues reported that up to 50% of the 
PAR4 intracellular Ca2+ signal is due to released ADP acting on the P2Y12 receptor and 
is conditional on prior PAR1 activation [40]. However, in a more recent study, PAR4-
mediated platelet aggregation was shown not to be dependent on ADP with PAR4 
acting in parallel rather than contingent on the ADP/P2Y12 - PI3K pathway [129]. 
Under conditions designed to mimic thrombin levels within the local environment of a 
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developing clot, we found that platelet responses to PAR4 stimulation were not 
dependent on input from other major agonist-receptor pathways and vice-versa. This is 
consistent with evidence PAR4 activation occurs well after platelet degranulation [130] 
and induces sustained intracellular Ca2+ and protein kinase C signals independent of 
additional support [114,129,130]. Importantly, therefore, our results identify PAR4 
signaling as a major mechanism through which pathological platelet activation and 
aggregation can continue despite current standard of care antiplatelet agents. 
 
Coagulation 
Activated platelets upregulate surface phosphatidylserine and release procoagulant 
microvesicles. The resulting surfaces facilitate assembly of activated clotting factor 
complexes leading to thrombin generation and fibrin formation. PAR4 inhibition has 
been shown to abolish thrombin-induced platelet phosphatidylserine exposure [248] and 
compared to PAR1, stimulation of PAR4 leads to faster and more robust thrombin 
generation [270]. These data suggest PAR4 has a role in platelet procoagulant activity. 
Consistent with this, BMS-986120 was associated with a small but significant reduction 
in fibrin-rich thrombus formation that occurred in the absence of PT or APTT 
prolongation.  
 
Whether this additional effect on platelet function is therapeutically beneficial or 
harmful is unknown. Aspirin and P2Y12 antagonists inhibit platelet procoagulant 
activity [271] and it has been suggested this may add to the increased bleeding seen 
with each of these agents. Scott syndrome, a congenital disorder in platelet, red cell, 
and lymphocyte phosphatidylserine exposure, is associated with a moderately severe 
bleeding phenotype [272]. However, it would seem unlikely PAR4 inhibition affects 
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phosphatidylserine exposure to the same broad extent as Scott syndrome and both 




Research into the antithrombotic potential of PAR4 antagonism is of major clinical 
importance given the large unmet clinical need for more effective antiplatelet therapy. 
We examined the effect of BMS-986120 on ex vivo human thrombosis using the highly 
validated Badimon chamber. Under conditions representative of deep arterial injury in a 
stenosed coronary artery, a single 60 mg oral dose of BMS-986120 prevented thrombus 
formation by nearly a third. Moreover, reductions were comparable in magnitude to 
high loading doses of aspirin ± clopidogrel, suggesting a high likelihood of in vivo 
antithrombotic efficacy. 
 
An interesting finding was that compared to current standard of care antiplatelet agents, 
PAR4 antagonism appeared to have greater specificity for inhibiting high versus low 
shear thrombus formation. Most atherothrombotic events occur at sites of high shear 
stress, whereas many treatment-related bleeding events occur in low shear 
environments [241–245,273,274]. Therefore, antiplatelet agents that are more selective 
for inhibiting high shear thrombus formation may allow at-risk vascular beds to be 
targeted with superior precision. Further research is required to confirm our findings 




One of the major challenges in developing more effective antithrombotic therapies is 
the avoidance of increased bleeding.  
 
Mechanistic data suggests PAR4 may be an ideal target because of its differential role 
in early and late platelet signaling. In animal studies, PAR4 inhibition with BMS-
986120 was associated with a substantially reduced bleeding risk as compared to 
clopidogrel  [131]. Combining our trial with a previous ascending-dose study, BMS-
986120 has been administered to a total of 62 healthy volunteers with no treatment-
related bleeding events recorded [146]. However, these trials were neither designed nor 
powered for the detection of bleeding and results from animal models do not always 
translate well to humans, as exemplified by PAR1 antagonists [9,80]. Thus, while data 
to date suggests we can be optimistic, whether or not PAR4 inhibition provides a lower 
risk of bleeding than existing agents remains to be determined.  
 
Future directions 
Results from this thesis have recently been confirmed in a phase 0 study in healthy 
volunteers examining the additional benefit of PAR4 antagonism when combined with 
the anticoagulant apixaban [275]. Extracorporeal administration of BMS-986141, a 
potent PAR4 antagonist similar to BMS-986120, substantially reduced total (-44.4%) 
and platelet-rich (-39.3%) ex vivo thrombus formation. BMS-986141 with apixaban 
caused a further modest reduction in total thrombus area (9.6% to 12.4%), especially 
under conditions of high shear stress.  
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We believe PAR4 inhibition has real potential for in vivo antithrombotic efficacy and 
that further investigation in larger phase II clinical trials is warranted. Often this 
involves combining the new agent with existing standard of care. However, this 
requires careful consideration, particularly if PAR4 inhibition is to be combined with a 
P2Y12 antagonist. PAR4 acts independently of the P2Y12/PI3K pathway to sustain 
GPIIb/IIIa activation. Thus, blocking both pathways is likely to promote potent 
GPIIb/IIIa inhibition [129]. As with current GPIIb/IIIa antagonists, this could provide 
highly efficacious antithrombotic protection but may also precipitate substantial 
bleeding. Consequently, we suggest combinations of PAR4 inhibition and existing 
antiplatelet agents are first explored in animal and human models of thrombosis and 
bleeding. Such studies would not only add to our understanding of thrombosis but may 
have important implications for future clinical trial design.  
 
A major area for future PAR4 inhibition research is exploration of the potential for 
additional clinical effects beyond platelet antagonism. Data from animal models 
suggests PAR4 inhibition may protect against ischaemia-reperfusion injury as well as 
restenosis in diabetic conditions [154–156]. Such pluripotent effects would be highly 
advantageous. PAR4 is also thought to be involved in the control of vascular tone 
[276,277] and this may have important clinical applications. However, to date, there 
have been no studies examining the in vivo vascular effects of PAR4 activation in man.   
 
Our research group has previously investigated the vascular actions of PAR1 through 
local infusion of a PAR1-AP into the dorsal hand vein and brachial artery of healthy 
volunteers. Results from these studies demonstrated for the first time that PAR1 
activation in humans results in endothelial-dependent arterial dilatation, endothelium-
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independent venoconstriction and release of tissue plasminogen activator [27]. To 
enable a similar future research programme into PAR4, we examined the safety and 
tolerability of systemic PAR4 agonism in mice with the highly selective PAR4-AP, 
AYPGKF-NH2. Even at suprathreshold doses, intravenous AYPGKF-NH2 was well 
tolerated with no evidence of acute systemic toxicity, thrombosis, inflammation, organ 
injury or dysfunction. Results from this thesis support the safety of AYPGKF-NH2 to 
investigate the in vivo effects of PAR4 in man. 
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8.4 EXOSITE 1 THROMBIN INHIBITION 
Pre-clinical data suggests exosite 1 thrombin antagonism may enable antithrombotic 
efficacy without the concomitant bleeding risk seen with current agents. We conducted 
a double-blind randomised controlled five-way crossover study to examine the 
anticoagulant and antithrombotic effects of exosite 1 thrombin inhibition with JNJ-9375 
in human blood using a translational model of ex vivo thrombosis. 
 
Coagulation 
Exosite 1 thrombin inhibition prolonged prothrombin time, activated partial 
thromboplastin time, and thrombin time in a dose-dependent manner. There was a 
strong correlation between plasma concentrations and coagulation times with thrombin 
time the most sensitive to the anticoagulant effect. These findings are consistent with 
previous in vitro studies [185] and suggest thrombin time could provide a useful and 
readily available clinical test for measuring the in vivo activity of exosite 1 thrombin 
inhibitors if required. 
 
Thrombosis 
This thesis provides the first evidence that exosite 1 thrombin inhibition with JNJ-9375 
substantially inhibits ex vivo human thrombosis. At the highest dose studied, JNJ-9375 
reduced total thrombus formation by over 40% at low shear and 30% at high shear. By 
applying immunofluorescent staining to histomorphometric quantification, we were 
able to show that reductions in thrombosis were driven by a decrease in fibrin-rich 
thrombus formation. This is consistent with data from animal studies [179,181,182]. 
Our results indicate exosite 1 has a major role in human thrombus formation and 
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It has been hypothesized the distinct way in which exosite 1 thrombin inhibition 
modulates thrombin may reduce bleeding. This is supported by data from animal 
studies [179] and although clinical trial evidence is lacking, the long-term follow-up of 
a patient with an exosite 1 thrombin antibody has afforded unique insights into the 
potential haemostatic sparing effects of exosite 1 thrombin inhibition in vivo [184]. 
However, precisely how exosite 1 thrombin inhibition might avoid bleeding remains to 
be fully understood. 
 
An obvious candidate is the greater capacity for exosite 1 thrombin inhibition to 
maintain adequate feedback activation and auto-amplification of thrombin production. 
This is because appropriate levels of propagation phase thrombin generation appear 
critical to stabilizing barrier function of the developing blood clot [278–281]. 
Alternatively, exosite 1 thrombin inhibition may avoid overly interfering with 
thrombin-mediated platelet responses relating to haemostasis. Previous studies have 
shown exosite 1 thrombin inhibition only partially inhibits thrombin-mediated platelet 
aggregation and does not affect platelet-collagen binding or haemostatic plug formation 
[183,261]. Our data supports these findings, demonstrating that in contrast to 






Following positive data from this and other preclinical studies, a phase 2 double blind 
RCT (NCT03251482) was undertaken comparing JNJ-9375 against apixaban for the 
prevention of thromboembolic events after elective knee surgery [282]. The planned 
enrolment was 1500 from multiple sites. The primary efficacy endpoint (asymptomatic 
or symptomatic venous thromboembolism) occurred in 12.2%, 33.3%, 27.3%, 30.0%, 
and 32.0% of patients randomised to apixaban 2.5 mg bd (n=49), JNJ-9375 0.3 mg/kg 
(n=30), JNJ-9375 0.6 mg/kg (n=33), JNJ-9375 1.2 mg/kg (n=30), and JNJ-9375 1.8 
mg/kg (n=97), respectively. There were no major bleeds with either JNJ-9375 or 
apixaban. Because JNJ-9375 was statistically less effective than apixaban, the study 
was stopped early (n=308). 
 
On the face of it, these results are highly disappointing. However, even at the highest 
dose of 1.8 mg/kg, plasma concentrations of JNJ-9375 can be estimated to be far lower 
than what we found to be efficacious. Thus, rather than dismissing exosite 1 thrombin 
antagonism and JNJ-9375 entirely, we believe results from this study simply validate 
our model and findings. Further studies are required with higher doses of JNJ-9375 or 
more potent exosite 1 thrombin inhibitors before meaningful conclusions can be drawn 
as to the potential of this novel class of anticoagulant.  
 
The management of patients with an indication for anticoagulant and antiplatelet 
therapy is an increasingly common issue. These patients continue to present a major 
challenge because of the difficulty balancing efficacy for the prevention of both arterial 
and thromboembolic events against the increased risk of bleeding seen with all current 
anticoagulant and antiplatelet combinations. It is suggested this may relate to the 
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overlapping effect of existing anticoagulants on thrombin-mediated platelet responses 
leading to excessive platelet inhibition when combined with aspirin and P2Y12 
antagonists. We propose the platelet-sparing effects of exosite 1 inhibition may avoid 
this issue, allowing optimal anticoagulant and optimal antiplatelet therapy to be 
combined more readily. However, this is speculative and the combined effects of 
exosite 1 thrombin inhibition and antiplatelet agents remain to be explored.  
 
Alternative strategies for more effective anticoagulation are also in development. Of 
primary interest are targeting factors XI and XII of the contact pathway. Importantly, 
factor XII appears to have a very limited role, if any, in haemostasis. However, the 
therapeutic potential of targeting factor XII may be severely undermined by the ability 
of the extrinsic pathway to activate factor XI and therefore bypass factor XII inhibition 
[283,284]. An exception to this may be thrombosis induced on the surface of medical 
devices such as vascular catheters, leads or extracorporeal circuits [285].  
 
In contrast to factor XII, inhibition of factor XI prevents amplification of coagulation 
by either pathway [284]. While the risk of bleeding may be marginally higher than 
factor XII inhibition, the overall therapeutic index would appear to be more favourable. 
Consequently, strategies to target factor XI have been the primary focus of most 
research and development. In a phase II study of patients (n=300) undergoing elective 
knee replacement, factor XI inhibition with an antisense oligonucleotide reduced the 
risk of post-operative VTE compared to enoxaparin (4% vs. 30%) without increasing 
the risk of bleeding [286]. Other compounds including active site peptidomimetic 
inhibitors of FXIa have completed phase I clinical trials with the results awaited [287]. 
There remains substantial work before any of these compounds enter clinical practice 
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and it will be of enormous interest to see how targeting opposite ends of the coagulation 
cascade (intrinsic / extrinsic pathway versus exosite 1 thrombin inhibition) compare and 






Cardiovascular disease remains one of the leading global causes of morbidity and 
mortality, driven largely by thrombotic and thromboembolic complications. Results 
from this thesis provide the first evidence that PAR4 inhibition with BMS-986120 and 
exosite 1 thrombin antagonism with JNJ-9375 substantially inhibit ex vivo human 
thrombosis. These emerging antiplatelet and anticoagulant strategies warrant further 
investigation in larger clinical trials and may provide the next paradigm shift in the 
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Duration of dual antiplatelet therapy in acute 
coronary syndrome 
Simon John Wilson,1 David E Newby,1 Dana Dawson,2 John Irving,3 Colin Berry4
ABSTRACT
Despite a large volume of evidence supporting the 
use of dual antiplatelet therapy in patients with acute 
coronary syndrome, there remains major uncertainty 
regarding the optimal duration of therapy. Clinical trials 
have varied markedly in the duration of therapy, both 
across and within trials. Recent systematic reviews and 
meta-analyses suggest that shorter durations of dual 
antiplatelet therapy are superior because the avoidance 
of atherothrombotic events is counterbalanced by the 
greater risks of excess major bleeding with apparent 
increases in all-cause mortality with longer durations. 
These findings did not show significant heterogeneity 
according to whether patients had stable or unstable 
coronary heart disease. Moreover, the potential hazards 
and benefits may differ when applied to the general 
broad population of patients encountered in everyday 
clinical practice who have markedly higher bleeding and 
atherothrombotic event rates. Clinicians lack definitive 
information regarding the duration of therapy in 
patients with acute coronary syndrome and risk scores 
do not appear to be sufficiently robust to address these 
concerns. We believe that there is a pressing need 
to undertake a broad inclusive safety trial of shorter 
durations of therapy in real world populations of patients 
with acute coronary syndrome. The clinical evidence 
would further inform future research into strategies for 
personalised medicine.
INTRODUCTION
A ruptured or eroded coronary atherosclerotic 
plaque is the principal underlying cause of an acute 
coronary syndrome. The greatest ‘at risk’ period 
is during this early phase of plaque instability and 
healing, with recurrent event rates peaking in the 
first month. By 3 months, the plaque has usually 
stabilised, healed and subsequent event rates return 
to the background rates seen in patients with stable 
coronary heart disease.1–3 Indeed, beyond 3 months, 
recurrent events commonly occur on plaques at 
other sites within the coronary circulation.3 From 
first principles, the first 3 months is the most critical 
time for interventions to reduce recurrent cardio-
vascular events after an acute coronary syndrome 
(ACS). This is consistent with event rates seen in 
all clinical trials of patients with acute coronary 
syndrome: an initial time-varying high event rate 
that reverts to a consistent linear lower event rate 
from 3 months onwards (table 1).1 2 4 5
Antiplatelet therapy
In an acute coronary syndrome, thrombus forma-
tion occurs under conditions of high shear stress 
and is principally driven by platelet aggregation 
(figure 1). This dominance of platelet aggregation 
during intracoronary thrombus formation reflects 
the dramatic effects that antiplatelet therapies have 
on clinical outcomes (table 2). Aspirin was the 
first antiplatelet therapy which induced a halving 
in event rates in patients with acute coronary 
syndrome:6 7 such a large effect size has rarely been 
surpassed in other domains of cardiology.
Given aspirin’s remarkable success, it is perhaps 
unsurprising that adjunctive antiplatelet therapies 
have been investigated to build on these bene-
fits, especially as there are multiple mechanisms 
of platelet activation beyond the cyclo-oxygenase 
pathway (figure 2). However, as platelets are essential 
to primary haemostasis, there is a balance between 
reducing the incidence of future cardiovascular 
events and causing harm from an increased risk of 
bleeding. The P2Y12 receptor antagonists are a class 
of drugs that have gained widespread acceptance 
since they appear to provide additional thrombotic 
protection at the expense of modest increases in 
bleeding. Their use is principally associated with 
reductions in recurrent myocardial infarction1 4 5 8 
and in a few trials, reductions in cardiovascular 
events and mortality.5 8 Other antiplatelet therapies 
(figure 2) are available but have variable net clinical 
benefit and for the purposes of this review, we will 
consider only dual antiplatelet therapy (DAPT) with 
aspirin and P2Y12 receptor antagonism.
Dual antiplatelet therapy
The benefit of dual antiplatelet therapy following 
an acute coronary syndrome was established by the 
CURE,1 COMMIT/CCS-28 and CLARITY-TIMI 
289 trials. Combined aspirin and clopidogrel 
therapy reduced the 1-year incidence of cardiovas-
cular events by approximately 20% compared with 
aspirin alone. More potent and consistent P2Y12 
receptor inhibition with either prasugrel or tica-
grelor was superior to clopidogrel in the subsequent 
TRITON4 and PLATO5 trials.
The evidence for dual antiplatelet therapy in 
patients with stable coronary heart disease is less 
distinct. In the CHARISMA trial,2 the addition 
of clopidogrel to aspirin in patients with estab-
lished cardiovascular disease or at high risk of 
clinical atherosclerotic disease did not reduce 
cardiovascular events and was associated with an 
increase in severe bleeding. There was, however, a 
suggestion of improved outcomes in patients with 
established atherothrombotic disease, particularly 
those with a history of myocardial infarction. The 
PEGASUS-TIMI 5410 trial compared aspirin mono-
therapy to a combination of aspirin and ticagrelor 
in patients with a previous myocardial infarction 
and at least one additional high-risk factor. At a 
mean of 33 months, ticagrelor (60 mg) reduced the 
Review
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incidence of cardiovascular death, myocardial infarction or stroke 
(7.77% vs 9.04%) at the expense of increased thrombolysis in 
myocardial infarction (TIMI) major bleeding (2.30% vs 1.06%) 
and a neutral effect on overall mortality. On the basis of these 
trials, combination antiplatelet therapy would appear to confer 
only a small ischaemic benefit at the cost of a significant bleeding 
risk. European11 and North American12 guidelines therefore do 
not recommend dual antiplatelet therapy in patients with stable 
atherothrombotic disease but acknowledge that with careful 
consideration, combined antiplatelet therapy may be beneficial in 
some high-risk patients.
Duration of dual antiplatelet therapy: clinical trials
Current European13 and North American12 guidelines advise 
continuing dual antiplatelet therapy for 1 year following an acute 
coronary syndrome. These recommendations are made on the 
basis of early studies4 5 14 15 demonstrating a sustained increased 
risk of thrombotic complications, including stent thrombosis and 
spontaneous cardiovascular events, beyond 6 months. However, 
the greatest absolute reductions in cardiovascular events with 
dual antiplatelet therapy are seen in the first 3 months (table 1) 
and since these studies, advances in drug-eluting stent technology 
have led to a substantially reduced incidence of late (>30 days) 
and very late (>1 year) stent thrombosis.16
In recent trials of patients treated with newer generation drug-
eluting stents, shorter durations of dual antiplatelet therapy 
(3 months to 6 months) were non-inferior to 1217–22 months or 
2423 months of treatment with regard to either. The primary 
end point was either a composite of cardiovascular events or 
cardiovascular events plus major bleeding. Moreover, all of these 
trials included patients with an acute coronary syndrome (range 
23% to 74% of study population) and in those who undertook 
prespecified subgroup analyses, there was no heterogeneity in 
treatment effect between stable and unstable coronary artery 
disease was observed (figure 3).
Beyond 12 months, there remains a residual risk of local and 
systemic atherothrombotic complications24 and a number of 
studies have examined whether extended dual antiplatelet therapy 
2 Wilson SJ, et al. Heart 2017;1:1–8. doi:10.1136/heartjnl-2016-309871
















0–1 4.3 5.5 1.2 22 [9, 32] 84
1–3 1.8 2.5 0.8 32 [13, 46] 240
3–6 1.8 1.8 0.0 4 [!27, 27] 5174
6–9 1.3 1.4 0.1 6 [!34, 34] 3171
9–12 1.1 1.3 0.2 14 [!32, 44] 1600
0–12 10.3 12.6 2.4 19 507
CHARISMA trial
0–28 6.8 7.3 0.5 7* 5591
Subgroup of patients with clinically evident atherosclerotic disease
0–28‡ 6.9 7.9 1.0 12 2800
*Primary endpoint – cardiovascular death, myocardial infarction and stroke.
ARR, absolute risk reduction; CI, confidence intervals; CVD, cardiovascular death; MI, myocardial infarction; NNT, number needed to treat; RRR, relative risk reduction.
Figure 1 Immunofluorescent staining of human thrombus (platelets, green; fibrin, red) formed at high shear"stress.
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(>12 months) following percutaneous coronary intervention may 
be beneficial. In the DES-LATE25 and ARCTIC-INTERRUPTION 
trials,26 prolonged treatment with dual antiplatelet therapy (18–30 
months vs 12 months) neither reduced the incidence of cardiovas-
cular events nor increased the risk of major bleeding. Among those 
patients presenting with an acute coronary syndrome, primary 
and secondary ischaemic end points did not differ from the global 
treatment population. In the DAPT trial,27 the largest and only 
double-blinded study, extended dual antiplatelet therapy (30 
months vs 12 months) reduced the risk of major adverse cardio-
vascular and cerebrovascular events (4.3% vs 5.9%), myocardial 
infarction (2.1% vs 4.1%) and stent thrombosis (0.4% vs 1.4%) 
but at a cost of increased moderate or severe bleeding (2.5% vs 
1.6%) and a borderline rise in all-cause mortality (2.0% vs 1.0%; 
p=0.05). Treatment effect did not differ between patients with or 
without a history of myocardial infarction for any of the co-pri-
mary end points including bleeding (figure 3).
Duration of dual antiplatelet therapy: systematic reviews and 
meta-analyses
Meta-analyses of trials using dual antiplatelet therapy in patients 
receiving intracoronary stents have compared short (3–6 
months), 12-month and prolonged (>12 months) durations of 
therapy.28 29 Longer treatment periods reduced the incidence 
of myocardial infarction and stent thrombosis but at a cost of 
increased major bleeding and with a tendency to increase overall 
mortality because of an increase in non-cardiovascular death. 
However, the majority of patients included in these analyses had 
stable coronary artery disease and few patients with acute coro-
nary syndrome were treated with ≤6 months of dual antiplatelet 
therapy. In a recent meta-analysis30 that included only patients 
with a history of acute coronary syndrome, prolonged dual 
antiplatelet therapy reduced the risk of cardiovascular death 
(RR 0.85; 95% CI: 0.74 to 0.98, p=0.03) without an increase 
in non-cardiovascular death (RR 1.03, 95% CI 0.86 to 1.23; 
p=0.76) or all-cause mortality (RR 0.92, 95% CI 0.83 to 1.03).
Atherothrombotic risk
The optimal duration of dual antiplatelet therapy is dependent on 
the balance between preventing future atherothrombotic events 
and the increased risk of bleeding from continued treatment. 
Following an acute coronary syndrome, predictors of athero-
thrombotic risk include ST deviation, diabetes mellitus, smoking 
status, left ventricular ejection fraction, stent type, number of 
3Wilson SJ, et al. Heart 2017;1:1–8. doi:10.1136/heartjnl-2016-309871
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stents and complexity of coronary artery disease. Subgroup anal-
yses have attempted to identify if any of these factors influence 
outcomes with regard to duration of dual antiplatelet treatment.
In the EXCELLENT trial,22 there was a threefold increase in 
the incidence of cardiovascular events (p<0.001 for interaction) 
among pat ients with diabetes mellitus treated with 6 months 
as compared with 12 months of dual antiplatelet therapy. In the 
ISAR-SAFE trial,20 rates of death, myocardial infarction, stent 
thrombosis, stroke or TIMI major bleeding tended to be higher 
in patients aged <67 years and lower in patients aged ≥67 years 
with 6 months compared with 12 months of dual antiplatelet 
treatment (p=0.03). These differences were driven by isch-
aemic complications rather than bleeding events. In the DAPT 
trial, men were nearly five times less likely to suffer from stent 
thrombosis if dual antiplatelet therapy was extended beyond 12 
months (p=0.04) and the reduction in major adverse cardiovas-
cular and cerebrovascular events with prolonged therapy (30 
months) was greater in those treated with prasugrel (vs clopido-
grel; p=0.03) or a first-generation drug-eluting stent (p=0.048). 
Similar trends were observed in DES-LATE25 and ARCTIC- 
INTERRUPTION.26
Audit of the British Cardiovascular Society Intervention data-
base indicates that in 2013/2014, a half of all percutaneous 
coronary intervention procedures were associated with residual 
disease (≥1 stenosis of >50% severity), fulfilling the criteria 
for incomplete revascularisation. Patients with acute coronary 
syndrome and incomplete revascularisation have a residual 
burden of coronary disease that is a substrate for recurrent 
plaque rupture, coronary thrombosis and future cardiac events.31 
32 Prolonged dual antiplatelet treatment may mitigate this risk 
but whether this translates to a more favourable risk-to-benefit 
balance for patients with incomplete revascularisation remains 
an area for future research.
Bleeding and total mortality
Large registries and trials have shown that major bleeding is 
associated with an increase in mortality that could potentially 
negate the benefits of dual antiplatelet therapy in acute coro-
nary syndrome.33–36 Importantly, these bleeding risks are not 
confined to the initial hospitalisation phase.33 35 The association 
between bleeding and mortality has been a consistent feature 
of acute coronary syndrome trials irrespective of whether the 
intervention being assessed and improvements in outcome are 
seen with interventions that are associated with a lower bleeding 
risk. For example, in the OASIS-5 trial,33 fondaparinux had 
similar antithrombotic benefits to enoxaparin but was associated 
with lower rates of major bleeding and marked reductions in 
all-cause mortality. Similar benefits have also been reported for 
randomised controlled trials of arterial access sites in patients 
treated with an invasive strategy for either ST-segment37 or 
non-ST-segment38 myocardial infarction. Again, because radial 
artery access was associated with less bleeding, overall all-cause 
mortality was lower.37 38 There have been various mechanisms 
proposed for the link between bleeding and mortality that 
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Figure 2 Platelet activation pathways and sites targeted by current and novel antiplatelet agents."Arachidonic acid; ADP, adenosine diphosphate; 
c, cyclic; Ca2+, calcium; AMP, adenosinemonophosphate; COX-1, cyclo-oxygenase-1; DAG, diacylglycerol; GMP, guanosine monophosphate; 
GP,"glycoprotein; IP3: inositol trisphosphate; PAR, protease activated receptor; PDE, phosphodiesterase; PI3K, phosphatidylinositol 3-kinase; 
PIP2: phosphatidylinositol 4,5-bisphosphate; PLC, phospholipase C; TP,"thromboxane receptor; TRPC, transient receptor potential channel; TXA2, 
thromboxane A2; vWF, von"Willebrand factor.
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include rebound hypercoagulability, discontinuation of anti-
thrombotic treatments, inflammation and ischaemia.39 The 
European Society of Cardiology Working Group on Thrombosis 
has called for clinical trials to address bleeding in acute coronary 
syndrome including the exploration of the duration of dual anti-
platelet therapy.39
Duration uncertainty
Currently there are variations in local and regional dual anti-
platelet therapy practices that are confusing for patients, primary 
care physicians and cardiologists. Indeed, while European13 
and North American12 guidelines recommend dual antiplatelet 
therapy for 12 months after an acute coronary syndrome, both 
acknowledge that shorter or longer durations may be appro-
priate. Duration of therapy is seen as a major priority for future 
research by numerous national and international guideline 
committees as well as having considerable financial implications, 
especially for the latest generation of P2Y12 receptor antago-
nists. However, major pharmaceutical companies have to date 
not funded trials comparing shorter (<12 months) durations of 
dual antiplatelet therapy, since, arguably, it may not be in their 
commercial interest to do so.
For clinicians and healthcare providers, there remains much 
uncertainty regarding the default duration of dual antiplatelet 
therapy for most patients with acute coronary syndrome. Current 
guidelines are largely based on evidence that predates potentially 
important technological advances, including second-generation 
drug-eluting stents, while in recent trials, only a minority of 
patients presented with an acute coronary syndrome and many 
of these studies were underpowered to detect differences due 
to low event rates. Selected populations included in randomised 
controlled trials have lower rates of bleeding and non-cardiovas-
cular death than the general population (table 3), since patients 
with any history of bleeding or major comorbidity were specif-
ically excluded from such trials. On the other hand, shorter 
durations of dual antiplatelet therapy may expose medically 
managed patients (such as due to complex disease) to an increased 
risk of atherothrombotic events. This is because stenting in acute 
coronary syndrome confers protection against atherothrombotic 
events40 41 and in the vast majority of clinical trials, only patients 
who underwent stent implantation were included. There is 
therefore a major concern that the evidence to date has been 
extrapolated to a broader population with a higher risk of both 
atherothrombotic events and adverse outcomes from bleeding. 
Accordingly, this has left uncertainty as to the relative benefits 
and risks of one period of treatment versus another in real-world 
patients with acute coronary syndrome.
Increased thrombin generation42 and platelet reactivity43 have 
been demonstrated for up to 2 years following a plaque rupture 
myocardial infarction. This may explain potentially more 
favourable outcomes with longer durations of dual antiplatelet 
theraphy in patients with acute coronary syndrome as compared 
to those with stable ischaemic heart disease undergoing percu-
taneous coronary intervention. However, switching from dual 
antiplatelet treatment to monotherapy (usually aspirin alone) 
is associated with a rebound prothrombotic effect, especially 
with regard to an excess of stent thrombosis.10 27 In the DAPT 
trial,27 this phenomenon occurred irrespective of the timing 
of switching to monotherapy. Thus, unless dual antiplatelet 
therapy is continued indefinitely, there will remain a small 
persistent short-term 3-month risk of rebound stent thrombosis 
and myocardial infarction following the transition from dual to 
single antiplatelet therapy.
Newer generation P2Y12 inhibitors provide more effective 
antithrombotic protection than clopidogrel but at the cost of 
increased bleeding. Given the greater expense of these agents 
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Figure 3 Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary 
syndrome."EXCELLENT trial (n=1443), 6 vs 12 months, patients presenting with ACS = 52% of study population; PRODIGY trial (n=2013), 6 vs 
24"months, patients presenting with ACS subgroup = 74% of study population; ISAR-SAFE trial (n=4000), 6 vs 12 months, patients presenting 
with ACS = 40% of study population; OPTIMIZE trial (n=3119), 3 vs 12 months, patients presenting with ACS = 37% of study population; ARTIC 
INTERRUPTION (n=1259), 12 vs 30 months, patients presenting with ACS = 26% of study population; DES-LATE (n=5045), 12 vs 24 months, 
patients"presenting with ACS = 61% of study population and DAPT (n=9961), 12 vs 30 months, patients presenting with ACS = 43% of study 
population.
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and the marked temporal decline in thrombotic risk that is 
evident over the first few months, an early ‘switch’ from tica-
grelor or prasugrel to clopidogrel after 1 month to 6 months 
has been advocated. While evidence from small cohort44 and 
pharmacodynamic studies45 suggest such an approach may be 
safe and reduce bleeding events, an overall lack of data limits 
any meaningful recommendations. TROPICAL-ACS (NCT 
01959451) is an ongoing clinical trial investigating whether 
a switch to clopidogrel treatment after 1 week of prasugrel is 
non-inferior to 12 months of standard treatment with prasu-
grel. Results from this and other similar randomised studies 
(SWAP-4, NCT 02287909) should provide insights into 
defining the best strategy for switching between P2Y12 antag-
onists.
Personalised medicine
Generic recommendations for length of dual antiplatelet therapy 
derived from a protocolised intervention in clinical trials will 
inevitably expose some patients to an excessive duration of 
treatment and disadvantage other patients by withdrawing 
therapy that protects them from myocardial infarction. The 
critical clinical question is therefore: can individuals who are 
more or less likely to benefit from shorter or longer durations 
of treatment be identified? While several risk tools have been 
developed to help determine the future incidence of coronary 
thrombotic events and major bleeding episodes for an indi-
vidual, the DAPT Score46 and PARIS registry risk Score47 were 
specifically designed to predict medium-term to long-term risks 
that are directly modified by continuing or interrupting dual 
antiplatelet therapy.
Using data from the DAPT trial, the DAPT Score was developed 
to determine the net clinical benefit of extending dual antiplatelet 
therapy from 12 months to 30 months (figure 4). Thirty-seven 
candidate variables were considered with 8 included in the final 
model. In the validation cohort the c-statistic was 0.64 for isch-
aemia and 0.64 for bleeding. The PARIS registry risk score was 
Figure 4 DAPT Score calculator for predicting risk/benefit of extending dual antiplatelet therapy from 12 months to 30 months.Available at www.
daptstudy.org. 
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Cardiovascular death 5.1% 2.1% 6.6% 4.0% 4.45% 17.8%
Non-cardiovascular death 0.7% 0.9% 1.7% 0.5% 0.95% 7.6%
Fatal bleeding 0.2% 0.4% 0.2% 0.3% 0.28% 0.9%
*From Information and Statistics Division of NHS"Scotland.
Review
similarly developed but was based on prospective observational 
data. Model discrimination for ischaemia (c-statistic 0.65) and 
bleeding (c-statistic 0.64) events were comparable to the DAPT 
score. Thus while these and other similar risk / benefit tools 
may provide a step forward, they do not as yet offer sufficiently 
robust predictive value for everyday clinical use.
Variables included in risk tools tend to predict both bleeding 
and myocardial infarction. High platelet reactivity was originally 
reported to identify patients at an increased risk of future athero-
thrombotic events.48 However, subsequent studies have failed 
to show an association between platelet reactivity and athero-
thrombotic outcomes49 or demonstrate that dose adjustment 
on the basis of on-treatment platelet reactivity is beneficial.50 
Routine platelet testing is therefore not recommended in patients 
prescribed P2Y12 and is unlikely to deliver a clinically useful 
prediction score. Further research is needed to define prediction 
tools with high discriminatory value in real-world patients, and 
the potential for net-clinical benefit according to the length of 
dual anti-platelet therapy.
CONCLUSIONS
It has been 15 years since the CURE trial demonstrated 
the benefit of dual antiplatelet therapy following an acute 
coronary syndrome and yet the optimal duration remains 
uncertain. With regard to thrombotic complications, recent 
clinical trials and meta-analyses suggest that with newer 
generation drug-eluting stents, 3 months to 6 months of dual 
antiplatelet therapy is non-inferior to 12 months of treatment. 
Prolonged treatment (>12 months) reduces the risk of stent 
thrombosis, myocardial infarction and possibly cardiovascular 
death but at the cost of increased major bleeding and with 
no net mortality benefit. However, these potential hazards 
and benefits of intervention may differ when applied to the 
general broad population of patients encountered in everyday 
clinical practice who have higher bleeding and atherothrom-
botic event rates.
While ongoing randomised clinical trials may address some of 
the residual uncertainties in select subgroups, we believe there 
is a pressing need to undertake a broad inclusive trial of shorter 
durations of therapy in broad populations of patients with acute 
coronary syndrome. Such a trial will need to be able to explore 
specific subgroups, such as those who are medically managed, 
undergo percutaneous coronary intervention or have coronary 
artery bypass graft surgery, as well as enable better identifica-
tion of atherothrombotic and bleeding risks from real world data 
to inform a more personalised approach to decisions regarding 
treatment duration.
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Predicting long-term bleeding risk 
after acute coronary syndrome: a step 
closer to optimising dual antiplatelet 
therapy!duration?
Simon Wilson, David E Newby
Dual antiplatelet therapy (DAPT) with 
aspirin and a P2Y12 antagonist improves 
cardiovascular outcomes in patients with 
acute coronary syndrome but at a cost of 
an increased risk of bleeding complica-
tions.1 There is marked variability in the 
thrombotic and bleeding risk between 
individuals with multiple patient and 
procedural factors identified but not yet 
fully understood. Generic recommenda-
tions for DAPT duration inevitably expose 
some patients to an excessive duration of 
treatment and bleeding risk while simulta-
neously disadvantaging other patients by 
withdrawing therapy that could protect 
them from atherothrombotic events. This 
is increasingly recognised as a major clin-
ical problem, and current European and 
North American Acute Coronary 
Syndromes (ACS) guidelines now 
acknowledge that shorter durations of 
DAPT may be considered in patients at 
high risk of bleeding while extended treat-
ment (>12 months) is an option in 
selected patients. To implement these 
guideline recommendations, robust 
prediction tools are required to facilitate 
the accurate identification of individuals 
who are more or less likely to benefit from 
shorter or longer durations of treatment.
The association between bleeding and 
mortality has been a consistent feature of 
acute coronary syndrome trials, irrespec-
tive of the intervention being assessed. 
The present paper by Alfredsson and 
colleagues2 fills an important gap since it 
provides the first longitudinal long-term 
bleeding risk score (0–30 months) for 
medically managed ACS patients treated 
with DAPT. Previous post-ACS bleeding 
risk tools have informed on short-term 
bleeding risk in patients predominantly 
managed with percutaneous coronary 
intervention3–5 or at a single time point (2 
years) in a population with a majority of 
stable coronary artery disease (~70%).6 
From 12 preselected candidate variables 
and using the Targeted Platelet Inhibition 
to Clarify the Optimal Strategy to Medi-
cally Manage (TRILOGY) ACS study 
database, the authors identified 10 base-
line predictors of Global Use of Strategies 
to Open Occluded Arteries (GUSTO) 
moderate/severe/life-threatening and five 
baseline predictors of thrombolysis in 
myocardial infarction (TIMI) major or 
minor bleeding (table 1). While many of 
the predictors for bleeding were common 
to those previously reported, other vari-
ables such as a history of peptic ulcer 
disease and angiography before rando-
misation (unique to the TRILOGY ACS 
database) were also identified. In sharp 
contrast to results from short-term 
bleeding risk tools and studies of long-term 
bleeding in mixed populations,6 7 female 
gender predicted a reduced long-term 
bleeding risk. These and other differences 
highlight the potentially time-dependent 
and population-specific contribution of 
risk factors for bleeding, emphasising the 
possible hazard of applying prediction 
tools to patient groups distinct from the 
reference cohort.
The bleeding risk prediction models 
derived by Alfredsson and colleagues 
showed moderate to good predictive 
accuracy with C-indices of 0.78 (95% 
CI 0.75 to 0.80) for the GUSTO model 
and 0.67 (95% CI 0.65 to 0.69) for the 
TIMI model. Internal validation with 
bootstrapping gave bias-adjusted C-index 
values of 0.77 and 0.65 for the GUSTO 
and TIMI models, respectively, comparing 
favourably to existing prediction tools. 
However, if risk scores are to be of clinical 
utility they must also be easy to estimate, 
generalisable to populations treated in 
clinical practice and perhaps most impor-
tantly, actionable.
All the current risk models for bleeding 
are based on metrics measured at a set time 
point, typically within the index presen-
tation. Measures of admission blood 
pressure or heart rate and cardiovascular 
or periprocedural medication can be 
difficult and time consuming to retrieve, 
particularly as patients are often trans-
ferred to and from a tertiary centre for 
angiography. Furthermore, given the high 
turnover of most cardiology departments, 
formally estimating an individual’s rela-
tive risk and benefit of continuing DAPT 
will often default to the outpatient clinic. 
Thus, even at the expense of a degree of 
model discrimination, prediction tools 
with a modest number of easily identifi-
able risk factors (eg, TIMI minor or major 
bleeding model in the current paper—five 
variables; Patterns of Non-Adherence 
to Anti-Platelet Regimens in Stented 
Patients (PARIS) registry risk score—six 
variables) may be of greater clinical utility, 
as they are more likely to be adopted in 
the ‘real world’.
Selected populations included in 
randomised controlled trials have lower 
rates of bleeding and non-cardiovascular 
death than the general population, since 
patients with any history of bleeding or 
major comorbidity are often specifically 
excluded from such trials. Applying risk 
tools derived from clinical trial data to 
broader populations may therefore under-
estimate true bleeding hazards. A relative 
strength of the prediction models derived 
by Alfredsson and colleagues is the high 
number of female patients (~40%), 
patients aged over 75 years (>22%) and 
important comorbidities in the study 
population, comparable to those found 
in large observational ACS registries.1 
External validation in a predominantly 
invasively managed ACS trial population 
(Thrombin-Receptor Antagonist Vora-
paxar in Acute Coronary Syndromes 
trial) demonstrated good generalisability 
of both risk tools to other acute coro-
nary syndrome (trial) populations with a 
C-index that was essentially unchanged 
for the TIMI minor or major bleeding 
model (0.68) and modestly attenuated for 
the GUSTO moderate/severe/life-threat-
ening bleeding model (0.69).
Patients with cerebrovascular disease are 
particularly sensitive to the bleeding risks 
of DAPT and a past history of transient 
ischaemic attack (TIA) or stroke is both 
a commonly encountered comorbidity 
and important risk factor for intracranial 
haemorrhage (ICH) in ACS populations. 
Unfortunately, many clinical trials of 
DAPT, including TRILOGY ACS, exclude 
such patients from the study population. 
Management of ACS patients with an indi-
cation for anticoagulation remains unclear 
with considerable heterogeneity in clinical 
practice reflecting the limited available 
data. This is even more problematic given 
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the recent widespread uptake of contem-
porary direct oral anticoagulants. In the 
PARIS registry risk score,6 triple therapy 
(DAPT + oral anticoagulant) at discharge 
was associated with a near twofold 
increased risk of major bleeding within 
2 years; although given the recruitment 
window was between 2009 and 2010, it 
is unlikely that individuals were receiving 
an oral anticoagulant other than a vitamin 
K antagonist. Prediction tools that inform 
on the short-, medium- and long-term 
risks and benefits of triple therapy are to 
be strongly welcomed as well as ongoing 
trials to assess the long-term discontin-
uation or resumption of antithrombotic 
therapies in patients with a history of ICH 
[ISRCTN71907627].
The CHA2DS2-VASc score has a pooled 
C-statistic of approximately 0.68 for 
predicting the risk of ischaemic stroke in 
non-anticoagulated patients, lower than 
most bleeding prediction scores. Never-
theless, this clinical tool is widely used 
because not only is it is easy to calcu-
late, the results are easy to translate into 
patient management. Presently, this is a 
shortcoming of all bleeding risk scores. 
Optimal DAPT duration depends on the 
balance between preventing future athero-
thrombotic events and the increased risk 
of bleeding from continued treatment. 
Without knowing the consequences of 
discontinuing therapy, how then can a 
2-year risk of major bleeding, for example 
of 5%, inform treatment? This is even 
more challenging if we consider that 
many of the risk factors for bleeding (eg, 
age, gender, type of presentation, renal 
dysfunction) predict higher atherothrom-
botic risk and vice-versa. On the basis of 
a high bleeding risk alone, prescribing 
shorter durations of DAPT will inevitably 
disadvantage some patients who stand to 
gain the most anti-ischaemic benefit. Clin-
ical tools that can predict the trade-off 
between ischaemic event reduction and 
occurrence of major bleeding events 
from continuing DAPT may be of greater 
practical use. Using data from the DAPT 
trial, the DAPT score was developed to 
help determine the net clinical benefit 
of extending dual antiplatelet therapy 
from 12 to 30 months in both ACS and 
non-ACS patients who underwent PCI.7 
However this and other similar risk/
benefit tools remain to be validated in 
broader populations and are perhaps too 
immature at present for mainstream use.
Currently, bleeding and thrombotic risk 
prediction models for DAPT in post-ACS 
patients are based on variables collected at 
a single time point and therefore provide 
a static determination of the risk of future 
events. In reality though the bleeding risk 
for an individual is dynamic, modified by 
the accumulation of positive or negative 
predictors of risk and the relative contri-
butions of these factors over time. The 
consequences of an event can also be time 
dependent, and it is important to keep 
in context the merits to the individual of 
increasing the risk of one type of event to 
prevent another. For example, the risk of 
death associated with early stent throm-
bosis is markedly higher than the risk 
of death associated with very late stent 
thrombosis.8 In contrast, there is much 
less temporal variability in the mortality 
from bleeding.9
Ideally, risk prediction tools are devel-
oped that allow modifiable longitudinal 
risk estimates to be generated at any given 
point, taking into account known dynamic 
variables and the time dependent severity 
of an event. Whether it is feasible to assim-
ilate all these factors into one unifying 
and implementable model remains to be 
determined. Until then, the TRILOGY 
ACS bleeding risk models presented by 
Alfredsson and colleagues represent a 
significant step forward in predicting 
long-term bleeding risks with DAPT after 
ACS to facilitate clinical decision making 
on an individual level.
Competing interests None declared.
Provenance and peer review Commissioned; 
internally peer reviewed.
© Article author(s) (or their employer(s) unless 
otherwise stated in the text of the article) 2017. All 
rights reserved. No commercial use is permitted unless 
otherwise expressly granted.
To cite Wilson!S, Newby!DE. Heart Published Online 
First: [please include Day Month Year]. doi:10.1136/
heartjnl-2017-311197




 1 Sahlén A, Varenhorst C, Lagerqvist B, et al. 
Outcomes in patients treated with ticagrelor or 
clopidogrel after acute myocardial infarction: 
experiences from SWEDEHEART registry. Eur Heart J 
2016;37:3335–42.
 2 Alfredsson J, Neely B, Neely ML, et al. TRILOGY 
ACS Investigators. Predicting the risk of bleeding 
during dual antiplatelet therapy after acute coronary 
syndromes. Heart 2017 Published Online First:!05 
April 2017.!doi:!10.1136/heartjnl-2016-310090:
 3 Subherwal S, Bach RG, Chen AY, et al. Baseline risk 
of major bleeding in non-ST-segment-elevation 
myocardial infarction: the CRUSADE (Can Rapid risk 
stratification of Unstable angina patients Suppress 
ADverse outcomes with Early implementation of the 
ACC/AHA Guidelines) Bleeding Score. Circulation 
2009;119:1873–82.
 4 Mehran R, Pocock SJ, Nikolsky E, et al. A risk score 
to predict bleeding in patients with acute coronary 
syndromes. J Am Coll Cardiol 2010;55:2556–66.
 5 Mathews R, Peterson ED, Chen AY, et al. In-hospital 
major bleeding during ST-elevation and non-ST-
elevation myocardial infarction care: derivation and 
validation of a model from the ACTION Registry®-
GWTG™. Am J Cardiol 2011;107:1136–43.
 6 Baber U, Mehran R, Giustino G, et al. Coronary 
thrombosis and major bleeding after PCI with!drug-
eluting stents: risk scores from PARIS. J Am Coll 
Cardiol 2016;67:2224–34.
 7 Yeh RW, Secemsky EA, Kereiakes DJ, et al. 
Development and validation of a prediction rule for 
benefit and harm of dual antiplatelet therapy beyond 
1 year after percutaneous coronary intervention. 
JAMA 2016;315:1735–49.
 8 Waksman R, Kirtane AJ, Torguson R, et al. Correlates 
and outcomes of late and very late drug-eluting 
stent thrombosis. JACC Cardiovasc Interv 
2014;7:1093–102.
 9 Généreux P, Giustino G, Witzenbichler B, et al. 
Incidence, predictors, and impact of post-discharge 
bleeding after percutaneous coronary intervention. J 
Am Coll Cardiol 2015;66:1036–45.
group.bmj.com on May 23, 2017 - Published by http://heart.bmj.com/Downloaded from 
448
Received on: August 11, 2017; final version accepted on: November 13, 2017.
From the British Heart Foundation Centre for Cardiovascular Science (S.J.W., D.E.N.), Medical Research Council Centre for Inflammation Research 
(J.R., S.C.), and Edinburgh College of Medicine (T.J.G.), University of Edinburgh, United Kingdom; Bristol Myers Squibb, Princeton, NJ (F.A.I., Z.W., 
M.C., S.G., X.M., J.Y.); and Royal Infirmary of Edinburgh, United Kingdom (H.N.).
The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.117.310104/-/DC1.
Correspondence to Simon J. Wilson, MD, British Heart Foundation Centre for Cardiovascular Science, Chancellor’s Building, University of Edinburgh, 
49 Little France Crescent, Edinburgh EH16 4SA, United Kingdom. E-mail simonwilson3@nhs.net
Platelets are central to thrombus formation, the leading cause of global mortality.1 Antiplatelet drugs are of proven ben-
efit for the treatment and prevention of atherothrombotic events 
in many clinical settings, but despite the introduction of newer 
agents in the last decade, important limitations persist. Aspirin 
and P2Y12 antagonists, the current standard of care oral anti-
platelet agents in patients with acute coronary syndrome, 
stroke, and peripheral arterial disease, prevent thromboxane 
A2 and ADP platelet activation, respectively.2–7 However, nei-
ther is effective against thrombin, the most potent of all platelet 
agonists,8 and both are associated with an increased incidence 
of bleeding that restricts their use in sensitive populations 
(eg, elderly, cerebrovascular disease) and reduces their net 
clinical benefit.5,9–12 Thus, despite contemporary antiplatelet 
pharmacotherapy, many patients remain at high risk of future 
atherothrombotic events,5–7,10,13,14 and there is a clear need for 
newer agents that can provide equivalent (or superior) anti-
thrombotic efficacy with an improved safety profile.
See accompanying editorial on page 287
In recent years, PAR4 (protease-activated receptor 4) antago-
nism has emerged as promising new antiplatelet strategy. PAR4 
is a G-protein coupled receptor expressed on the platelet sur-
face that together with PAR1 (protease-activated receptor 1) is 
responsible for thrombin-mediated platelet activation and aggre-
gation.15 Thrombin has a key role in the coagulation cascade, but 
by targeting the platelet receptor rather than the protease, this 
avoids directly interfering with thrombin-induced fibrin pro-
duction. PAR1 has greater affinity for thrombin than PAR4, but 
© 2017 The Authors. Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and 
reproduction in any medium, provided that the original work is properly cited.
Objective—BMS-986120 is a novel first-in-class oral PAR4 (protease-activated receptor 4) antagonist with potent and selective 
antiplatelet effects. We sought to determine for the first time, the effect of BMS-986120 on human ex vivo thrombus formation.
Approach and Results—Forty healthy volunteers completed a phase 1 parallel-group PROBE trial (Prospective Randomized 
Open-Label Blinded End Point). Ex vivo platelet activation, platelet aggregation, and thrombus formation were measured 
at 0, 2, and 24 hours after (1) oral BMS-986120 (60 mg) or (2) oral aspirin (600 mg) followed at 18 hours with oral 
aspirin (600 mg) and oral clopidogrel (600 mg). BMS-986120 demonstrated highly selective and reversible inhibition of 
PAR4 agonist peptide (100 !M)-stimulated P-selectin expression, platelet-monocyte aggregates, and platelet aggregation 
(P<0.001 for all). Compared with pretreatment, total thrombus area (!m2/mm) at high shear was reduced by 29.2% (95% 
confidence interval, 18.3%–38.7%; P<0.001) at 2 hours and by 21.4% (9.3%–32.0%; P=0.002) at 24 hours. Reductions 
in thrombus formation were driven by a decrease in platelet-rich thrombus deposition: 34.8% (19.3%–47.3%; P<0.001) at 
2 hours and 23.3% (5.1%–38.0%; P=0.016) at 24 hours. In contrast to aspirin alone, or in combination with clopidogrel, 
BMS-986120 had no effect on thrombus formation at low shear (P=nonsignificant). BMS-986120 administration was not 
associated with an increase in coagulation times or serious adverse events.
Conclusions—BMS-986120 is a highly selective and reversible oral PAR4 antagonist that substantially reduces platelet-rich 
thrombus formation under conditions of high shear stress. Our results suggest PAR4 antagonism has major potential as a 
therapeutic antiplatelet strategy.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02439190.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38: 
448-456. DOI: 10.1161/ATVBAHA.117.310104.)
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despite early clinical promise, the addition of vorapaxar (the only 
licensed PAR1 antagonist) to standard care failed to meet its pri-
mary efficacy outcome in patients with acute coronary syndrome 
and was associated with an excess of major bleeding, especially 
intracranial hemorrhage, in phase3 clinical trials.13,16 PAR4 was 
originally thought to simply provide some redundancy to PAR1 
platelet signaling at high thrombin concentrations.17 However, 
due to differences in activation kinetics and downstream path-
ways, it is now evident that PAR1 and PAR4 have distinct and 
complementary roles in the early and late phases of platelet 
activation and aggregation, respectively.18–20 PAR1 activation 
is brisk but transient and requires input from the P2Y12-PI3K 
(phosphatidylinositol 3-kinase) pathway to maintain platelet 
aggregation.19,20 In contrast, PAR4 is activated at higher throm-
bin concentrations and induces a slow but prolonged intracellular 
signal that acts independently to sustain irreversible aggrega-
tion.17,18,20 Furthermore, PAR4 activation occurs after ADP secre-
tion, and thrombin depends on PAR4 but not PAR1 to induce 
full platelet spreading.21 Thus, several lines of evidence indicate 
that while PAR1 and other agonist-signaling pathways may have 
important roles in initiating platelet activation, the primary func-
tion of PAR4 appears to be in sustaining irreversible platelet 
aggregation and thrombus propagation. This suggests that selec-
tively targeting PAR4-mediated thrombin activity may protect 
against occlusive thrombus formation while avoiding interfering 
with hemostatic platelet responses to the same extent as PAR1 
antagonists and other antiplatelet agents.22
BMS-986120 is a first-in-class, oral, highly selective, and 
reversible PAR4 antagonist antiplatelet agent. In preclinical ani-
mal models, BMS-986120 demonstrated potent antithrombotic 
activity with a substantially wider therapeutic window when 
compared with clopidogrel.22 The purpose of the present phase 
1 parallel-group PROBE trial (Prospective Randomized Open-
Label Blinded End Point) was to build on these observations and 
examine for the first time, the antiplatelet and antithrombotic 
effects of BMS-986120 in humans using a translational model 
of ex vivo thrombosis. We determined whether reductions in 
thrombus formation were driven by a decrease in platelet-rich or 
fibrin-rich thrombus formation and whether these effects were 
greater under rheological conditions of low or high shear stress.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
All 40 volunteers (81 volunteers were screened) completed the 
study in full. The demographics and baseline characteristics of 
study volunteers were similar in the 2 treatment groups (Table). 
BMS-986120 was well tolerated with no clinically significant 
effect on any of the biochemical, hematologic, coagulation, 
physical, or ECG safety assessments conducted throughout 
the study (Table I in the online-only Data Supplement). There 
were no serious adverse events. One episode of minor bleed-
ing was reported. This occurred 12 hours after aspirin admin-
istration, self-resolved, and did not recur.
Pharmacokinetic Profile of Oral BMS-986120
BMS-986120 was rapidly absorbed with peak plasma con-
centrations occurring at 2 hours (255±136 ng/mL; Figure 1). 
Plasma concentrations of BMS-986120 were halved by 4 
hours (133±100 ng/mL) and <10% of the peak concentration 
by 24 hours (21±9 ng/mL).
Effect of BMS-986120 on Platelet 
Activation and Aggregation
BMS-986120 demonstrated strong and reversible inhibition 
of PAR4 agonist peptide (AP; 100 !M)-stimulated plate-
let activation and aggregation (P<0.001 for all). Compared 
with pretreatment, PAR4 AP-stimulated increases in plate-
let P-selectin expression (%), platelet-monocyte aggre-
gates (%), and platelet aggregation (%) were reduced by 
91.7% (95% confidence interval [CI], 81.0–102.4), 80.6% 
(95% CI, 68.6%–92.6%), and 85.0% (95% CI, 82.0–88.1) 
at 2 hours and by 53.9% (95% CI, 43.2%–64.7%), 41.1% 
(95% CI, 28.9%–53.2%), and 6.0% (95% CI, 2.9%–9.0%) 
at 24 hours (P<0.001 for all; Figure 2). Plasma concentra-
tions of BMS-986120 correlated with P-selectin expression 
(#=!0.87), platelet-monocyte aggregates (#=!0.88), and 
platelet aggregation (#=!0.82; P<0.001 for all; Figure III 
in the online-only Data Supplement). There was no effect 
on PAR1 AP, ADP, or arachidonic acid platelet responses 
(P=nonsignificant [ns] for all; Figure 2).
Effect of Aspirin±Clopidogrel 
on Platelet Aggregation
Aspirin administration reduced arachidonic acid-stimulated 
platelet aggregation by 74.5% (95% CI, 71.6%–77.3%; 
P<0.001). In combination with clopidogrel, aspirin reduced 
arachidonic acid-stimulated platelet aggregation by 73.7% 
(95% CI, 70.9%–76.5%; P<0.001) and ADP-stimulated 
platelet aggregation by 41.9% (95% CI, 35.2%–48.7%; 
P<0.001), respectively (Figure IV in the online-only Data 
Supplement).
Effect of BMS-986120 on Ex Vivo 
Thrombus Formation
BMS-986120 reduced total thrombus formation at high shear 
(P<0.001) but not at low shear (P=ns; Figure 3). Compared 
with pretreatment, total thrombus area (!m2/mm) at high shear 
was reduced by 29.2% (95% CI, 18.3%–38.7%; P<0.001) at 
2 hours and by 21.4% (95% CI, 9.3%–32.0%; P=0.002) at 24 
hours. Plasma concentrations of BMS-986120 correlated with 
total thrombus formation at high shear (#=!0.47; P<0.001) 
but not at low shear (#=!0.18; P=ns; Figure III in the online-
only Data Supplement).
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Reductions in total thrombus area were driven by a 
decrease in platelet deposition (Figure 4). At high shear, 
platelet-rich thrombus area was reduced by 34.8% (95% CI, 
19.3%–47.3%; P<0.001) at 2 hours and 23.3% (95% CI, 
5.1%–38.0%; P=0.016) at 24 hours. Reductions in fibrin-
rich thrombus area at 2 (!14.7%; 95% CI, !22.5% to !6.2%; 
P=0.002) and 24 hours (!7.9%; 95% CI, !16.3% to 1.4%; 
P=0.09) were small by comparison. BMS-986120 had no 
effect on either platelet-rich or fibrin-rich thrombus formation 
at low shear (P=ns for all).
Effect of Aspirin±Clopidogrel on Ex 
Vivo Thrombus Formation
Aspirin and aspirin in combination with clopidogrel both 
reduced thrombus formation at high and low shear, also 
driven by decrease in platelet-rich thrombus. Aspirin 
reduced total thrombus area and platelet-rich thrombus area 
by 30.2% (95% CI, 15.6%–42.2%; P<0.001) and 41.7% 
(95% CI, 22.9%–56.0%; P<0.001), respectively, and by 
32.4% (95% CI, 18.3%–44.0%; P<0.001) and 46.4% (95% 
CI, 29.1%–59.5%; P<0.001), respectively, when used in 
combination with clopidogrel.
In contrast to BMS-986120, aspirin and aspirin in combi-
nation with clopidogrel both reduced total thrombus area at 
low shear (!17.4%; 95% CI, !27.0% to !6.5%; P=0.003 and 
!13.5%; 95% CI, !23.6% to !2.1%; P=0.02). There was no 
effect on fibrin-rich thrombus deposition at low or high shear 
(P=ns for all).
Discussion
In this phase 1 PROBE designed clinical trial, we have 
shown for the first time that PAR4 antagonism with 
BMS-986120 reduces ex vivo human thrombus formation 
under conditions representative of deep arterial injury in 
a stenosed coronary artery. BMS-986120 demonstrated 
selective and reversible antiplatelet effects with concen-
tration-dependent inhibition of thrombus formation and 
PAR4 AP-stimulated platelet activation and aggregation. 
Our results provide further insights into the role of PAR4 in 
human thrombogenesis and raise major promise for BMS-
986120 as an antiplatelet agent in the treatment and preven-
tion of arterial thrombosis.
Assessment of the antiplatelet and antithrombotic effects 
of PAR4 inhibition has previously been limited by a lack of 
compound specificity and availability.23–25 In comparison with 
earlier compounds, including P4pal-10, YD-3, and its deriva-
tive ML354,25–27 BMS-986120 has antiplatelet activity against 
$ thrombin, demonstrated greater potency and selectivity of 
effect in preclinical and phase 1 studies of platelet inhibition, 
and is the first orally bioavailable PAR4 antagonist.22,28 In the 
present study, a single dose of BMS-986120 resulted in near 
complete inhibition of PAR4 AP-stimulated platelet activa-
tion and aggregation at 2 hours, with a return toward base-
line at 24 hours. Importantly, there was no effect on PAR1 
AP, ADP, or arachidonic acid-stimulated platelet activity. Our 
data, therefore, add to previous studies indicating that BMS-
986120 is a highly selective and reversible antiplatelet agent 
with potent activity against PAR4-stimulated platelet activa-
tion and aggregation in humans.
The antithrombotic effects of BMS-986120 in humans 
were examined using the Badimon perfusion chamber—a 
well validated model for measuring ex vivo thrombus forma-
tion in humans.29–36 Using the same model and under the same 
flow conditions, previous studies in healthy volunteers have 
demonstrated reductions in high shear thrombus formation of 
18.7% after a single 300-mg oral dose of clopidogrel, 28% 
with a 60-mg oral dose of edoxaban and 56% with extracor-
poreal coadministration of tirofiban (50 ng/mL).29,36,37 In the 
present study, a single dose of BMS-986120 (60 mg) reduced 
high shear thrombus formation by nearly a third. This is con-
sistent with preclinical animal data22,23 and comparable with 
reductions in thrombus formation we observed with high load-
ing doses of aspirin and clopidogrel. Importantly, therefore, 
we have shown that oral PAR4 antagonism with BMS-986120 
substantially reduces ex vivo human thrombus formation. 
Moreover, reductions were similar in magnitude to clinically 
approved antiplatelet agents suggesting a high probability of 
in vivo antithrombotic efficacy.






Men (%) 20 (100) 20 (100)
Age, y (SD) 23.6 (3.4) 28.7 (10.0)
BMI, kg/m2 (SD) 23.6 (2.6) 25.4 (3.5)
Race (%)
  White 19 (95) 19 (95)
  Black/African 1 (5) 0
  Asian 0 1 (5)
Hemoglobin, g/dL (SD) 14.2 (0.42) 14.6 (0.85)
Platelet count, !109 c/L (SD) 230 (45) 221 (49)
APTT, s (SD) 30.9 (2.2) 30.8 (2.6)
PT, s (SD) 12.3 (0.9) 11.9 (0.7)
APTT indicates activated partial thromboplastin time; BMI, body mass index; 
and PT, prothrombin time.
Figure 1. Pharmacokinetics of BMS-986120. BMS-986120 was 
rapidly absorbed with a half-life of 4 h. Data shown are mean 
plasma concentrations of BMS-986120 (±95% confidence inter-
vals) after administration of a single oral 60-mg dose.












Figure 2. BMS-986120 demonstrated highly selective, potent, and reversible inhibition of PAR (protease-activated receptor) 4-stimulated 
platelet activation and aggregation. Box plots of platelet activation and aggregation in response to (A–C) PAR4 Agonist peptide (AP; 100 
!M), (D and E) PAR1 AP (100 !M), (F) PAR1 AP (25 !M), (G) ADP (10 !M), and (H) arachidonic acid (AA; 5 mmol/L), in volunteers (Continued )
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BMS-986120 seemed to have less of an effect on throm-
bus formation at low shear than either aspirin alone or aspirin 
in combination with clopidogrel. Although further studies are 
required to confirm whether PAR4 antagonism is more selec-
tive for inhibiting thrombus formation at high shear than exist-
ing agents, distinct mechanisms of platelet aggregation are 
known to operate under different rheological conditions.38,39 
Low shear rates reflect flow conditions found in patent epi-
cardial arteries and some veins, whereas the majority of ath-
erothrombotic events invariably occur at areas of high shear 
stress seen in diseased arteries.40,41 Indeed, most myocardial 
infarctions arise from stenotic atherosclerotic plaques with 
rheological conditions comparable with those in our high 
shear chamber.42–44 Antiplatelet agents that are more selective 
for inhibiting thrombus formation at high shear may allow at-
risk vascular beds to be targeted with greater specificity. Given 
many treatment-related bleeding events are likely to occur 
from vessels with low shear rates,45–49 this could facilitate a 
wider safety profile.
As expected from an antiplatelet agent, reductions in 
thrombus were driven by a decrease in platelet deposition; 
however, there was also a small but significant reduction in 
fibrin-rich thrombus formation. PAR4 is reported to be the 
predominant platelet PAR responsible for phosphatidylser-
ine exposure, microparticle shedding, and thrombin genera-
tion.50 Our results add to these studies, indicating that PAR4 
may have a role in platelet procoagulant activity during ex 
vivo human thrombus formation. Whether this is beneficial or 
not is uncertain, but it is worth noting BMS-986120 was not 
associated with an increase in coagulation assay times, and 
no bleeding-related clinical findings or adverse events were 
reported in a previous phase 1 single- and multiple-ascending 
dose study.28
PAR4 is expressed within the vasculature, and PAR4 
antagonism may, in addition to protecting against throm-
bosis, serve to limit vascular complications in at-risk 
patients. Human vascular smooth muscle cells upregulate 
PAR4 in response to glucose,51 and elevated expression of 
A
B C
Figure 3. BMS-986120 reduced thrombus formation at high shear but not at low shear. A, Representative image of porcine aortic media 
exposed to human blood at high shear stained to quantify total thrombus area. Sections were stained with polyclonal goat antihuman 
fibrin(ogen) antibody and CD61 monoclonal mouse antihuman antibody before treatment with 3,3%-diaminobenzidine substrate chromo-
gen. Sections were then counterstained with a modified Masson trichrome (hematoxylin and sirius red, 0.1%). Effect of (B) BMS-986120 
and (C) aspirin (ASA)±clopidogrel (Clop.) on total thrombus area at high and low shear. Statistical comparisons (least significance differ-
ence test) vs 0 h are represented above each plot. ns indicates nonsignificant. *P<0.05, **P<0.01, ***P<0.001.
Figure 2 Continued. randomized to BMS-986120. Data shown are the adjusted mean (+) normalized to unstimulated values. The line 
within the box represents the median, upper and lower edges of the box represent the 75th and 25th percentiles, and upper and lower 
whiskers represent the 95th and 5th percentiles. Statistical comparisons (least significance difference test) vs 0 h are represented above 
each plot. ns indicates nonsignificant. *P<0.05, **P<0.01, ***P<0.001.
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PAR4 has been reported in the tunica media of atherec-
tomy and saphenous vein tissue from patients with diabetes 
mellitus.51 Moreover, PAR4 deficiency protected against 
excessive remodeling induced by carotid artery ligation in 
streptozotocin-diabetic mice.52 PAR4, therefore, seems to 
be a key regulator of exaggerated intimal thickening in diabe-
tes mellitus, and future studies examining the antiproliferative 
potential of PAR4 antagonism would be of significant thera-
peutic interest.
Our study has some limitations. First, although the 
exposed porcine aortic media presents many of the common 
constituents of a disrupted atherosclerotic plaque, includ-
ing type I collagen, it may not contain tissue factor (TF).53–55 
TF activates the coagulation cascade and is an important 
Figure 4. Reductions in thrombus formation were driven by a decrease in platelet-rich thrombus formation. Representative image of 
thrombus formed at high shear stained to allow quantification of (A) platelet-rich and (B) fibrin-rich thrombus area. Sections were stained 
with polyclonal goat antihuman fibrin(ogen) antibody and CD61 monoclonal mouse antihuman antibody before counterstaining with tyra-
mide Cy3 (cyanine 3) and FITC (fluorescein isothiocyanate). Effect of (C) BMS-986120 and (D) aspirin (ASA)±clopidogrel (Clop.) on platelet 
and fibrin deposition at low and high shear. Data shown are adjusted means±95% confidence intervals. Statistical comparisons (least sig-
nificance difference test) vs 0 h are represented above each plot. ns indicates nonsignificant. *P<0.05, **P<0.01, ***P<0.001.
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contributor to thrombogenicity.56,57 Nevertheless, this does 
not overly limit our model for the assessment of thrombosis 
because binding of blood-borne circulating TF is sufficient 
to allow activation of the coagulation cascade and thrombus 
propagation.53,54,58–60 Indeed, previous studies have demon-
strated that thrombus formed from human blood perfused 
over exposed porcine tunica media (devoid of TF) stains 
heavily for TF.53,54 Second, we assessed a single oral dose 
of BMS-986120 and did not explore the effect of prolonged 
BMS-986120 administration on thrombus formation, such 
as would occur with the secondary prevention of myocardial 
infarction and stroke. However, because this was the phase 1 
trial designed to examine the antithrombotic effects of oral 
PAR4 antagonism in humans for the first time, we felt our 
study design was appropriate. Third, BMS-986120 was dosed 
in isolation, and future studies to determine the antiplatelet 
and antithrombotic effects of PAR4 antagonism in combina-
tion with current agents would be of interest. Finally, although 
no episodes of bleeding occurred in volunteers administered 
BMS-986120 and BMS-986120 was not associated with an 
increase in bleeding times in a previous phase 1 safety and 
tolerability study,28 the safety profile of PAR4 antagonism in 
humans remains to be defined.
In conclusion, we have demonstrated that PAR4 antago-
nism with BMS-986120—a highly selective and reversible 
oral PAR4 antagonist—substantially reduces ex vivo throm-
bus formation in healthy volunteers under conditions of high 
shear stress. BMS-986120 was well tolerated with no change 
in coagulation assays or serious adverse events. Given the 
potential hemostatic sparing effects of PAR4 antagonism, 
our results suggest that BMS-986120 has major potential as a 
novel antiplatelet agent and that further investigation in clini-
cal trials is warranted.
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Highlights
• Inhibition of thrombin-mediated platelet activation through PAR4 (protease-activated receptor 4) antagonism represents a promising new 
antiplatelet strategy because of the potential for reduced bleeding.
• BMS-986120 is a first-in-class, oral, highly selective, and reversible PAR4 antagonist antiplatelet agent.
• A single dose of BMS-986120 substantially reduced ex vivo thrombus formation in healthy volunteers under conditions of high shear stress, 
driven by a reduction in platelet-rich thrombus deposition.
• Our results suggest PAR4 antagonism with BMS-986120 holds major promise as a novel antiplatelet strategy because of the potential for a 
wider therapeutic window in terms of antithrombotic efficacy and bleeding risk.







0 h 2 h 24 h
BMS-986120 60 mg
0 h 2 h 24 h
Aspirin 600 mg Aspirin 600 mg + 
Clopidogrel 600 mg
18 h
P, T P, T P, T
Treatment Arm A (n=20)
Treatment Arm B (n=20)
Follow up 




Screening visit (≤ 14 
days before treatment)
P = platelet studies; T = perfusion chamber
P, T P, T P, T
Table	I.	Safety	Assessments	
Test	variable BMS-986120	(n=20) Aspirin	±	Clopidogrel	(n=20)
0	hour 2	hour 24	hour 0	hour ASA ASA	+	Clop
ALT,	U/L	(SD) 19.0	(6.1) 18.7	(6.2) 		17.8	(6.4)** 26.3	(14.8) 25.9	(14.2) 25.4	(13.3)
AST,	U/L	(SD) 20.7	(4.6) 20.9	(5.7) 			18.0	(3.6)*** 23.6	(7.4) 23.4	(6.8) 		21.0	(4.5)**
Bilirubin,	mg/dL	(SD) 0.70	(0.3) 0.80	(0.3)* 0.62	(0.3) 0.76	(0.2) 0.73	(0.2) 		0.66	(0.2)**
CreaEne	Kinase,	U/L	(SD) 197	(190) 187	(188) 			115	(83)*** 186	(144) 171	(128) 			108	(61)***
Urea,	mmol/L	(SD) 5.1	(0.96) 		4.6	(0.76)** 			4.1	(0.77)*** 5.0	(1.0) 4.7	(0.93) 		4.5	(0.98)**
CreaEnine,	mg/dL	(SD) 0.83	(0.06) 0.81	(0.09) 0.82	(0.08) 0.89	(0.11) 0.86	(0.09) 0.86	(0.10)
Haemoglobin,	g/dL	(SD) 14.2	(0.4) 14.2	(0.4) 14.2	(0.3) 14.6	(0.8) 14.4	(0.8) 14.3	(1.3)
Platelet	count,	x109	c/L	(SD) 229	(45) 227	(46) 228	(46) 221	(49) 220	(50) 216	(53)
APTT,	seconds	(SD) 30.9	(2.1) 30.3	(2.7) 30.4	(2.1) 30.8	(2.5) 30.3	(3.3) 30.1	(2.9)
PT,	seconds	(SD) 12.3	(0.9) 12.3	(0.9) 12.1	(0.8) 11.9	(0.7) 12.3	(0.7)** 12.1	(0.7)





















































































































































This was a phase I parallel group (n=20 per treatment arm) prospective 6	
randomized open-label blinded endpoint (PROBE) trial conducted at a single 7	
site (Clinical Research Facility, Royal Infirmary of Edinburgh, Scotland) 8	
between the 23rd September 2015 and 1st March 2016. Ex vivo platelet 9	
aggregation, platelet activation and thrombus formation were measured at 0 10	
(pre-treatment), 2 and 24 h after oral administration of (a) 60 mg of BMS-11	
986120 or (b) 600 mg aspirin with a second 600 mg aspirin and 600 mg 12	
clopidogrel at 18 h (Figure I in the online-only Data Supplement). Aspirin ± 13	
clopidogrel were included as a positive control and assay validation tool.  14	
 15	
The trial was sponsored by Bristol-Myers Squibb (BMS) and was designed 16	
collaboratively with the host academic center. The study was approved by the 17	
local research ethics committee, conducted in accordance with the 18	
Declaration of Helsinki and with the written informed consent of all volunteers. 19	
Clinical Trial Authorization was provided by the Medicines and Healthcare 20	
products Regulatory Authority (MHRA) of the United Kingdom. 21	
 22	
Study End-Points 23	
The primary outcome was the effect of BMS-986120 on total thrombus area 24	
as compared to pre-treatment. Secondary and exploratory end-points 25	
included the effect of study drug (BMS-986120 or aspirin ± clopidogrel) on 26	
platelet aggregation, p-selectin expression, platelet-monocyte aggregates, 27	
and thrombus composition (platelet- and fibrin-rich thrombus area). 28	
 29	
Study Population 30	
Healthy non-smoking male and female volunteers between the ages of 18 and 31	
65 years (inclusive) and with a body mass index (BMI) of 18 to 32 kg/m2 32	
underwent screening including detailed medical history, physical examination, 33	
laboratory blood tests, urinalysis and 12-lead electrocardiogram (ECG). 34	
Exclusion criteria were women of child-bearing potential and any clinically 35	
significant coexisting condition including hypertension, hyperlipidemia, 36	
diabetes mellitus, gastrointestinal disease that could affect drug absorption, 37	
coagulopathy, recent infective or inflammatory condition, known liver disease 38	
or screening blood tests indicative of renal, liver, clotting, thyroid or 39	
hematological abnormality. Volunteers must not have been taking any 40	
prescription medications for 4 weeks, over-the-counter medications, herbal 41	
supplements and vitamins for 1 week, and alcohol or caffeine containing 42	
products for 72 hours prior to and for the duration of the study. 43	
 44	
Dose Selection 45	
BMS-986120 is a competitive, reversible inhibitor of PAR4 AP induced platelet 46	
aggregation (Kon=0.12 ± 0.043 nM-1min-1, Koff=0.0082 ± 0.0016 min-1, 47	
Kd=0.098 ± 0.016 nM). In cynomolgus monkeys, BMS-986120 demonstrated 48	
dose-dependent (0.2-1.0 mg/kg) preservation of carotid arterial flow following 49	
	 2	
electrolytic injury at the expense of a slight increase in mesenteric and kidney 1	
bleeding times1. In a single ascending (0.5-180 mg) and multiple ascending 2	
dose study (2.5-100 mg daily for up to 14 days) in healthy volunteers, BMS-3	
986120 was found to be safe and well tolerated with complete and reversible 4	
inhibition of PAR4 agonist peptide (AP) stimulated platelet aggregation at ≥10 5	
mg daily2. On the basis of these studies, a 60 mg dose was selected for the 6	
present phase 1 trial as this was calculated to be sufficient to inhibit platelet 7	
aggregation 2 h post dose and would be at the edge of a potential 8	
pharmacodynamic effect at 24 h. This would allow for “dose ranging” with a 9	
single dose of BMS-986120 whilst remaining well within the safety 10	
experience.  11	
 12	
Doses of aspirin (600 mg) and clopidogrel (600 mg) were selected to reflect 13	
the maximal antithrombotic efficacy that might reasonably be expected in 14	
clinical practice following initiation of these antiplatelet agents in an acute 15	
setting.  16	
 17	
Study Outcome Measures 18	
Blood Sampling and Agonists 19	
All blood samples for pharmacodynamic and pharmacokinetic assessments 20	
were drawn uncuffed through a 17G cannula in the ante-cubital fossa. For 21	
each time point, the first 2.5 mL of blood was discarded. PAR1 and PAR4 APs 22	
(SFLLRN and A-Phe(4-F)-PGWLVKNG respectively) were provided by 23	
Bristol-Myers Squibb (Princeton, USA), adenosine diphosphate (ADP) by 24	
Sigma-Aldrich (Gillingham, UK) and arachidonic acid (AA) by Alpha 25	
Laboratories (Eastleigh, UK). 26	
 27	
Pharmacokinetic Assessment 28	
Plasma concentrations of BMS-986120 were determined at 0, 1, 2, 3, 4, 5, 6, 29	
9 and 24 h post treatment using a validated liquid chromatography tandem-30	
mass spectrometry (LC-MS/MS) method with a lower limit of quantification 31	
(LLQ) of 0.250 ng/mL, with an accuracy coefficient of variation of <5 % and 32	
precision (intra- and inter-assay) coefficients of variation of <10 %. Blood 33	
samples were collected into 3 mL K2EDTA vacutainers (Becton-Dickinson, 34	
Cowley, UK) and placed on wet ice. Within 1 h of collection, samples were 35	
centrifuged at 1200 g (2-8 °C) for 10 min. Plasma was decanted and stored at 36	
-20 °C before analysis. 37	
 38	
Platelet Aggregation 39	
Platelet aggregation was assessed by optical aggregometry (PAP-8E; 40	
Bio/Data Corp, Horsham, PA, USA) of platelet-rich plasma (PRP). To obtain 41	
PRP, 18 mL of blood was collected, mixed immediately with 2 mL of 3.8 % 42	
sodium citrate, and then centrifuged at 300 g (room temperature) for 15 min. 43	
For reference, 2 mL of PRP was centrifuged at 5500 g for 6 min to obtain 44	
platelet-poor plasma (PPP). All samples were allowed to equilibrate for 10 min 45	
(37 °C) after the addition of agonist and the peak aggregation recorded. 46	
 47	
Platelet Activation 48	
Platelet p-selectin expression and platelet-monocyte aggregates were 49	
determined by flow cytometry. Blood (5 mL) was collected into 50 µL of 75 50	
	 3	
mM D-phenylalanyl-L-propyl-L-arginine chloromethylketone (PPACK; Enzo 1	
Life Sciences, Exeter, UK) then immediately aliquoted into eppendorfs pre-2	
filled with or without agonist and the following conjugated monoclonal 3	
antibodies: allophycocyanin (APC)-conjugated CD14, phycoerythrin (PE)-4	
conjugated CD62P and fluorescein isothiocyanate (FITC)-conjugated CD42a 5	
(Becton-Dickinson). All antibodies were diluted 1:10. Samples were incubated 6	
for 20 min at room temperature before fixing with 1 % paraformaldehyde (p-7	
selectin) or FACS-Lyse (Becton-Dickinson; platelet-monocyte aggregates). All 8	
samples were analysed within 24 h using a FACSCalibur flow cytometer 9	
(Becton-Dickinson). Data analysis was performed using FlowJo v10 (Treestar, 10	
Oregon, USA). 11	
 12	
Ex Vivo Perfusion Model of Thrombosis 13	
The effect of study compound on ex vivo thrombus formation was assessed 14	
using the Badimon perfusion chamber as previously described3. In brief, a 15	
pump was used to draw native (unanticoagulated) blood directly from an 16	
antecubital vein through a series of three cylindrical perfusion chambers 17	
maintained at 37°C in a water bath. Each chamber contained a strip of 18	
porcine aorta from which the intima and a thin layer of media had been 19	
removed. The ultrastructure of porcine aorta closely resembles that of human 20	
arteries and by removing the intima and a thin layer of media, blood is 21	
exposed to collagen fibres (type I and type III), proteoglycans, basement 22	
membrane, elastin, smooth muscle cells and other constituents common to an 23	
atherosclerotic plaque4-8. Rheological conditions in the first chamber were set 24	
to simulate those of patent medium-sized coronary arteries (inner lumen 25	
diameter, 2.0 mm; vessel wall shear rate, 212 s-1; mean blood velocity, 5.3 26	
cm/s; Reynolds number: 30), whereas those in the second and third 27	
chambers simulate those of mild to moderately stenosed coronary arteries 28	
(inner lumen diameter, 1.0 mm; vessel wall shear rate: 1690 s-1; mean blood 29	
velocity, 21.2 cm/s; Reynolds number: 60). Shear conditions at the vessel wall 30	
were calculated from the expression for shear rate given for a Newtonian fluid 31	
in tube flow9,10. Each study lasted for exactly 5 min during which flow was 32	
maintained at a constant rate of 10 mL/min. All studies were performed using 33	
the same perfusion chamber and by the same operator. 34	
 35	
Histomorphometric Analysis 36	
As thrombus forms along the entire length of the exposed porcine aortic strip, 37	
the mean transverse cross-sectional area gives a reliable reflection of total 38	
thrombus6. Following fixation, the proximal and distal 1 mm of the exposed 39	
substrate were discarded and the remainder cut into eight segments. 40	
Individual segments were then embedded in paraffin wax from which 4-µm 41	
sections were prepared for histomorphometric analysis. 42	
 43	
To detect total thrombus area, endogenous hydrogen peroxide activity was 44	
blocked using 3 % hydrogen peroxide solution (Leica Microsystems GmbH, 45	
Wetzlar, Germany) for 5 minutes. Sections were then incubated at room 46	
temperature for 1 hour with polyclonal rabbit anti-human fibrin(ogen) antibody 47	
(1.2 µg/mL, Dako, Glostrup, Denmark; Cat. No. A0080) and monoclonal 48	
mouse anti-human CD61 antibody (1.28 µg/ml, Dako; Cat. No. M0753). 49	
Antigen visualisation was performed using a Bond Polymer refine detection kit 50	
	 4	
(Leica Microsystems GmbH) and treatment with 3,3'-diaminobenzidine 1	
substrate chromogen (66 mM, Dako). Finally, sections were counterstained 2	
with a modified Masson’s trichrome (hematoxylin and sirius red 0.1 %; Figure 3	
II in the online-only Data Supplement). 4	
 5	
To examine the effect of study drug(s) on fibrin-rich and platelet-rich thrombus 6	
formation, endogenous hydrogen peroxide activity was blocked using 3 % 7	
hydrogen peroxide solution (VWR, Radnor, PA, USA) for 10 min and non-8	
specific binding blocked using 20 % normal goat serum (Biosera, Nuaille, 9	
France) in Tris-Buffered Saline with 0.01% Tween (TBST)). Sections were 10	
then incubated with polyclonal rabbit anti-human fibrin(ogen) antibody (1.2 11	
µg/ml) to detect fibrin and CD61 monoclonal mouse anti-human antibody 12	
(0.32 µg/ml) to detect platelets. Following TBST washes, goat anti-rabbit 13	
peroxidase (1:500; Abcam, Cambridge, UK) was applied and the presence of 14	
antigen visualized with Tyramide Cy3 (1:50; Perkin Elmer, Boston, MA, USA; 15	
Cat. no. NEL744B001KT) and FITC (1:50; Perkin Elmer, Waltham, MA, USA; 16	
Cat. no. NEL741B001KT) before nuclear counterstaining with DAPI (5 µg/ml; 17	
Sigma-Aldrich; Cat. No. D9542). 18	
 19	
Prior to the first experimental sample, non-specific binding of the primary 20	
antibodies was excluded using tissue negative controls (perfusion chamber 21	
porcine sections exposed to saline rather than blood). To ensure staining for 22	
platelets and fibrin(ogen) antigen was the result of detection of the antigen, 23	
secondary antibody controls (with the primary antibody absent) were run in 24	
parallel for each volunteer. No labelling was observed.  25	
 26	
A semi-automated slide scanner (Axioscan Z1; Zeiss, Jena, Germany) and 27	
image analysis software (Definiens, Munich, Germany) were used by a 28	
blinded operator to quantify thrombus area and composition. Digital images of 29	
each section were acquired at ×20 magnification. High-resolution classifiers 30	
based on colour were established to detect total thrombus, platelet and fibrin 31	
area.  32	
 33	
Safety and tolerability 34	
The primary safety end-point was the incidence of serious adverse events 35	
(SAEs) or death during and for up to 30 days post dosing. Adverse events 36	
(AEs) not meeting the SAE threshold were also recorded. All volunteers 37	
received telephone follow up on day 8. Reports of SAEs and AEs could 38	
originate from the volunteer, investigator or study personnel. Additional safety 39	
endpoints included changes in hematological and biochemical indices, 40	
hematuria (including microhematuria), alteration in the 12-lead 41	
electrocardiogram (ECG), or abnormal findings on physical examination 42	
performed at baseline, 2 and 24 h post dosing.  43	
  44	
Statistical Analysis 45	
Following study completion, the database was locked and all statistical 46	
analyses carried out independent of the sponsor. The demographic and 47	
baseline characteristics of volunteers are expressed as mean ± standard 48	
deviation (SD) for continuous variables and percentages for categorical 49	
variables. The effect of study drug(s) on endpoints was assessed by general 50	
	 5	
linear mixed effects models, with perfusion procedure (baseline, 2 and 24 h) 1	
as fixed effects and subjects as random effects. Mean within-subject 2	
differences for the change from baseline were generated and analysed using 3	
the Least Significance Difference (LSD) test. Prior to model fitting, total 4	
thrombus area, platelet area and fibrin area were log-transformed. 5	
Associations between plasma concentrations of BMS-986120 and study end-6	
points were determined by Spearman’s rank-order correlation (ρ). Two sided 7	
p-values of ≤0.05 were considered statistically significant. Analyses were 8	
performed using SPSS version 21.0 (IBM Corp., Armonk, New York) and R 9	
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Aims JNJ-64179375 (hereafter JNJ-9375) is a first-in-class, highly specific, large molecule, exosite 1 thrombin inhibitor. In
preclinical studies, JNJ-9375 demonstrated robust antithrombotic protection with a wider therapeutic index when
compared to apixaban. The purpose of the present study was to examine for the first time the antiplatelet, antico-




Fifteen healthy volunteers participated in a double-blind randomized crossover study of JNJ-9375 (2.5, 25, and 250 lg/
mL), bivalirudin (6lg/mL; positive control), and matched placebo. Coagulation, platelet activation, and thrombus for-
mation were determined using coagulation assays, flow cytometry, and an ex vivo perfusion chamber, respectively.
JNJ-9375 caused concentration-dependent prolongation of all measures of blood coagulation (prothrombin time,
activated partial thromboplastin time, and thrombin time; P < 0.001 for all) and agonist selective inhibition of throm-
bin (0.1 U/mL) stimulated platelet p-selectin expression (P < 0.001) and platelet-monocyte aggregates (P = 0.002).
Compared to placebo, JNJ-9375 (250 lg/mL) reduced mean total thrombus area by 41.1% (95% confidence inter-
vals 22.3 to 55.3%; P < 0.001) at low shear and 32.3% (4.9 to 51.8%; P = 0.025) at high shear. Under both shear con-
ditions, there was a dose-dependent decrease in fibrin-rich thrombus (P < 0.001 for both) but not platelet-rich
thrombus (P = ns for both).
....................................................................................................................................................................................................
Conclusion Exosite 1 inhibition with JNJ-9375 caused prolongation of blood coagulation, selective inhibition of thrombin-
mediated platelet activation, and reductions in ex vivo thrombosis driven by a decrease in fibrin-rich thrombus for-
mation. JNJ-9375 represents a novel class of anticoagulant with potential therapeutic applications.
! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !
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Introduction
The coagulation cascade plays a central role in thrombosis and the path-
ophysiology of thrombo-embolic events, the leading cause of global
mortality.1 Anticoagulants are of proven benefit in a wide range of
thrombo-embolic disorders, but despite recent improvements, impor-
tant limitations persist. All the currently licensed agents, including direct
oral anticoagulants (DOACs), act to either inhibit thrombin generation
or block the active site of the protease directly.2 Consequently, they
provide broad inhibition of all thrombin activity, which although effica-
cious, invariably fails to discriminate between protease interactions relat-
ing to thrombosis and those essential to haemostasis. Treatment related
bleeding remains a major concern and for many patients this leads to
dosing restrictions or exclusion from anticoagulation altogether.3–9
JNJ-64179375 (hereafter JNJ-9375) is a first-in-class, recombinant, fully
human, IgG4 monoclonal antibody anticoagulant that binds reversibly
and with high affinity and specificity to the exosite 1 region of throm-
bin.10 Exosite 1 is a positively charged domain on the surface of thrombin
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that together with exosite 2 serves to regulate enzymatic activity of the
protease by providing an initial binding site for substrates, co-factors, and
inhibitors.11–13 JNJ-9375 therefore acts to inhibit the interaction of
thrombin with its exosite 1 substrates, which include fibrinogen, but
retains function of both the active site and exosite 2.10 This capacity to
inhibit fibrinogen binding while preserving other (non-exosite 1) prote-
ase interactions offers the potential for a wider therapeutic index, and in
preclinical animal models JNJ-9375 was associated with substantially less
bleeding when compared to apixaban at doses of equivalent antithrom-
botic efficacy.10 In the present study, we sought to examine for the first
time the anticoagulant and antithrombotic effects of exosite 1 thrombin




Healthy non-smoking male and female volunteers aged between 18 and
45 years (inclusive) with a body mass index (BMI) of 18–35 kg/m2 were en-
rolled in this study. All volunteers underwent a detailed screening assessment
for eligibility. Exclusion criteria included women who were pregnant or still
lactating, or any clinically significant coexisting condition including hyperten-
sion, hyperlipidaemia, diabetes mellitus, cardiovascular disease, recent infec-
tive or inflammatory condition, coagulopathy, known liver disease or
screening blood tests indicative of renal, liver, clotting, thyroid, or haemato-
logical abnormality. Volunteers were not permitted to take any prescription
or non-prescription medication (including acetylsalicylic acid, paracetamol,
vitamins, and herbal supplements) within 14 days of an experimental visit.
Prior to each visit, volunteers must have abstained from alcohol for 24 h and
food including caffeine-containing products for 8 h. Informed written consent
was obtained from all volunteers before enrolment. The study was approved
by the local research ethics committee (reference 16-HV-025) and con-
ducted in accordance with the Declaration of Helsinki.
Study design
This was a double-blind randomized controlled five-way crossover study
conducted at a single site (Clinical Research Facility, Royal Infirmary of
Edinburgh, Scotland) between the 24 May 2016 and 1 July 2016. Study meas-
ures were performed during extracorporeal infusion of JNJ-9375 (estimated
final concentration of 2.5, 25, and 250 lg/mL), bivalirudin (positive control;
estimated final concentration of 6 lg/mL; The Medicines Company,
Abingdon, UK) at a dose equivalent to recommendations at the time of per-
cutaneous coronary intervention (PCI), and matched placebo [10 mM phos-
phate, 8.5% (w/v) sucrose, 0.04% (w/v) polysorbate 20, 10lg/mL
ethylenediaminetetraacetic acid, pH 7.1; Janssen Research and
Development] upstream of the perfusion chambers. Three perfusion cham-
ber studies were performed at the first experimental visit and two perfusion
chamber studies at the second experimental visit.
Study objectives
The primary objective was to assess the relationship of JNJ-9375 dose con-
centrations to ex vivo thrombus formation under conditions of both low and
high shear stress, and to compare these effects with placebo under the same
rheological conditions. Bivalirudin, which blocks both exosite 1 and the active
site of thrombin, was used as a positive control. Secondary objectives in-
cluded a similar comparison of compound effects on platelet activation,
markers of coagulation, and the fibrin and platelet components of thrombus
formation. Finally, correlations between measured chamber concentrations
of study drug and pharmacodynamic endpoints were explored.
Perfusion chamber experiment
Thrombus formation was assessed using the Badimon chamber, a well-vali-
dated perfusion model for measuring the effect of study drugs on ex vivo hu-
man thrombus formation.14–21 In brief, a pump was used to draw native
(unanticoagulated) blood from an antecubital vein directly through a series of
three cylindrical perfusion chambers maintained at 37!C in a water bath.
Each chamber contained a strip of porcine aorta from which the intima and a
thin layer of media had been removed. Rheological conditions in the first
chamber were set to simulate those of patent medium-sized arteries (inner
lumen diameter 2.0 mm; vessel wall shear rate 212 s-1; mean blood velocity
5.3 cm/s; Reynolds number 30), whereas those in the second and third cham-
bers were set to simulate those of mild to moderately stenosed coronary ar-
teries (inner lumen diameter 1.0 mm; vessel wall shear rate 1690 s-1; mean
blood velocity 21.2 cm/s; Reynolds number 60). Shear conditions at the ves-
sel wall were calculated from the theoretical expression for shear rate given
for a Newtonian fluid in tube flow.22,23 Each study lasted for exactly 5 min
during which flow was maintained at a constant rate of 10 mL/min. All studies
were performed using the same perfusion chamber and by the same
operator.
Study outcome measures
Chamber concentrations of study drug
Blood samples for determination of serum JNJ-9375 and plasma bivalirudin
concentrations were taken immediately distal to the perfusion chamber into
3.5 mL serum gel and 2.7 mL sodium citrate (3.2%) tubes (Becton-Dickinson,
Cowley, UK). JNJ-9375 samples were allowed to clot for 30 min then centri-
fuged at 1500 g (20!C) for 20 min. Bivalirudin samples were centrifuged at
1500 g (15!C) for 15 min within 1 h of collection. Samples were then ali-
quoted and stored immediately at -70!C before analysis. Concentrations of
JNJ-9375 were determined by electrochemiluminescence using the Meso
Scale Discovery platform and plate reader (Rockville, MD, USA). JNJ-9375
concentrations were regressed from the standard curve in Watson LIMS
(version 7.4.1, Thermo, PA, USA) using a five-parameter logistic regression
model with 1/Y2 weighting.
Coagulations assays
Blood samples for coagulations assays [prothrombin time, activated partial
thromboplastin time, and thrombin time (undiluted and diluted)] were col-
lected immediately distal to the final perfusion chamber into 4.5 mL sodium
citrate (0.38% final v/v) tubes (Becton-Dickinson). Samples were centrifuged
at 1500 g (15!C) for 20 min within 1 h of collection. Plasma was then ali-
quoted and stored immediately at -70!C before analysis using a STA-
Compact-Max analyser (Stago, Parsippany, NJ, USA). The following reagents
were used, for prothrombin time, STA-Neoplastine CI Plus, for activated
partial thromboplastin time, STA-PTT Automate, and for thrombin time,
STA-Thrombin.
Platelet activation
Platelet p-selectin expression and platelet-monocyte aggregates are sensitive
markers of in vivo platelet activation.24–26 Blood (2.7 mL) was collected imme-
diately distal to the final perfusion chamber into tubes containing 0.3 mL of
3.8% sodium citrate and Pefabloc FG (final concentration 1.5 mg/mL;
Quadratech Diagnostics, Surrey, UK). After 5 min, samples were aliquoted
into Eppendorfs pre-filled with or without agonist [adenosine diphosphate
(ADP) 20lM, Sigma-Aldrich, Gillingham, UK; human alpha thrombin 0.1 U/
mL, Enzyme Research Laboratories, Swansea, UK] and the following conju-
gated monoclonal antibodies: allophycocyanin (APC)-conjugated CD14, phy-
coerythrin (PE)-conjugated CD62P, and fluorescein isothiocyanate (FITC)-
conjugated CD42a (Becton-Dickinson). All antibodies were diluted 1:10.
Samples were incubated for 15 min at room temperature before fixing with
1% paraformaldehyde (p-selectin) or FACS-Lyse (Becton-Dickinson;
platelet-monocyte aggregates). All samples were analysed within 24 h using a










































..FACSCalibur flow cytometer (Becton-Dickinson). Data analysis was per-
formed using FlowJo v10 (Treestar, Oregon, USA).
Thrombus formation
After each perfusion experiment, the porcine strips with attached throm-
bus were removed and fixed in 4% paraformaldehyde for 24 h at 4!C
prior to being prepared for histological analysis. As thrombus forms lon-
gitudinally along the entire length of the exposed porcine aortic strip, the
mean cross-sectional area gives a reliable representation of total throm-
bus formation.27 Following fixation, the proximal and distal 1 mm of the
exposed substrate were discarded and the remainder cut into eight seg-
ments. Segments were embedded in paraffin wax and 4-lm sections
prepared.
To detect total thrombus area, endogenous hydrogen peroxide activity
was blocked using 3% hydrogen peroxide solution (Leica Microsystems
GmbH, Wetzlar, Germany) for 5 min. Sections were then incubated at
room temperature for 1 h with polyclonal rabbit anti-human fibrin(ogen)
antibody (1.2 lg/mL, Dako, Glostrup, Denmark; Cat. No. A0080) and
monoclonal mouse anti-human CD61 antibody (1.28 lg/mL, Dako; Cat.
No. M0753). Antigen visualization was performed using a Bond Polymer
refine detection kit (Leica Microsystems GmbH) and treatment with 3,30-
diaminobenzidine substrate chromogen (66 mM, Dako). Finally, sections
were counterstained with a modified Masson’s trichrome (haematoxylin
and sirius red 0.1%).
To examine the effect of study drug(s) on fibrin-rich and platelet-rich
thrombus formation, endogenous hydrogen peroxide activity was
blocked using 3% hydrogen peroxide solution (VWR, Radnor, PA, USA)
for 10 min and non-specific binding blocked using 20% normal goat serum
(Biosera, Nuaille, France) in Tris-Buffered Saline with 0.01% Tween
(TBST). Sections were then incubated with polyclonal rabbit anti-human
fibrin(ogen) antibody (1.2 lg/mL) to detect fibrin and CD61 monoclonal
mouse anti-human antibody (0.32 lg/mL) to detect platelets. Following
TBST washes, goat anti-rabbit peroxidase (1:500; Abcam, Cambridge,
UK) was applied and the presence of antigen visualized with Tyramide
Cy3 (1:50; Perkin Elmer, Boston, MA, USA; Cat. no. NEL744B001KT) and
FITC (1:50; Perkin Elmer, Waltham, MA, USA; Cat. no. NEL741B001KT)
before nuclear counterstaining with 40,6-diamidino-2-phenylindole (5 lg/
mL; Sigma-Aldrich; Cat. No. D9542).
A semi-automated slide scanner (Axioscan Z1; Zeiss, Jena, Germany) and
image analysis software (Definiens, Munich, Germany) were used by a
blinded operator to quantify thrombus area and composition. Digital images
of each section were acquired at "20 magnification. High-resolution classi-
fiers based on colour were established to detect total thrombus area, fibrin-
rich thrombus area, and platelet-rich thrombus area.
Statistical analysis
After study completion, the database was locked and all statistical analy-
ses carried out by an independent statistician. Categorical variables are
expressed as percentages, and continuous variables are expressed as
mean ± standard deviation (SD). The effects of study compounds on
study endpoints were assessed by general linear mixed effect models with
period and study compound as fixed effects, subjects as random effects.
Chamber endpoints were log-transformed and assessed separately by
shear rate (low and high). From the models, point and interval estimates
for means and mean differences vs. placebo (absolute and %) were gener-
ated and analysed using the Least Significance Difference (LSD) test. The
correlation between plasma JNJ-9375 concentrations and study
endpoints were determined by Pearson’s (r) or Spearman’s rank-order
correlation (q) as appropriate. Two-sided P-values of <_0.05 were
..............................................................................................................................................................................................................................
Table 1 Effects of JNJ-64179375 on indices of thrombosis and coagulation
Placebo JNJ-9375 (2.5 lg/mL) JNJ-9375 (25 lg/mL) JNJ-9375 (250 lg/mL) Bivalirudin (6 lg/mL)
PT (s) 13.7 (10.5, 16.9) 13.9 (10.7, 17.1) 15.8 (12.6, 19.0) 30.0 (26.8, 33.2) 36.6 (33.4, 39.8)
APTT (s) 28.9 (23.3, 34.6) 31.4 (25.7, 37.0) 41.6 (35.9, 47.3) 63.5 (57.8, 69.2) 91.5 (85.8, 97.2)
TT (s) 15.6 (-12.7, 43.8) 24.9 (-3.3, 53.2) 80.9 (52.6, 109.2) 245.6 (217.3, 273.9) 351.2 (323.0, 379.5)
Dilute TT (s) <LLOQ <LLOQ <LLOQ 151.5 (126.5, 176.6) >501a
P-Selectin GMFI
Unstimulated 4.6 (3.6, 5.6) 3.9 (2.9, 4.9) 3.7 (2.7, 4.7) 3.9 (2.9, 4.9) 3.2 (2.2, 4.2)
ADP 20 lM 17.8 (11.6, 24.0) 12.1 (6.0, 18.1) 17.8 (11.9, 23.8) 15.6 (9.7, 21.6) 15.3 (9.4, 21.2)
Thrombin 0.1 U/mL 161.6 (100.3, 222.8) 86.5 (28.0, 145.0) 7.8 (-53.5, 69.1) 1.6 (-62.8, 65.9) -1.6 (-59.6, 56.3)
PMA GMFI
Unstimulated 33.0 (20.6, 45.4) 35.6 (24.0, 47.3) 27.6 (15.9, 39.3) 25.0 (13.3, 36.7) 25.0 (13.3, 36.7)
ADP 20 lM 48.9 (28.2, 69.5) 54.9 (35.8, 73.9) 48.5 (30.1, 67.0) 50.1 (31.7, 68.6) 46.4 (28.0, 64.8)
Thrombin 0.1 U/mL 401.0 (180.3, 621.6) 414.6 (193.3, 635.8) 175.3 (-45.7, 396.3) 120.7 (-99.5, 340.9) 85.0 (-123.2, 293.3)
Total thrombus area (lm2/mm)
Low shear 9571 (7669, 11 945) 10 283 (8239, 12 834) 8936 (7161, 11 153) 5640 (4519, 7039) 3318 (2659, 4141)
High shear 14 367 (10 734, 19 229) 12961 (9684, 17 347) 13 898 (10 384, 18 602) 9729 (7269, 13 022) 6312 (4716, 8448)
Platelet-rich thrombus area (lm2/mm)
Low shear 1255 (834, 1889) 1610 (1055, 2456) 1117 (742, 1681) 1200 (798, 1806) 832 (545, 1269)
High shear 7302 (4790, 11 131) 5844 (3834, 8909) 6405 (4202, 9763) 5463 (3584, 8327) 4111 (2697, 6267)
Fibrin-rich thrombus area (lm2/mm)
Low shear 10 349 (7535, 14 212) 10 634 (7651, 14 782) 9865 (7183, 13 547) 4190 (3051, 5755) 1162 (836, 1616)
High shear 9598 (7997, 11 521) 9176 (7645, 11 014) 8100 (6749, 9722) 4625 (3854, 5552) 1776 (1480, 2132)
Data shown are means with 95% confidence intervals.
ADP, adenosine diphosphate; APTT, activated partial thromboplastin time; GMFI, geometric mean fluorescent intensity; LLOQ, less than lower limit of quantification; PT, prothrom-
bin time; TT, thrombin time.
a14 of 15 results >501 s.






































..considered statistically significant. All statistical calculations were per-
formed using SAS version 9.4.
Results
All 15 enrolled volunteers (10 male) completed the study in full, with no
safety concerns. Mean age of the volunteers was 26± 5 years with a BMI
of 24± 3 kg/m2.
Chamber concentrations of study drug
Compound concentrations in the effluent of the perfusion chamber
(JNJ-9375 1.93 ± 0.68, 22.3± 5.86, and 214.0 ± 20.8lg/mL; bivalirudin
6.92± 11.3 lg/mL) closely matched the targeted concentrations (JNJ-
9375 2.5, 25, and 250 lg/mL; bivalirudin 6 lg/mL).
Effect of JNJ-9375 on coagulation assays
JNJ-9375 caused dose-dependent prolongation of all measured blood
coagulation markers, with thrombin time the most sensitive to the anti-
coagulant effect (Table 1). Pearson’s correlation coefficient between
chamber plasma concentrations of JNJ-9375 and coagulation assays was
0.98 for prothrombin time, 0.87 for activated partial thromboplastin
time, and 0.91 for thrombin time (P < 0.001 for all; Supplementary mate-
rial online, Figure S1).
Effect of JNJ-9375 on ex vivo platelet
activation
Compared to placebo, JNJ-9375 2.5, 25, and 250lg/mL inhibited throm-
bin (0.1 U/mL) stimulated platelet p-selectin expression [geometric
mean fluorescent intensity (GMFI)] by 46.5% [95% confidence intervals
(CI) 4.6 to 97.5%; P = 0.07], 95.2% (95% CI 43.2 to 147.2%; P < 0.001),
and 99.0% (95% CI 46.1 to 151.9%; P < 0.001) and platelet-monocyte
aggregates (GMFI) by -3.4% (95% CI -56.1 to 49.4%; P = 0.90), 56.3%
(95% CI 2.2 to 110.4%; P = 0.04), and 69.9% (95% CI 16.2 to 123.6%;
P = 0.01). Chamber plasma concentrations of JNJ-9375 correlated with
both platelet p-selectin expression (q = -0.83, P < 0.001) and platelet-
monocyte aggregates (q = -0.64, P < 0.001). In contrast, JNJ-9375 had no
effect on ADP (20 lM) stimulated platelet activation (P = ns for all).
Bivalirudin exhibited a similar selective profile (Table 1; Figure 1).
Effect of JNJ-9375 on ex vivo thrombus
formation
Ex vivo total thrombus formation was reduced at both low and high shear
stress at the 250lg/mL concentration (Figure 2). Compared to placebo,
JNJ-9375 (2.5, 25, and 250lg/mL) reduced mean total thrombus area by
-7.4% (95% CI -41.6 to 18.5%; P = 0.60), 6.6% (95% CI -23.1 to 29.2%;
P = 0.62), and 41.1% (95% CI 22.3 to 55.3%; P < 0.001) at low shear and
by 9.8% (95% CI -26.6 to 35.7%; P = 0.54), 3.3% (95% CI -35.8 to 31.1%;
P = 0.85), and 32.3% (95% CI 4.9 to 51.8%; P = 0.025) at high shear.
Figure 1 The effect of study compound on ex vivo platelet activation. Extra-corporeal administration of JNJ-9375 inhibited thrombin-simulated (A) p-selec-
tin expression and (B) platelet-monocyte aggregates in a dose-dependent manner but had no effect on ADP activity. Data shown are the adjusted means
(±95% confidence intervals) and individual points. Statistical comparisons (Least Significance Difference test) vs. placebo are represented above each plot:
*P < 0.05, **P < 0.01, ***P < 0.001. ADP, adenosine diphosphate; GMFI, geometric mean fluorescent intensity; PMA, platelet-monocyte aggregates.












































Chamber plasma concentrations of JNJ-9375 correlated with total
thrombus area at low (q = -0.56, P < 0.001) and high (q = -0.32, P = 0.03)
shear (Supplementary material online, Figure S1).
Reductions in total thrombus area were driven by a dose-dependent
decrease in fibrin-rich thrombus deposition under both shear conditions
(Figure 3). At peak dose (250 lg/mL), JNJ-9375 reduced fibrin-rich
thrombus area by 59.5% (95% CI 37.8 to 73.7%; P < 0.001) at low shear
and 51.8% (95% CI 37.7 to 62.7%; P < 0.001) at high shear. There was no
reduction in platelet-rich thrombus area (P = ns for all). Chamber plasma
concentrations of JNJ-9375 correlated with fibrin-rich thrombus area
at low (q = -0.66, P < 0.001) and high (q = -0.70, P < 0.001) shear
(Supplementary material online, Figure S1).
Effect of bivalirudin on ex vivo thrombus
formation
Bivalirudin reduced total thrombus area at both low and high shear, also
driven by a decrease in fibrin-rich thrombus formation (Figures 2 and 3).
In contrast to JNJ-9375, there was a modest reduction (P = 0.01) in
platelet-rich thrombus formation at high shear (Figure 3).
Discussion
In this double-blind randomized controlled crossover study, ex vivo
administration of JNJ-9375, a highly specific exosite 1 thrombin inhibitor,
resulted in dose-dependent prolongation of blood coagulation and selec-
tive inhibition of thrombin-stimulated platelet activation. Thrombosis
was reduced under rheological conditions of both low and high shear
stress, driven principally by a reduction in fibrin-rich thrombus forma-
tion. We conclude that JNJ-9375 holds promise as an anticoagulant for
the prevention and treatment of thrombo-embolic events, and our
results provide further insights into the role of exosite 1 in human
thrombogenesis.
The outstanding challenge in anticoagulation is the development of
drugs that can provide equivalent (or superior) antithrombotic efficacy
but with a significantly lower bleeding risk. While the safety of JNJ-9375
has yet to be demonstrated in clinical trials, several lines of evidence indi-
cate the potential for favourable outcomes. On a mechanistic level, se-
lective inhibition of thrombin through exosite 1 specific antagonism is
attractive because of the potential to inhibit fibrinogen binding without
overly interfering with other (active site and exosite 2 dependent) prote-
ase interactions relating to haemostasis. For example, both the active
site and exosite 2 are involved in catalytic feedback activation of clotting
cofactors V, VIII, XI, and XIII, with deficiencies of each of these factors as-
sociated with bleeding diatheses.28–31
Thrombin is also a potent platelet agonist, and whilst over-aggregation
may lead to pathological events, early platelet responses are central to
haemostasis. Thrombin activates platelets through binding to platelet
surface GPIb and protease-activated receptors 1 (PAR1) and 4
(PAR4).32 Exosite 1 interacts with PAR1 to facilitate efficient receptor
cleavage,33 whereas PAR4 activation and GPIb binding are largely depen-
dent on the active site and exosite 2, respectively.34,35 In the present
study, JNJ-9375 selectively inhibited thrombin-stimulated platelet activa-
tion but was not associated with a reduction in platelet deposition. This
is consistent with previous reports that exosite 1 inhibition only weakly
inhibits thrombin-induced platelet aggregation and does not affect
Figure 2 The effect of study compound on ex vivo total thrombus formation. Extra-corporeal administration of JNJ-9375 inhibited total thrombus forma-
tion in a dose-dependent manner at both (A) low shear stress (212 s-1) and (B) high shear stress (1690 s-1) shear stress. Data shown are the adjusted means
(±95% confidence intervals) for [Log] total thrombus area (lm2/mm) and individual points. Statistical comparisons (Least Significance Difference test) vs. pla-
cebo are represented above each plot: *P < 0.05, **P < 0.01, ***P < 0.001. 9375, JNJ-9375.








.platelet collagen binding.36,37 Collectively, these results suggest poten-
tially favourable differential effects on thrombin-platelet responses, that
could be especially useful in clinical situations where combined treat-
ment with an antiplatelet is required.38,39 This is speculative and requires
further exploration. Future studies examining the effects of JNJ-9375 on
platelet adhesion, thrombosis, and bleeding, alone and in combination
with existing antiplatelet agents would be of interest.
Mechanistic evidence that exosite 1 thrombin inhibition may be asso-
ciated with a low haemorrhagic potential is supported by data from ani-
mal studies of thrombosis and bleeding. Using a baboon arteriovenous
Figure 3 The effect of study compound on the components of thrombus formation. Extra-corporeal administration of JNJ-9375 inhibited fibrin-rich
thrombus deposition in a dose-dependent manner at both (A) low shear stress (212 s-1) and (C) high shear stress (1690 s-1) shear stress, as compared to pla-
cebo. JNJ-9375 had no effect on platelet-rich thrombus deposition at either shear stress. Bivalirudin reduced fibrin-rich thrombus deposition at low and high
shear stress, and platelet-rich thrombus deposition at high shear stress. Data shown are the adjusted means (±95% confidence intervals) for [Log] fibrin- or
platelet-rich thrombus area (lm2/mm) and individual points. Statistical comparisons (Least Significance Difference test) vs. placebo are represented above
each plot: *P < 0.05, **P < 0.01, ***P < 0.001. 9375, JNJ-9375.



























































































shunt model, Cadroy et al.37 found that exosite 1 thrombin inhibition
prevented thrombus formation but did not affect the ability to form hae-
mostatic plugs. More recently, JNJ-9375 demonstrated a substantially
wider therapeutic index when compared to apixaban in rats and cyno-
molgus monkeys.10 Further insight comes from the case report of an
anti-exosite 1 thrombin IgA antibody (from which JNJ-937 was subse-
quently synthesized to mimic) identified in a patient presenting with a
large traumatic subdural haematoma and persistently abnormal clotting
studies.40 Despite evidence of intense anticoagulation (prothrombin
time 40 s; activated partial thromboplastin time >240 s; thrombin time
with bovine thrombin 173 s), the patient made a full recovery without
surgical intervention and had no abnormal bleeding events during 8 years
of follow-up.
Anticoagulants must in addition to avoiding unwanted bleeding pro-
vide clinically efficacious antithrombotic protection. Examination of the
effect of exosite 1 thrombin inhibition on human thrombosis has previ-
ously been limited to studies using heparinised blood in a rabbit aortic
angioplasty model41 and cone and plate chamber.42 This is the first
description of the ex vivo antithrombotic effects of exosite 1 thrombin in-
hibition in native human blood under flow conditions. At a dose of
250 lg/mL, JNJ-9375 reduced total thrombus area by over 40% and 30%
at low and high shear, respectively. Under the same conditions, high
dose bivalirudin (equivalent to that used at the time of PCI) reduced
thrombus formation by 65% at low shear and 56% at high shear; while in
previous studies reductions of 14% with heparin (70 IU/kg bolus plus
15 IU/kg/h infusion),19 26–28% with oral edoxaban (60 mg)43 and up to
40% with serial dosing of the parenteral direct factor Xa inhibitor, DX-
9065a,20 were reported. Importantly therefore, we have shown that
exosite 1 thrombin antagonism alone with JNJ-9375 substantially
reduces ex vivo human thrombus formation. Moreover, reductions were
comparable (if not superior) in magnitude to the clinically approved anti-
coagulant edoxaban suggesting a high probability of in vivo antithrombotic
efficacy.
JNJ-9375 resulted in dose-dependent prolongation of prothrombin
time, activated partial thromboplastin time, and thrombin time. As
expected, thrombin time was most sensitive to the anticoagulant effect.
Although DOACs are licensed for use without the need for routine
monitoring, there are clinical situations in which readily available assays
to measure anticoagulant activity may be useful. Our data suggest that if
indicated, thrombin time, and to a lesser extent prothrombin time and
activated partial thromboplastin time, may provide a useful assay for
measuring the effect of exosite 1 inhibition and JNJ-9375 activity.
Our study has some potential limitations. First, only a modest number
of volunteers were studied. However, problems associated with intra-
group variability were minimized by the crossover design that allowed
each volunteer to serve as their own control. Second, although the ex-
posed porcine aortic media used in the perfusion model presents many
of the common constituents of an injured human blood vessel (including
type I collagen), it is unlikely to contain tissue factor (TF).44–46 Tissue fac-
tor (TF) activates the coagulation cascade and is an important contribu-
tor to thrombogenicity.47,48 Nevertheless, this does not overly limit our
model for the assessment of thrombosis because binding of blood borne
circulating TF is sufficient to allow activation of the coagulation cascade
and thrombus propagation.44,45,49–51 Indeed, previous studies have con-
firmed that thrombus formed from human blood perfused over porcine
tunica media (devoid of TF) stains heavily for TF.44,45 Third, we used an
anti-fibrin(ogen) antibody, which recognizes both fibrinogen and fibrin,
to examine the fibrin component of thrombus formation. However, the
chamber is perfused by saline at the end of the experiment washing
away unbound cells, proteins, and other molecules, such as fibrinogen,
leaving only adherent thrombus. Thus, histomorphometric quantification
of fibrin-rich thrombus area is unlikely to be affected by this cross-
reacting antibody, and our findings are consistent with previous studies
using the same immunohistochemical approach.52–55 Fourth, while we
have shown that exosite 1 thrombin inhibition reduces fibrin-rich throm-
bus formation, determining how JNJ-9375 alters the dynamics of clot
development, stabilization, and dissolution might further inform thera-
peutic potential and are areas for future exploration. Finally, the study in-
cluded ex vivo experiments only, and thus lacked hard clinical endpoints
necessary to draw any conclusions regarding the safety or efficacy of this
novel anticoagulant in practice. However, given this was a translational
study designed to examine for the first time the effects of exosite 1
thrombin inhibition with JNJ-9375, we felt our study design appropriate.
In conclusion, JNJ-9375, a highly specific exosite 1 thrombin inhibitor,
demonstrated substantial reductions in ex vivo thrombosis in native hu-
man blood under flow conditions. These reductions were driven by a de-
crease in fibrin-rich thrombus formation and were comparable in
magnitude to clinically approved anticoagulants. Our findings suggest
JNJ-9375 represents a promising novel class of anticoagulant, and that
further clinical studies are warranted. A Phase 2 trial comparing
the safety and efficacy of JNJ-9375 to apixaban in patients undergoing
elective total knee replacement surgery is currently underway
(ClinicalTrials.gov: NCT03251482).
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of Diesel Exhaust on Cardiovascular
Function and Oxidative Stress
AU1 c Simon J. Wilson, Mark R. Miller, and David E. Newby
Abstract
Significance: Air pollution is a major global health concern with the particulate matter (PM) being especially
associated with marked increases in cardiovascular morbidity and mortality. Diesel exhaust emissions are a
particularly rich source of the smallest sizes of PM (‘‘fine’’ and ‘‘ultrafine’’) in urban environments, and it is
these particles that are believed to be the most detrimental to cardiovascular health.
Recent Advances: Controlled exposure studies to diesel exhaust in animals and man demonstrate alterations in
blood pressure, heart rate, vascular tone, endothelial function, myocardial perfusion, thrombosis, atherogenesis,
and plaque stability. Oxidative stress has emerged as a highly plausible pathobiological mechanism by which
inhalation of diesel exhaust PM leads to multiple facets of cardiovascular dysfunction.
Critical Issues: Diesel exhaust inhalation promotes oxidative stress in several biological compartments that can
be directly associated with adverse cardiovascular effects.
Future Directions: Further studies with more sensitive and specific in vivo human markers of oxidative stress
are required to determine if targeting oxidative stress pathways involved in the actions of diesel exhaust PM
could be of therapeutic value. Antioxid. Redox Signal. 00, 000–000.
Keywords: diesel exhaust, cardiovascular function, oxidative stress
Background
Overview
In 2012, the World Health Organization estimatedthat air pollution was responsible for up to 7.3 million
premature deaths globally, predominantly from cardiovas-
cular disease (178). Air pollution is a major public health
concern with both indoor and outdoor air pollution ranking in
the top 10 risk factors for all-cause death worldwide (89).
Increasing industrialization and the rapid expansion of urban
environments in developing countries means that, for many,
exposure to air pollutants is unavoidable.
Air pollution
Air pollution is a complex mixture of gases (e.g., ozone,
carbon monoxide, nitrogen oxides), volatile organic com-
pounds, and particulate matter (PM). PM is generally divided
into coarse (diameter <10 lm), fine (diameter <2.5 lm), and
ultrafine (diameter <100 nm) fractions (43). Coarse PM is
derived from numerous sources, including burning of natural
materials, silica-based crustal particles, construction or road
dust, and mechanical abrasion (e.g., brake wear). Fine and
ultrafine fractions of PM in urban environments chiefly arise
from industrial burning of fossil fuels and from traffic-related
sources ( b F1Fig. 1).
Epidemiological evidence suggests that while gaseous air
pollutants, including carbon monoxide, ozone, and nitrogen
oxides, can have serious health effects, the strongest associ-
ations for mortality and cardiovascular disease are with PM
(21, 50, 55, 111, 117), particularly combustion-derived fine
PM (100, 144). Indeed, in a prospective cohort study of 8111
adults residing across six major U.S. cities, an increased rate
ratio of mortality (after adjustment for potential confounders)
was found for combustion-derived fine PM, but not coarse
PM or crustal fine PM (39, 84). This may reflect the ability of
smaller particles to penetrate deep into the lung (44) and
potentially translocate into the circulation, as well as present
a larger reactive surface area with a host of adsorbed surface
chemicals that include redox-active organic compounds and
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reactive metals (157). Vehicle exhaust emissions, and diesel
exhaust in particular, are especially rich in the combustion-
derived nanoparticles that make up a significant proportion of
urban fine and ultrafine PM.
Diesel exhaust
In the late 20th century, a number of regulatory bodies
advocated the use of diesel vehicles due to their seemingly
greater environmental friendliness, including lower emis-
sions of carbon dioxide, hydrocarbons, and lead, compared to
petrol cars. Government incentives and superior fuel econ-
omy led to a marked increase in the popularity of diesel
engine cars, particularly in the European and Indian markets.
However, emissions from diesel exhaust can be *100-fold
higher in particle numbers than gasoline engines (147, 148,
163) due to the greater proportion of smaller particles emitted
per unit mass of PM (84, 131). Diesel exhaust emissions,
therefore, represent a major source of harmful combustion-
derived PM, and despite the greater recognition of their po-
tential health effects, levels of these pollutants are expected
to increase in urban environments of many countries over the
next few years.
At present, the precise mechanisms underlying exposure
to combustion-derived PM and increased cardiovascular
morbidity remain incompletely understood although there is
increasing evidence that oxidative stress may have a key
role. While it can be argued that much can (and should) be
done to clean the air without knowing these mechanisms,
such an approach risks unnecessary resource expenditure as a
consequence of under- or overtargeting specific pollutants.
Furthermore, even at air pollution levels below current in-
ternational guidelines, associations between fine PM expo-
sure and cardiovascular events have been found, particularly
in sensitive individuals (13, 21, 24, 156, 184). b AU3A greater un-
derstanding of the pathways linking air pollution exposure to
cardiovascular disease may allow the development of specific
therapies for individuals at greatest risk and permit a more
directed and cost-effective adjunct to future global environ-
mental strategies.
This review examines the evidence for the associations
between PM and cardiovascular dysfunction. We focus on
the findings from controlled exposure studies, which provide
a unique insight into the means by which diesel exhaust and
other combustion-derived PM can induce cardiovascular
impairment. The potential for diesel exhaust to generate
oxidative stress is examined with emphasis and then given
to evidence linking PM-induced oxidative stress to adverse
cardiovascular responses.
PM and Cardiovascular Disease
Epidemiological evidence
Acute exposure. Meta-analyses and multicity studies of
daily changes in exposure to PM have demonstrated a 0.5–2%
increase in cardiovascular mortality with each 10–20 lg/m3
increase in PM air pollution (3, 41, 77, 85, 122). Acute ex-
posure to traffic-derived PM has been linked to the trigger-
ing of acute myocardial infarction (16, 128). Indeed, due to
the ubiquitous nature of air pollution, traffic exposure was
FIG. 1. The relative size
of the three main fractions
of PM and the principle
sources in urban environ-
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identified as carrying the highest population attributable risk
for precipitating an acute coronary syndrome event in a re-
cent meta-regression analysis (114).
Hospital rates for all major cardiovascular admissions have
been shown to increase in parallel with short-term levels of
ambient fine PM, with the largest association for heart failure
(1.28% increase in risk per 10 lg/m3 increase in same-day
fine PM (95% confidence interval [CI]: 0.78–1.78) (42). It
was estimated that for every 10 lg/m3 decrease in fine PM,
annual hospital admissions for heart failure and stroke would
be reduced by 1.3% and 0.8%, respectively. A similar associ-
ation between short-term (7 day) levels of ambient PM and
incidence of stroke was demonstrated in a comprehensive
meta-analysis of 94 studies (152). Elevated fine PM was shown
to predict a 1.1% rise in event rate ([95% CI: 1.1–1.2] per
10 lg/m3), while ambient coarse PM showed a weaker asso-
ciation (0.3% increase per 10 lg/m3 [95% CI: 0.3–0.4%]).
Long-term exposure. The long-term effects of air pol-
lution on mortality are mostly associated with fine PM and
have been shown to be generally greater than for short-term
exposure (21). In a recent meta-analysis, the pooled effect
estimate was 6% (95% CI: 4–8) for all-cause and 11% (95%
CI: 6–16) for cardiovascular mortality per 10 lg/m3 increase
in fine PM (68). Miller et al. in a study of 65,893 postmen-
opausal women without previous cardiovascular disease
found a 21% increased risk for coronary heart disease events
(AU4 c RR 1.21, 95% CI: 1.04–1.42) and a 35% increased risk for
cerebrovascular disease events (RR 1.35, 95% CI: 1.08–1.68)
for every 10 lg/m3 increment in fine PM over a median
follow-up of 6 years (100). The results for mortality were
more striking with a relative risk of death of 2.21 (95% CI:
1.17–4.16) from coronary heart disease (definite diagnosis)
and 1.83 (95% CI: 1.11–3.00) from cerebrovascular disease
per 10 lg/m3 increment of fine PM. Large European cohort
studies have shown similar long-term associations between
cardiovascular events and background level air pollution,
even in high-income nations where fine PM concentrations
meet international guidelines (13, 24, 156).
There is also substantial evidence that long-term exposure
to PM promotes atherogenesis. After correction for potential
confounders, increased ambient levels of fine PM or traffic-
related air pollution were associated with both a greater ex-
tent and rate of progression of coronary atherosclerosis, as
determined by coronary artery calcium scores (70, 78). Stu-
dies using carotid intima-medial thickness as a surrogate
marker for atheroma have demonstrated analogous results
(12, 78, 82, 83). In older individuals, small increases in short-
and long-term exposure to fine PM were associated with
narrower retinal arteriolar diameters suggestive of impaired
microvasculature function (2).
Controlled exposure studies
Epidemiological data have afforded strong evidence of
associations between PM exposure and cardiovascular dis-
ease. Controlled exposure studies in man provide an ex-
tremely useful means to examine the associations derived
from epidemiological studies in the absence of many con-
founders present in the real world. By exposing volunteers to
relevant levels of specific pollutants and using sensitive ex-
perimental techniques to measure targeted endpoints, they
can help evaluate the possible underlying pathophysiological
mechanisms responsible for the acute cardiovascular effects
of air pollutants and provide greater certainty of causality.
Arterial tone and blood pressure. Panel studies have
demonstrated an association between short-term increases in
ambient fine PM and elevated blood pressure (6, 19, 45, 90).
Controlled exposure studies suggest that this may relate to
alterations in arterial tone. In healthy volunteers (20, 129) and
patients with metabolic syndrome (129), inhalation of fine
PM resulted in acute brachial vasoconstriction (129). Diesel
exhaust exposure has been shown to increase central arterial
stiffness ( b F2Fig. 2) (96) and produce a small but consistent rise
in diastolic blood pressure (20).
Cardiac autonomic function. Short-term increases in
ambient air pollution, particularly fine PM, are associated with
FIG. 2. The effect of dilute diesel exhaust on central arterial stiffness in healthy volunteers. (A) Following exposure
to dilute diesel exhaust, augmentation pressure increased immediately compared to filtered air and normalized over 30 min
( p = 0.01, diesel exhaust vs. filtered air, repeated-measures ANOVA, n = 12). (B) The augmentation index demonstrated a
similar response ( p = 0.02, respectively, diesel exhaust vs. filtered air, repeated-measures ANOVA, n = 12). Reproduced
with permission from Lundback et al. (96). ANOVA, analysis of variance. To see this illustration in color, the reader is
referred to the web version of this article at www.liebertpub.com/ars
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a higher incidence of arrhythmia and cardiovascular death (21,
40, 126, 137). Heart rate variability (HRV) is a noninvasive
measure of cardiac autonomic dysfunction with reduced HRV
predicting an increased risk of adverse cardiovascular events
in both healthy individuals (169) and vulnerable patients (80).
Several panel studies have reported a decrease in HRV with
elevated levels of ambient fine PM (56, 88, 97, 133), sug-
gesting a potential role for cardiac autonomic dysfunction in
the cardiovascular mortality associated with PM. However, the
direction and magnitude of change across all available studies
are variable and inconsistent (22, 107). Results from controlled
exposures have been more consistent with reductions in HRV
following inhalation of concentrated ambient particles (CAPs)
(37, 57, 58) but not dilute diesel exhaust (107, 130). Thus, the
composition and source of PM appear to be an important de-
termination of the effects of air pollution on HRV and it re-
mains to be established if diesel exhaust induces alterations in
cardiac autonomic function.
Endothelial dysfunction. The vascular endothelium con-
trols barrier function and through the synthesis and release of
local mediators, such as nitric oxide and tissue plasminogen
activator (tPA), helps regulate vascular tone and maintain an
atheroprotective environment. Endothelial dysfunction is one
of the earliest pathological processes involved in the devel-
opment of atherosclerosis (176) as well as being an important
determinant of subsequent cardiovascular events (62, 64).
Mills et al. demonstrated that short-term exposure to
diesel exhaust impairs resistance vessel responses to both
endothelium-dependent and endothelium-independent vaso-
dilatation ( b F3Fig. 3) (106). Subsequent studies have exhibited
similar results (172) with altered vasomotor function occur-
ring soon after exposure (within 2 h) and remaining evident
24 later (167). Inhalation of diesel exhaust has been shown to
reduce the ability of the endothelium to release tPA (a marker
of endogenous fibrinolysis) in both healthy volunteers (11,
92, 106) and patients with stable ischemic heart disease
(108). Lucking et al. demonstrated that impaired vasomotor
and endothelial responses following diesel exhaust exposure
were nearly abolished by the use of a particle trap (92). This
suggests these effects were driven by the PM fraction of
diesel exhaust as opposed to the gaseous copollutants and
FIG. 3. The effect of di-
lute diesel exhaust on fore-
arm blood flow in healthy
volunteers. Infused forearm
blood flow 2–4 h after diesel




verapamil. For all dose–re-
sponses, p < 0.0001. For die-
sel exposure (C) versus air
(B), bradykinin p < 0.05,
acetylcholine p < 0.05, so-
dium nitroprusside p < 0.001,
and verapamil p = NS. Re-
produced with permission
from Mills et al. (106).
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have been linked to the surface constituents of the particles
rather than the carbon core (105).
Systemic inflammation. Atherosclerosis is inherently a
chronic inflammatory condition and elevated systemic markers
of inflammation, such as C-reactive protein (CRP) (138), white
cell counts (175), and myeloperoxidase (66, 146), are strong
predictors of cardiovascular death, myocardial infarction, and
stroke. Evidence that diesel exhaust inhalation can invoke
systemic inflammation (demonstrated by elevated circulating
leukocytes, tumor necrosis factor alpha (TNF-a), interleukin-6
(IL-6), and acute-phase response proteins) is strongest in ani-
mal models (113, 139, 181) and longitudinal studies (35, 69,
168, 171). In contrast, results from controlled exposure studies
in man are less consistent (167), with several studies demon-
strating little or no observable effect (65, 91, 106).
Cardiac ischemia. ST-segment depression on exercise
testing or ambulatory electrocardiography is used as a nonin-
vasive marker of myocardial ischemia and predicts an in-
creased risk of adverse cardiovascular events in patients with
established ischemic heart disease (30, 159). Panel studies of
elderly subjects (36) and those with a history of myocardial
infarction (28, 125) found that higher ambient levels of PM air
pollution were associated with an increased occurrence of ST-
segment depression during submaximal exercise stress testing
or on ambulatory electrocardiography. During a 1-h controlled
exposure to diesel exhaust, Mills et al. demonstrated an in-
crease in exercise-related ST-segment depression in patients
with stable ischemic heart disease, compared to filtered air
( b F4Fig. 4) (108). In a similar study by the same group, a small, but
nonsignificant increase in maximal ST-segment depression
was observed immediately postexposure during a formal ex-
ercise treadmill test (-185 lV [-115 to -203] vs. -217 lV
[-139 to -245]; p = 0.07; unpublished data).
Atherothrombosis. Acute cardiovascular events, includ-
ing myocardial infarction and stroke, are primarily the result
of occlusive arterial thrombosis following rupture of ath-
erosclerotic plaques. Studies in mice have demonstrated that
PM exposure potentiates atherosclerosis (161) and is asso-
ciated with increased markers of plaque instability (9, 23). In
humans, short-term diesel exhaust exposure increased ex vivo
thrombus formation (91), driven by the particulate constitu-
ents of the exhaust (92). Plausible mechanisms for enhanced
thrombogenicity include increased platelet hyper-reactivity
(31, 49, 61, 74, 134), loss of vascular endothelium-derived
nitric oxide, and alterations in coagulation, including in-
creased fibrinogen (31, 54, 151) and plasminogen activator
inhibitor-1 (31), and decreased release of tPA (106) and tis-
sue factor pathway inhibitor (31).
Biological Pathways
PM inhalation leads to cardiovascular disease
The pathophysiological mechanism(s) underlying the
association between pulmonary exposure to combustion-
derived PM and cardiovascular disease remain incompletely
FIG. 4. Myocardial ischemia during 15-min intervals of exercise-induced stress and exposure to dilute diesel
exhaust or filtered air in men with prior myocardial infarction. (A) Shows the average change in the heart rate and in the
ST-segment in lead II. (B) Shows the maximum ST-segment depression during inhalation of dilute diesel exhaust compared
with filtered air ( p = 0.003), and (C) shows the total ischemic burden during inhalation of diesel exhaust compared with
filtered air ( p < 0.001); the values in (B) and (C) are averages of the values in leads II, V2, and V5. In all three panels, red
indicates exposure to diesel exhaust, and blue exposure to filtered air. T bars denote standard errors. From Mills et al. (107)
Copyright ª (2007) Massachusetts Medical Society. Reprinted with permission. mVsec, millivolt seconds. To see this
illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
DIESEL EXHAUST AND CARDIOVASCULAR FUNCTION 5
ARS-2017-7174-ver9-Wilson_1P.3d 06/26/17 10:32pm Page 5
understood (F5 c Fig. 5). The classical hypothesis is that inhaled
particles deposited deep in the alveoli of the lung activate
local inflammatory cells leading to a ‘‘spill-over’’ of proin-
flammatory mediators into the bloodstream, which then im-
pair cardiovascular function (5, 67, 150). Alternatively,
inhaled particles may trigger sensory receptors on the alve-
olar surface, stimulating alterations in autonomic nervous
system activity, which in turn promote cardiovascular dys-
function (132, 133).
More recently, it has been proposed that nanosized
combustion-derived particles are able to translocate across
the alveolar membrane into the bloodstream to directly in-
teract with the cardiovascular system (46, 51, 52, 149). Other
mechanisms have been suggested that may build on these
pathways, including stimulation of sensory afferents in the
upper respiratory or gastrointestinal tract (following muco-
ciliary clearance) and accumulation of PM in nonvascular
tissues with subsequent amplification of local inflammatory
responses. While it remains unclear which, if any, of these
predominate, there is a potential role for oxidative stress at
numerous points in all these pathways (101). Oxidative stress
has therefore emerged as one of the possible major patho-
biological mechanisms underlying the cardiovascular effects
of diesel exhaust inhalation (103).
Oxidative Stress
What is oxidative stress?
Reactive oxygen species (ROS) is a term used to describe a
variety of oxidizing molecules that include both free radicals
(molecules with one unpaired electron such as superoxide
anion [O2
-!] and hydroxyl free radical [OH!]) and nonradicals
(e.g., hydrogen peroxide [H2O2] and peroxynitrite [ONOO
-]).
ROS are a by-product of normal cellular metabolism but can
also be produced from exogenous sources (e.g., particulates
themselves). They have the potential to cause deleterious ef-
fects and their levels are finely regulated by antioxidants to
maintain redox homeostasis and cellular function. Oxidative
stress refers to a net excess of ROS, through an increase in
ROS, a decrease in cellular antioxidant capacity, or combi-
nation of both. This can lead to indiscriminate oxidation of a
wide range of cellular molecules, resulting in dysregulation of
cellular function, cell death, and tissue damage. ROS genera-
tion and oxidative stress have been implicated in the patho-
genesis of many disease processes (73, 135).
Evidence for the role of oxidative stress
in cardiovascular disease
Oxidative modification of low-density lipoprotein (LDL)
has been shown to be an important step in the pathogenesis
of atherosclerosis. Within the vessel wall, oxidized LDL
activates macrophages and other inflammatory cells leading
to the accumulation of lipid-laden foam cells and plaque
formation (47). Antioxidant therapies have been shown to
attenuate plaque progression in animal and observational
studies, although the results from randomized controlled
trials have largely been negative (27). Oxidative stress may
promote hypertension through vascular smooth muscle cell
proliferation and hypertrophy (145), quenching of nitric ox-
ide by superoxide and other ROS (98), generation of vaso-
constrictor products, including F2-isoprostanes (32) and
upregulation of the Rho/Rho-associated kinase pathway
(160). Increased markers of vascular oxidative stress have
been demonstrated in animal models of hypertension (118,
164, 179) although less reliably in human studies (33, 124,
142, 174).
Oxidative stress plays an important role in the pathogen-
esis of heart failure. Lipid peroxidation refers to the oxidative
FIG. 5. Hypothetical
pathways through which
inhaled PM determines ef-
fects on the cardiovascular
system. To see this illustra-
tion in color, the reader is
referred to the web version
of this article at www
.liebertpub.com/ars
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degeneration of lipids by ROS and can lead to decreased cell
membrane integrity and function. Markers of lipid perox-
idation, including exhaled breath pentane and circulating
malondialdehyde, have been shown to be elevated in patients
with congestive heart failure (38, 154) and following myo-
cardial infarction (177). Exogenous generators of ROS result
in increased resting tension, structural damage to myocytes,
and contractile failure in isolated perfused rat hearts; effects
that are reduced by coadministration of antioxidants (59,
180). Belch et al. demonstrated that plasma levels of free
radicals and antioxidants (thiols) were both significantly,
although weakly, correlated with the severity of left ven-
tricular systolic impairment (15). Reperfusion injury fol-
lowing myocardial ischemia is believed, at least in part, to be
mediated by a burst of oxidative stress (63, 185). Accord-
ingly, attenuation of free radical production has been shown
to enhance contractile recovery in animal models (17, 18).
Evidence that diesel exhaust induces oxidative stress
Combustion-derived PM is highly oxidizing and is capable
of initiating free redox cycling reactions in physiological so-
lutions and biological environments (1, 79, 102, 121, 158).
Increased markers of ROS (e.g., superoxide, H2O2) and oxi-
dative stress (e.g., superoxide dismutase-1, heme oxygenase-
1, tetrahydrobiopterin, thiobarbituric acid reactive substances,
15-F2t-isoprostane, 8-hydroxy-2-deoxyguanosine) have been
demonstrated within the vascular wall (9, 93–95, 119, 161,
173), heart (10, 34, 53, 60), lung (60, 116), and plasma (9, 93,
116) of animals following pulmonary exposure to PM or ve-
hicle exhaust. Other investigators have found these pollutants
to induce an increased expression of inflammatory cytokines
(e.g., intracellular adhesion molecule-1, IL-6, TNF-a) that are
under the regulatory control of redox-sensitive transcription
factors (75, 76, 86, 87).
Diesel exhaust particles and urban air pollution have been
shown to oxidize LDL in vitro (72) and in vivo (153), re-
spectively. Exposure of Apo E-/- mice to diesel exhaust in-
creased the expression of oxidative stress markers (inducible
nitric oxide synthase [iNOS], CD36, and nitrotyrosine) in
aortic plaque (9) and led to upregulation of lectin-like oxi-
dized LDL receptors (94). Fine PM was found to decrease the
ability of high-density lipoprotein to protect LDL from oxi-
dation (5).
In human studies, higher concentrations of ambient fine
PM concentrations were associated with increased urinary
levels of 8-hydroxy-2-deoxyguanosine and malondialdehyde
(both markers of oxidative stress) (8, 136, 140). Interestingly,
Sørensen et al. reported that plasma malondialdehyde was
increased by fine PM exposure in women, but not in men,
suggesting that sex differences may add to the complexity of
systemic PM responses (155). Controlled exposure studies
have shown that vehicle exhaust precipitated increased levels
of malondialdehyde in exhaled breath condensate (141), ur-
ate and reduced glutathione (antioxidants) in airway lavage
(14, 110), 8-hydroxy-2-deoxyguanosine in urine (162), and
the expression of genes related to oxidative stress (e.g., dual-
specificity phosphatase-1, glutathione S-transferase M4,
peroxiredoxin-1, and heme oxygenase-1) in peripheral blood
monocytes (127). Finally, in a meta-analysis of cross-
sectional, panel, and controlled exposure studies, inhalation
of combustion-derived PM was found to be consistently as-
sociated with oxidatively damaged DNA and lipid perox-
idation in blood, urine, and exhaled breath condensate (112).
Evidence that oxidative stress drives diesel
exhaust-induced vascular dysfunction
To examine the role of oxidative stress in driving the
pathological effects of diesel exhaust, several studies have
assessed the effects of combustion-derived PM exposure with
and without exogenous administration of either antioxidants
or inhibitors of ROS generating pathways.
Animal studies. In rat aortic ring models, addition of
superoxide dismutase and other free radical scavengers (e.g.,
tiron) abolished the inhibitory effect of diesel exhaust on
endothelium-dependent (25, 26, 71, 102) and endothelium-
independent (25, 102) aortic relaxation ( b F6Fig. 6). Similarly,
alterations in phenylephrine-stimulated vascular tone were
inhibited by N-acetylcysteine (170) and the iNOS inhibitor,
1400W (10). Knuckles et al. demonstrated that l-nitro-
arginine-methyl-ester, an endothelial nitric oxide synthase
(eNOS) inhibitor, reversed the proconstrictor effects of diesel
exhaust, suggesting that generation of superoxide from un-
coupling of eNOS may be a mechanism for diesel exhaust-
induced vascular dysfunction (81).
Intratracheal instillation of diesel exhaust particles in mice
results in pulmonary inflammation, increased systemic oxi-
dative stress (as determined by a decrease in plasma Trolox
equivalent antioxidant capacity), and proaggregatory effects
in pial cerebral venules (116). These effects were reversed
by pretreatment with the antioxidant l–2-oxothiazolidine-
4-carboxylic acid. Matrix metalloproteinases (MMPs) are
important regulators of vascular remodeling. Lund et al.
demonstrated that in mice, increases in expression of vascular
MMP-2 and ROS in response to vehicle emissions (95) could
be ameliorated by oral coadministration of the antioxidant, 4-
hydroxy-TEMPO (Tempol) (95).
Human studies. Evidence directly linking PM-induced
oxidative stress with vascular dysfunction in man is chal-
lenging due to the fewer techniques available for use in
readily collectable biological samples (i.e., blood and urine)
and a more restricted set of antioxidants or administration
routes. Nevertheless, there is emerging literature supporting
the role of oxidative stress in cardiovascular effects of air
pollution.
In a study of 76 students living in Taipei, small increases in
background levels of PM were associated with a reduction in
HRV, accompanied by an increase in plasma levels of 8-
hydroxy-2-deoxyguanosine (29). Liu et al. demonstrated that
increases in black carbon and fine PM exposure caused al-
terations in brachial artery diameter, blood pressure, and
heart rate, which were associated with increased plasma
thiobarbituric acid reactive substances (90). However, in both
of these studies, concomitant increases in other biological
markers, including CRP, fibrinogen, and endothelin-1, mean
that oxidative stress alone cannot be assumed to be the cause
of vascular impairment.
Sack et al. examined the effect of pretreatment with an
antioxidant regimen (N-acetylcysteine and ascorbate) on
diesel-induced brachial vasoconstriction in healthy volun-
teers. Surprisingly, antioxidant treatment augmented, rather
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than reversed, the vasoconstrictor effects of diesel exhaust
(143). Ultrafine PM can alter fibrin clot structure in vitro and
this may contribute to the increased incidence of thrombo-
embolic events related to combustion-derived air pollution.
These alterations were inhibited by the presence of mannitol,
a scavenger of OH! (99). In a randomized, double-blind,
controlled exposure study in middle-aged healthy volunteers,
fish oil supplementation, which is high in the antioxidant
omega-3 fatty acid (4), successfully attenuated reductions in
HRV and acute increases in LDL and triglyceride concen-
trations in response to acute exposure to CAPs (166). In a
similar study by Zhong et al., alterations in heart rate, HRV,
and white blood cell counts following a 2-h controlled ex-
posure to fine PM were almost completely mitigated by vi-
tamin B supplementation (183). B vitamins have anti-
inflammatory, antioxidant, and immunoepigenetic effects (7,
182). Finally, inhalation of diesel exhaust has frequently been
shown to attenuate vasodilatation to endothelium-derived
and nonendothelium-derived nitric oxide. While this is in-
direct evidence for a role of oxidative stress, these results are
consistent with reduced nitric oxide bioavailability due to
scavenging by superoxide free radicals.
Summary
Epidemiological evidence has repeatedly demonstrated
that acute and chronic exposure to PM, especially
combustion-derived fine and ultra-PM, is strongly associated
FIG. 6. The effects of diesel exhaust particulate with and without SOD on (A–F) contraction and relaxation in
isolated rat aortic rings and (G, H) generation of oxygen-centered free radicals. (A, B)AU7 c DEP had no effect on
phenylephrine-induced vasoconstriction. (C) Acetylcholine-induced relaxation was attenuated by DEP (maximum relaxa-
tion reduced from 91 – 4% to 49 – 6% with 100 lg/ml DEP; p < 0.001) but was restored by SOD (maximum relaxation,
73 – 6%; p < 0.001). (D, E) DEP caused a modest inhibition of relaxation to NO donor drugs [sodium nitroprusside, 2-(N,N-
dimethylamino)-diazenolate-2-oxide], an effect that could be reversed by SOD ( p < 0.01). (F) DEP inhibited verapamil-
induced relaxation ( p < 0.001) by a mechanism independent of SOD. Two-way repeated-measures ANOVA: ***p < 0.001
(AU8 c ns, not significant), control versus DEP; {{p < 0.01, and {{{p < 0.001 (NS, not significant), DEP versus DEP + SOD. (G)
Sample spectra after 60 min showing the characteristic three-peaked spectrum produced by oxidation of the spin trap
TEMPONE-H (1 mM); DEP (10 lg/ml) caused a large increase in peak amplitude, an effect that was partially reduced by
coincubation with SOD (100 U/ml). (H) EPR intensity generated by auto-oxidation (control), DEP, or pyrogallol (100 lM)
over a 1-h period, in the presence (open symbols) or absence of SOD (solid symbols). EPR intensity is calculated using the
area under the curve of the first derivative of the first line of the three-line spectrum generated. Data are mean – standard
error (n = 6). Paired t-tests: *p < 0.05, DEP versus DEP + SOD; **p < 0.01, control versus DEP; {{p < 0.01, pyrogallol versus
pyrogallol + SOD. Reproduced with permission from Miller et al. (102). EPR, electron paramagnetic resonance; SOD,
superoxide dismutase.
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with adverse cardiovascular outcomes. Diesel exhaust emis-
sions are of greatest concern in urban environments, where
they are a major source of fine and ultrafine PM. Using con-
trolled exposure studies, combustion-derived PM and diesel
exhaust particles in particular have been shown to promote a
wide array of adverse cardiovascular effects that may un-
derlie the observed increases in cardiovascular morbidity and
mortality. These include alterations in blood pressure, heart
rate and vascular tone, endothelial dysfunction, myocardial
ischemia, thrombosis, atherogenesis, and plaque instability
(F7 c Fig. 7).
Our understanding of the biological pathways that link the
lung response to inhaled pollutants to their cardiovascular
effects has advanced significantly over the past decade but
remains incomplete. The proinflammatory response to PM,
both in the lung and (less consistently) systemically, provides
a prominent mechanism through which inhalation of diesel
exhaust could contribute to oxidative stress and cardio-
vascular impairment. However, PM-induced increases in
markers of oxidative stress have been shown to be more
pronounced than classical biomarkers of systemic inflam-
mation (113), and multiple studies have demonstrated little
or no increase in systemic inflammatory mediators despite
observable cardiovascular dysfunction. Similar to epidemi-
ological studies (22), controlled exposure studies have dem-
onstrated mixed results with regard to induced alterations in
autonomic function as determined by HRV (107). Further
assessment of the effects of diesel exhaust inhalation on
cardiac autonomic function is required, but alternative met-
rics of these neural reflexes can be challenging to perform and
more difficult to interpret. On the contrary, recent studies in
animal and man have provided convincing evidence that in-
haled nanoparticles translocate into the circulation and ac-
cumulate at sites of vascular inflammation (104, 115, 120).
This provides a mechanism through which environmen-
tal nanoparticles could directly impair cardiovascular func-
tion and exacerbate pre-existing disease. Precisely how
combustion-derived PM translocates across the pulmonary
alveolar membrane and the pathobiological consequences of
uptake into vascular plaque will be an important area of future
research.
Oxidative stress has emerged as a highly plausible and
unifying pathobiological mechanism by which inhalation of
diesel exhaust emissions leads to cardiovascular dysfunction.
Three lines of evidence support this hypothesis. First, oxi-
dative stress plays an important role in many cardiovascular
disease processes, including vascular dysfunction, athero-
sclerosis, myocardial injury, and heart failure. Second, diesel
exhaust is highly oxidizing and increased levels of ROS and
markers of oxidative stress have been demonstrated in mul-
tiple cardiovascular compartments following exposure. Fi-
nally, an increasing number of studies have shown that
coadministration of antioxidants can attenuate or reverse the
cardiovascular effects of diesel exhaust on a number of car-
diovascular endpoints, including alterations in endothelial
function, vasomotor responses, thrombosis, and regulators of
vascular remodeling ( b F8Fig. 8).
Exposure to diesel air pollution is ubiquitous and un-
avoidable in almost every urban environment. On a popula-
tion level, interventions that reduce levels of air pollutants,
especially combustion-derived PM, represent a clear strategy
to limit the adverse health effects of air pollution. These
include the use of particle traps fitted to exhaust pipes, and the
modification of fuels and engine technology to ensure more
complete combustion. For high-risk populations, targeted
therapies to mitigate the effects of PM exposure may be
FIG. 7. Possible pathophysiological mechanisms responsible for the acute and chronic cardiovascular effects of
diesel exhaust inhalation. To see this illustration in color, the reader is referred to the web version of this article at
www.liebertpub.com/ars
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useful, particularly as even at levels below current interna-
tional guidelines, associations between fine PM exposure and
increased cardiovascular risk have been demonstrated in
sensitive individuals. In recent years, there have been an in-
creasing number of studies examining whether various
pharmacological agents can prevent the effects of air pollu-
tion. Given the apparent central role of oxidative stress in the
action of combustion-derived PM, agents that scavenge
oxygen-derived free radicals, inhibit enzymatic sources of
these radicals [e.g., NAD(P)H oxidase], or replenish the
specific antioxidant stores consumed by PM would seem
likely to be of most benefit. At present, however, most evi-
dence relates to early experimental animal models with
varying endpoints and pollutant exposure, while in humans,
evidence that statins, B vitamins, omega-3 fatty acids, vita-
min A, and vitamin C supplementation may mitigate some
of the adverse cardiopulmonary effects of PM exposure is
limited to observational or healthy volunteer studies only (48,
109, 123, 165, 166, 183). It therefore remains unclear which
agents may offer an effective therapeutic profile and in view
of the predominantly disappointing results of large clinical
trials of antioxidants on cardiovascular disease in general, a
considerable evidence base in man would be required before
a therapeutic strategy could be proposed in addition to im-
provements in air quality.
Conclusions
Combustion-derived fine and ultrafine PM precipitates a
diverse array of adverse effects within the cardiovascular
system. Diesel exhaust is a prominent source of combustion-
derived fine and ultrafine PM in urban environments and is
likely to be a major contributor to the global excess of car-
diovascular morbidity and mortality attributable to air pol-
lution. Oxidative stress appears to be a prominent mechanism
underlying the detrimental effects of diesel exhaust on many
facets of the cardiovascular system. Further studies are re-
quired to determine if targeting oxidative stress pathways
involved in the actions of PM could be of therapeutic value in
addition to strategies to reduce air pollution.
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and Hernández-López E. Increased malondialdehyde in
peripheral blood of patients with congestive heart failure.
Am Heart J 131: 146–152, 1996.
39. Dockery DW, Luttmann-Gibson H, Rich DQ, Link MS,
Mittleman MA, Gold DR, Koutrakis P, Schwartz JD, and
Verrier RL. Association of air pollution with increased
incidence of ventricular tachyarrhythmias recorded by
implanted cardioverter defibrillators. Environ Health
Perspect 113: 670–674, 2005.
40. Dockery DW, Pope CA, Xu X, Spengler JD, Ware JH, Fay
ME, Ferris BG, and Speizer FE. An association between
air pollution and mortality in six U.S. cities. N Engl J Med
329: 1753–1759, 1993.
41. Dominici F, McDermott A, Zeger SL, and Samet JM.
Airborne particulate matter and mortality: timescale ef-
fects in four US cities. Am J Epidemiol 157: 1055–1065,
2003.
42. Dominici F, Peng RD, Bell ML, Pham L, McDermott A,
Zeger SL, and Samet JM. Fine particulate air pollution
and hospital admission for cardiovascular and respiratory
diseases. JAMA 295: 1127–1134, 2006.
43. Donaldson K, Duffin R, Langrish JP, Miller MR, Mills
NL, Poland CA, Raftis J, Shah A, Shaw CA, and Newby
DE. Nanoparticles and the cardiovascular system: a crit-
ical review. Nanomedicine (Lond) 8: 403–423, 2013.
44. Donaldson K, Stone V, Clouter A, Renwick L, and
MacNee W. Ultrafine particles. Occup Environ Med 58:
211–216, 2001.
45. Dvonch JT, Kannan S, Schulz AJ, Keeler GJ, Mentz G,
House J, Benjamin A, Max P, Bard RL, and Brook RD.
Acute effects of ambient particulate matter on blood
pressure: differential effects across urban communities.
Hypertension 53: 853–859, 2009.
46. Elder A and Oberdörster G. Translocation and effects of
ultrafine particles outside of the lung. Clin Occup Environ
Med 5: 785–796, 2006.
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ANOVA" analysis of variance
CAP" concentrated ambient particle
CI" confidence interval
CRP"C-reactive protein
eNOS" endothelial nitric oxide synthase
EPR" electron paramagnetic resonance
HRV" heart rate variability
IL" interleukin






ROS" reactive oxygen species
SOD" superoxide dismutase
TNF-a" tumor necrosis factor alpha
tPA" tissue plasminogen activator
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